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…Neuroscience goes directly to work on the brain - and the mind follows… 
 
Leon Kass 
 
 
 
“If the human brain were so simple that we could understand it,  
we would be so simple that we couldn´t.” 
 
Emerson M. Pugh 
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Abstract 
The five subtypes of the dopamine receptor play an important role in the human brain. The 
dopamine D4 receptor is involved in processes of behaviour control and is assumed to be 
responsible for the emergence of the attention deficit hyperactivity disorder (ADHD) as well as 
psychotic diseases like schizophrenia. While most of the other dopamine receptors are well 
known there is a lack of suitable radioligands for the examination of the D4 receptor by functional 
neuroimaging via positron emission tomography (PET). This is due to the extremely low 
distribution density of D4 in the central nervous system. In this work the radiosynthesis of such D4 
ligands was developed and pharmacologically evaluated. Therefore, selected pharmaceutical lead 
structures were labelled via nucleophilic substitution with no-carrier-added (n.c.a.) [18F]fluoride at 
an aromatic ring and subsequently coupled in a 1-2 step build-up reaction to the desired ligands. 
As first approach, an efficient radiosynthesis of the highly selective [18F]FAUC 316 ligand 
([18F]1) was developed. Starting from 18F-labelling of the symmetric iodonium salts bis(4-
bromophenyl)iodonium triflate and bis(4-iodophenyl)iodonium triflate the corresponding 4-
[18F]fluorohalobenzenes were obtained in radiochemical yields (RCY) of up to 60 %. Pd-catalyzed 
cross-coupling of the labelling products and piperazine with Pd2(dba)3 or Pd(OAc)2 led to 4-
[18F]fluorophenylpiperazine in a RCY of up to 42 %. During the synthesis of standard and 
precursors 5-Cyanoindol-2-carbaldehyd was synthesized in four reaction steps with an overall 
yield of 15 % and coupled to [18F]FAUC 316. The overall-RCY after high performance liquid 
chromatography (HPLC) separation was 10 %. 
 [18F]FAUC 316 was not suitable for further evaluation steps in vivo due to the very high non-
specific binding content determined by in vitro autoradiography. Alternatively, the radioligands 6-
(4-[4-[18F]fluorobenzyl]piperazine-1-yl)benzodioxine ([18F]33a), 6-(4-[4-[18F]fluoro-(3-methoxy-
benzyl)]piperazine-1-yl)benzodioxine ([18F]33b), 6-(4-[4-[18F]fluoro-(3-hydroxybenzyl)]piperazine-
1-yl)benzodioxine ([18F]33d) und 6-(4-[6-[18F]fluoropyridine-3-yl]piperazine-1-yl)benzodioxine 
([18F]33e) were synthesized as benzodioxine derivatives with decreasing lipophilicity. For this 1-
(1,4-benzodioxine-6-yl)piperazine (30) was coupled with the corresponding aldehyde derivatives 
by a reductive amination reaction in overall-RCY of 35 %, 20 %, 9 % and 15 %, respectively. 
In vitro autoradiography on rat brain slices confirmed the correlation between non-specific 
binding and lipophilicity and lend [18F]33d and [18F]33e as putative radiotracers. Since [18F]33e 
showed better D4 selectivity, ex vivo organ uptake, metabolization rate and brain distribution 
were determined. 
Examinations showed a principle qualification of [18F]33e for the visualization of the D4 
receptors, but due to a lack of experiences a clear relation of D4 to the ligand was not possible up 
to now. Further examinations in vivo are required to verify the ability of mapping D4 receptors by 
this new radioligand.  
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Kurzzusammenfassung 
Die fünf Subtypen des Dopaminrezeptors spielen eine entscheidende Rolle im menschlichen 
Hirn. Der Dopamin-D4 Rezeptor ist dabei maßgeblich an Steuerungsprozessen des Verhaltens und 
deren Pathologien beteiligt und wird für die Ausbildung des Aufmerksamkeitsdefizit Syndroms 
(ADHS) sowie weiterer psychotischer Krankheitsbilder verantwortlich gemacht. Während die 
meisten Dopaminrezeptoren gut untersucht sind, fehlt es jedoch beim D4 Rezeptor aufgrund 
seiner enorm geringen Hirnverteilungsdichte an Radioliganden für ein funktionelles Neuroimaging 
mittels der Positronen-Emissions-Tomographie (PET). In dieser Arbeit wurde die Radiosynthese 
potentieller D4 Liganden entwickelt und diese anschließend pharmakologisch evaluiert. Dazu 
wurden ausgewählte Leitstrukturen  über eine nukleophile Substitutionsreaktion mit trägerarmen 
(n.c.a.) [18F]Fluorid am aromatischen Ring markiert und in einer 1-2 stufigen Aufbaureaktion zu 
den gewünschten Zielmolekülen umgesetzt. 
Zunächst wurde eine effiziente Radiosynthese des hochselektiven [18F]FAUC 316 ([18F]1) 
entwickelt. Ausgehend von der 18F-Fluorierung der symmetrischen Iodonium-Salze Bis(4-
bromphenyl)iodonium triflat  und Bis(4-iodphenyl)iodonium triflat zu den entsprechenden 4-
[18F]Fluorhalogenbenzolen in radiochemischen Ausbeuten (RCA) bis zu 60 % wurde durch Pd-
katalysierte Kreuzkupplung der Markierungsprodukte und Piperazin mit Pd2(dba)3 oder Pd(OAc)2 
4-[18F]Fluorphenylpiperazin in RCA bis 42 % dargestellt. Parallel wurde neben der Standard- und 
Vorläufersynthese 5-Cyanoindol-2-carbaldehyd in vier Reaktionsschritten und einer 
Gesamtausbeute von 15 % synthetisiert und mittels einer reduktiven Aminierung zum [18F]FAUC 
316 gekoppelt. Die Gesamt-RCA nach erfolgreicher Hochdruckflüssigchromatographie (HPLC)-
Separation belief sich auf 10 %. 
Aufgrund des sich aus einer in vitro Autoradiographie ergebenen hohen nicht-spezifischen 
Bindungsanteils des [18F]FAUC 316 war dieses für weiter reichende Untersuchungen in vivo nicht 
geeignet. Stattdessen wurden die Radioliganden 6-(4-[4-[18F]Fluorbenzyl]piperazin-1-yl)benzo-
dioxin ([18F]33a), 6-(4-[4-[18F]Fluor-(3-methoxybenzyl)]piperazin-1-yl)benzodioxin ([18F]33b), 6-(4-
[4-[18F]Fluor-(3-hydroxybenzyl)]piperazin-1-yl)benzodioxin ([18F]33d) und 6-(4-[6-[18F]Fluor-
pyridin-3-yl]piperazin-1-yl)benzodioxin ([18F]33e) als Benzodioxin-Derivate mit abnehmender 
Lipophilie dargestellt. Dazu wurde die Vorstufe 1-(1,4-Benzodioxin-6-yl)piperazin mit den 
entsprechenden Aldehyden in einer gesamt-RCA von 35 %, 20 %, 9 % und 15 % gekoppelt. 
Die Autoradiographie an Rattenhirnschnitten bestätigte den Zusammenhang zwischen nicht-
spezifischer Bindung und Lipophilie und zeigte die potentielle Eignung von [18F]33d und [18F]33e 
als Radioligand. Aufgrund seiner günstigeren Affinität wurde von [18F]33e ex vivo die 
Organaufnahme, Hirnverteilung sowie Metabolisierungsraten bestimmt. 
Die Untersuchungen zeigten eine prinzipielle Eignung von [18F]33e zur Darstellung der D4 
Rezeptoren, aufgrund mangelnder Erfahrungswerte ist eine eindeutige Zuordnung bislang jedoch 
nicht möglich. Weitere Untersuchungen in vivo sind erforderlich, um die Darstellbarkeit der D4 
Rezeptoren mittels [18F]33e zu verifizieren. 
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 1. Introduction 
“Cogito ergo sum” – Man is presumed to be the only animal able to reflect its thinking. 
This designates our existence. Since the realization that the brain is the location of 
cognitive abilities, its function engrosses generations of scientists and still fascinates 
mankind. 
Hippocrates of Kos described already in the “Corpus Hippocratum” the brain and 
mentioned epilepsy as a functional brain disease1, but it was a long way until the 
awareness of a chemical signal transmission by Dale and Loewi (NP 1936) and its 
pathological aberrances. Nevertheless, the next step was now set to the corresponding 
neuroreceptors as the main interests. 
In vivo neuroreceptor imaging was conceivable for the first time in the mid of the 
1970s with the emergence of autoradiographic methods using radiotracers2. The 
possibility of a clinical application with new tomographic methods enabled the young 
field of neuroscience to determine functional correlations of neuroreceptor / 
neurotransmitter systems in the human brain. Nowadays, despite the development of a 
series of alternative non-radioactive brain imaging techniques, autoradiography still 
represents an integral part in functional brain mapping. Typical examples for 
neuroreceptor imaging with radiopharmaceuticals include: (1) normal physiology3, (2) 
pathophysiology4, for example, the interaction of receptors in psychiatric diseases or 
differentiation between state and trait, (3) disease monitoring4 for observation of 
progression or recession of a disease or a treatment, and (4) drug design and 
development including mechanisms and dosing5. The targets for some of the first 
successful radioligands for the central nervous system (CNS) were the in high density 
expressed receptors of dopamine D26 and serotonin 5-HT2A7 but meanwhile more than 
150 PET radioligands, labelled with 11C or 18F, for circa 20 neuroreceptor subtypes (from 
about 80 known and about 600 assumed8) were developed, including other dopamine9 
and serotonin subtypes10,11 , dopamine and serotonin transporters12-14 , adrenergic15, 
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nicotinic cholinergic16, muscarinic cholinergic17, GABAergic18,19 , histamine20, and others.  
 2. Basics and Methods  
2.1 Imaging of neurofunctions with positron emission 
tomography (PET) 
Positron emission tomography (PET) represents a modern nuclear medicine imaging 
technique which is mainly used for diagnostics and research in oncology21-23, cardiology24-
27, neurology28-31, and psychiatry32-34.  
 
 
Figure 2.1: Coincidence measurement of a normal PET scan setup. In the radionuclide of the 
tracer a proton converts into a neutron which results in the emission of a positron and an electron 
neutrino. After thermalisation the positron subsequently annihilates with an electron to γ-rays. 
For imaging only coincedently detected signals cause a count. p = proton, n = neutron, e+ = 
positron, e- = electron, νe = electron neutrino. 
 
Basic principle of PET is the recombination of a positron and an electron. Positrons 
represent the anti matter of electrons and vice versa. The recombination and subsequent 
annihilation results in axial symmetrically emitted γ-quantums of 511 keV, respectively, 
which can be detected easily. The positron sources consist of neutron deficient nuclides 
(e.g. 11C, 13N, 18F, etc.) which are stabilized by conversion of a proton to a neutron and 
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simultaneous emission of a positron and an electron neutrino. While the cross section for 
interaction with matter of the electron neutrino is extremely low, the positron is captured 
“real in time and space” by its anti matter (Fig. 2.1). After thermalisation the positron 
forms an exotic atom, the para-positronium, in a singulet state (S = 0) which decays by 
annihilation. Since only small kinetic energy of the positron is left this results in a 
generally negligible linear momentum during annihilation. Comparatively the 
unsymmetrical annihilation of the ortho positronium (triplet state, S = 1) is very rare35 
with 0.4 % in water and not perturbing. Thus, the collision of the positron with an 
electron causes in over 99.6 % of the cases the above mentioned coincedently and 
antipodal emitted γ-quantums. The γ-quantums are registered outside of the body by the 
circular arranged detectors of the PET scanner. The position of annihilation is located 
through a simultaneous detection of 511 keV incidents on the interception of the virtual 
lines (lines of response = LOR) between two detectors, respectively. The resolution of this 
method is mainly limited by the starting kinetic energy of the emitted positron which 
defines the local average range until thermalisation and annihilation. 
The application of a pharmaceutical labelled with a positron emitting nuclide allows an 
in vivo high-resoluting monitoring of the radiopharmaceutical non-invasively with a 
comparatively small radioactivity of tracers. Due to the generally small amounts of 
pharmaceuticals which are applied, physiological equilibriums remain unaffected36. The 
particular characteristic of this method is the possibility of an actual molecular imaging of 
biochemical processes in contrast to alternative tomographic methods like (X-ray) 
computer tomography (CT), nuclear magnetic resonance (NMR) and single photon 
emission computer tomography (SPECT). Since the coincidence measurement of the β+-
decay enables an exact correction for absorption and scattering of photons along the 
LORs, in contrast to SPECT radioactivity can be measured quantitatively by PET37. 
Assumed that the metabolism of the radiotracer is generally known bio-mathematical 
models allow for a quantification of these processes38-40. 
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2.2 Steps of radioligand development 
As illustrated in Figure 2.2, the development of a PET radioligand is a complex and 
multidisciplinary process. Starting from the identification of the biological target or ligand 
up to human studies or even approval, often plenty of years are needed and thousands of 
disappointments have to be got over. Due to that fact and the comparable small number 
of radiochemical working groups, statistically only every 15 years a new radiotracer 
comes to approval41.  
 
Figure 2.2: Simplified scheme of PET neuroreceptor radiopharmaceutical development (adapted 
with changes from5). Despite very strong interdisciplinary cooperation, core tasks of 
radiochemistry are shown in red.  
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Following descriptions especially shall enlighten the steps of development directly 
regarded to the radiochemist in developing a CNS radioligand.  
2.2.1 Preceding considerations 
The identification of the biological target which is the first and particularly for 
commercial drug development most important step is not discussed here in detail. 
Reasons are that the interests of this work lay in the reverse questioning of the relevance 
of a neuroreceptor of the central nervous system as such an appropriate target. 
Therefore, first considerations focus on the selection of a suitable ligand for labelling. 
Although the success of a radiopharmaceutical is mostly based on empiricism and 
serendipity a number of criteria will increase the chances: (1) the affinity of the ligand for 
the target receptor has to be high enough in compliance with its selectivity and target 
density. Because not all of the about 600 assumed different subreceptors can be tested or 
are known at all, it has to be balanced which are of critical interest. Determination of the 
binding profile has to be conducted to obtain affinities which is part of biological 
evaluation and is described in chapter 2.2.4. (2) The physico-chemical parameters of the 
potential tracers such as lipophilicity have to be in an adequate range for solubility, 
uptake and binding conditions. Consequences of lipophilicity are explicitly specified in 
chapter 2.5. (3) A radionuclide for PET or alternatively SPECT has to be selected before a 
basic labelling concept can be developed. While large molecules about 1000 u can be 
linked with a radiometal carrying marker, smaller ones need to be labelled by one of their 
atoms by a radionuclide (authentic tracer) or a radionuclide carrying substitute with 
similar physico-chemical properties (analogue tracer). (4) The limited prediction of 
success let it seem meaningful to keep option open for an easy derivatisation of the 
chosen ligand for a rapid readjustment of physikochemical parameters without decisive 
alteration of the chosen radiolabelling process and as far as possible of its 
pharmacological affinities. 
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2.2.2 Selection and production of short-lived positron emitting 
radionuclides especially fluorine-18 
As described above radionuclides for PET applications involve organic elements and 
metals (Tab. 2.1). Irrespective of the nature of the element a suitable PET nuclide has to 
fulfill a few basic demands. The physical half life should be in a range which is preferably 
short for a low exposure of patients and repeatability of experiments but nevertheless 
long enough to permit a few synthetic steps. The half life of some relevant organic 
nuclides like 13N (T1/2 = 9.96 min) or 15O (T1/2 = 2.03 min) is so short that integration in 
larger molecules is impossible in most cases but they can be converted on-line to small 
tracers like [13N]NH3 or [15O]OH2. Furthermore, the maximum decay energy and thus 
kinetic energy of the emitted positrons should be as low as possible because it limits the 
resolution of this imaging method. Beside this, electron capture (EC) as a competing 
decay mode exists for most positron emitters and is not desired in high percentage.  
 
Tab. 2.1: Nuclear data of important radionuclides for positron-emission tomography and their 
production routes [from42-45]. 
Nuclide Half life 
Percentage of 
β+-Decay 
Maximum β+-
Energy [MeV] 
Production 
Route 
11C 20.4 min β+ (99.8 %) 0.96 14N(p,α)11C 
13N 10.0 min β+ (100 %) 1.19 
12C(d,n)13N 
16O(p,α)13N 
15O 2.0 min β+ (99.9 %) 1.72 
14N(d,n)15O 
15N(p,n)15O 
18F 109.7 min β+ (97 %) 0.64 
18O(p,n)18F 
20Ne(d,α)18F 
73Se 7.1 h β+ (65 %) 1.30 75As(p,3n)73Se 
82Rb 1.3 min β+ (96 %) 3.35 
generator 
82Sr(T1/2 = 25d) 
120I 1.4 h β+ (64 %) 4.1 122Te(p,3n)120I 
 
  
Chapter 2: Basics and Methods 8 
Due to its low positron energy of 650 keV (mean tissue/water range of 0.3 mm) and its 
balanced half life of 109.7 min, fluorine-18 is a nearly ideal nuclide for PET and is the most 
often used radionuclide for diagnostics with PET although it is rarely an original part of a 
natural biomolecule. In favour its half life permits imaging protocols long enough for 
investigation of even slow tracer kinetics of up to about 6 h23. Radiometals can only be 
used as part of complex systems why application is more limited. However, the fact that 
many of them can be obtained as daughter nuclides from a generator is an 
unquestionable advantage and enables clinical utilization far away from a cyclotron unit. 
Since they are neutron deficient nuclides, positron emitters can generally not directly be 
produced by neutron bombardment in a reactor or by spallation sources. Major source of 
PET nuclides is therefore the bombardment with charged particles like protons or 
deuterons in a cyclotron. These projectiles are accelerated by an electric field circulated 
by a magnetic field and deflected by a capacitor to hit the target. Targets are special 
designed for its application as liquid or gas targets but always intensively cooled. In Figure 
2.3 a cross-section scetch of a water target for the production of [18F]fluoride is 
presented. After radiation of enriched [18O]OH2 with a 17 MeV proton beam the aqueous 
[18F]fluoride solution is directly transfered by a shielded capillary system into a hot cell.  
 
 
Figure 2.3: Interior of a cyclotron (GE PETtrace) for the production of PET-relevant nuclides 
(left)46. Position of targets is indicated by a blue circle. As an example the scheme of a middle 
pressure water target for production of [18F]F- over the 18O(p,n)reaction is displayed (right)42. The 
interior space of 3.5 mm thickness ingests a volume of 1.3 ml.  
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For electrophilic [18F]F2 production a Ne or [18O]O2 gas target  is used. Due to the low 
mass of produced [18F]fluorine an amount of inactive fluorine has to be added followed 
by a second short irradiation to override chemical adsorption47. Problems of the presence 
of such a carrier are discussed in the next chapter. 
2.2.3 Development of labelling methods with fluorine-18 
Radiosyntheses of organic molecules are very different from conventional organic 
chemistry. Thereby three alternatives are to differentiate depending on the amount of 
inactive tracer or rather isotope, called carrier. The chemistry of carrier-added (c.a.) 
reactions is more similar to those which are performed non-radioactive. Though, for most 
applications such as neuroreceptor imaging, a high amount of carrier is inappropriate due 
to its pharmacological influence. Therefore, in most cases a carrier free (c.f.) situation is 
aspired. Due to the fact that this is only possible for nuclides without natural abundance 
(or extremely little such as technetium or astate) the normal situation involves a small 
amount of carrier (no-carrier-added = n.c.a.). This is displayed in the molar activity (AM) or 
specific activity (AS)48: 
. (2.1) 
. (2.2) 
For low specific / molar activity material are inactive reaction partners in an extreme 
excess. Thus, the reaction kinetics of labelling processes with reactants of high AS (AM) is 
pseudo first order. Besides the short half-life, non-equimolarity and nanomolare range 
make n.c.a. reactions difficult and necessitate special synthetic techniques. Because of 
the difficulty to determine the specific activity of n.c.a. [18F]fluoride direct after 
production, reproducibility is often more problematic than in the same but non-
radioactive and therefore equimolecular reactions. Nevertheless, selecting fluorine-18 as 
the radionuclide of choice the next step has to be a feasible radiosynthesis strategy. In 
most cases especially in authentic labelling the fluorine carrying moiety is aromatic. It is 
preferred due to the normally higher in vivo stability of aromatic fluoro compounds. This 
leads to two conceivable options from the general concepts of fluoro-organic chemistry: 
electrophilic and nucleophilic substitution.  
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A problem that should not be underestimated is the identification and separation of 
the obtained products which can only identified indirectly by chromatographic methods 
using a standard compound due to the extremely low masses under n.c.a. conditions. 
Thus, accidental consistency can appear and losses of activity due to adsorption often 
cause bad comparability of yields when working under n.c.a. conditions.  
Apart from the few times when simple solid phase extraction can be used, separation 
of products requires generally high performance (pressure) liquid chromatography 
(HPLC). Besides alluded losses of n.c.a. compounds HPLC separation involves other 
problems: 
- When the number or concentration of reactants is high it can overlay the active 
product fraction. Efficient prepurification sometimes including a derivatisation 
step can help but has to be in balance with time and accessory product loss. 
- Similar substituents can be challenging. In some cases even the substitution of 
nitro by fluorine leads to such compounds which cannot be separated acceptably 
by HPLC. Reduction of nitro to amine after fluorination results in viable separation 
but presents an undesired time consuming secondary reaction step. 
 
Electrophilic fluorination  
The electrophilic fluorination with elemental F2 is a suitable method in organic 
chemistry although its toxicity, reactivity and gaseous state makes it difficult to handle. 
Furthermore, handling a radioactive species causes even higher problems. The main 
problem, however, in using [18F]F2 is, that it cannot be obtained without a considerable 
amount of inactive fluorine. Thus, reactions are always carrier-added ([18F]F- < 3.7·1015 
Bq/mmol; [18F]F2 < 3.7·1011 Bq/mmol)49. Electrophilic fluorination is therefore only 
suitable to generate radiotracers when a pharmacologically and metabolically relevant 
amount can be tolerated, e.g. aromatic amino acids like 2-[18F]fluoro-L-tyrosine50 or 6-
[18F]fluoro-L–DOPA51,52. For these and other aromatic compounds many different 
electrophilic fluorination methods are described using [18F]F2 or AcOO[18F]F53, Xe[18F]F254 
often in combination with demetallation reactions with silicon, germanium, stannyl and 
mercury. Over the years several reviews about electrophilic fluorination were published 
describing these methods in detail55-57. 
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Nucleophilic fluorination 
In principle [18F]fluoride can be obtained almost free of inactive fluoride (only very 
small amounts of fluorine-19 from surroundings). Therefore, no-carrier-added 
nucleophilic fluorination methods play a more decisive role and are the only possibility for 
the 18F-fluorination of neuroligands with high AS. One problem is, that n.c.a. [18F]fluoride 
is obtained in form of an aqueous solution from the target. Here, the fluoride is highly 
solvatisated (Δhydrate = 506 kJ/mol) and therefore not nucleophilic. Before a 18F-
substitution can be conducted, the [18F]fluoride solution has to be dried generally by 
azeotropic distillation with acetonitrile. Then the dry [18F]fluoride is resolubilized by a 
polar and aprotic solvent, e.g. dimethyl sulfoxide (DMSO), N,N-dimethyl formamide 
(DMF), N,N-dimethyl acetamide (DMAA) or acetonitrile (MeCN). To avoid a loss of 
radioactivity during distillation, as well as wall adsorption, carbonates or oxalates are 
added as non-nucleofugic base and non-isotopic carrier. The binding strength of the 
counter cation (mostly potassium or cesium) to the dried [18F]F- affects its chemical 
reactivity. Voluminous complexes of the cation with crown ethers or aminopolyethers 
such as Kryptofix®2.2.2, create a nearly “naked” fluoride in dipolar aprotic solvents and 
increase its nucleophilicity and hence its reactivity dramatically but unfortunately also its 
basicity58-60.  
 
 
Figure 2.4: Nucleophilic aromatic 18F-fluorination of activated arenes.60,61 
 
A limitation of an aromatic nucleophilic fluorination is the required electron deficiency 
of the aromatic ring. Nucleophilic substitution can be achieved through the presence of 
an activating group. Favourable are electron withdrawing substituents in ortho or para 
position to a leaving group. For activating eminently suitable are nitro, cyano or carbonyl 
groups because they feature good π-acceptors with high Hammett σ-constants62. Further 
reaction steps can contain the cleavage of these groups as well as cleavage or 
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transformation of contingently required protection groups. 
For the underlying SN(Ar) mechanism in arenes, fluorine itself is one of the best leaving 
group but cannot be used for n.c.a. syntheses. It is followed by the nitro group and the 
trimethylammonium cation. The latter often results in higher yields but in case of poorly 
activating substituents and of sterical hindrance [18F]fluoromethane is obtained as main 
product63,64. Other halogens can also be used especially for SN(Ar) reaction in pyridines65.  
2.2.4 Special methods in n.c.a. 18F-fluorination 
The above described methods display the basic methods of direct labelling with 
fluorine-18. Due to their limitation many applications demand progressive methodical 
developments, including special precursors, substrates, reaction parameters or pathways. 
Following labelling methods used in this work are considered in detail. 
2.2.4.1 Secondary labelling compounds 
As mentioned in chapter 2.2.3 it is desirable to introduce fluorine-18 at the latest 
possible reaction step, due to the short half life of 109.7 min. Therefore, direct 
nucleophilic fluorination represents the preferred labelling method. Further eligible 18F-
labelling reactions consist of maximum two steps: the actual 18F-fluorination and, if 
necessary, cleavage of protection groups. Nevertheless, some aromatic molecules do not 
admit direct labelling due to a lack of electron withdrawing activation. Other 
disadvantages of direct fluorination are the relatively harsh conditions needed. 
Decomposition or racemisation can occur with sensitive compounds. In these cases build-
up syntheses are necessary starting from small molecules. An assortment of these small 
aromatic molecules which are meanwhile established as labelling synthons are listed in 
Figure 2.5. Some of these synthons have to be build in some reaction steps themselves. 
N.c.a. 4-[18F]fluorophenol for example cannot be obtained by direct labelling (Fig. 2.5; A). 
For build-up of 18F-fluorinated arylethers the synthon has to be generated by labelling the 
ketone and its transformation by Bayer-Villiger oxidation and subsequent saponification 
of the ester66. Other build-up syntheses include oxidation, reduction or hydrolysation of a 
strongly activating aryl-substituent which lead to a variation of secondary compounds. 
Typical starting agents are ketones (Fig. 2.5; B67, C68,69), aldehydes (Fig. 2.5; D70, E71,72) or 
sulfonyles (Fig. 2.5; F73,74) and pyridines (Fig. 2.5; G75,76). As substituents with extremely 
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high Hammet constants the nitro (Fig. 2.5; H77) and nitrile (Fig. 2.5; I78,79) group are of 
special interest and can be easily converted to amines. It is tried to avoid longer pathways 
but in some cases yields and reaction time reach the level of direct labelling. For the 
synthons a further advantage consists in an increased possibility of generating 
trimethylammonium triflates as precursors. More complex biomolecules mostly contain 
methylation sensitive moieties like basic amines.  
Nevertheless, the most common used secondary labelling compounds are not 
aromatic. 2-[18F]fluoroethyl tosylate80 and [18F]fluoromethyl bromide81 are mostly used to 
substitute the methyl of a methoxy group but can commonly not used in authentic 
labelling.  
 
Figure 2.5: List of important aromatic synthons for build-up syntheses.  
 
In aromatic 18F-chemistry [18F]fluorobenzaldehyde and its derivatives are the most 
versatile building blocks. The highly activating carbonyl group leads to high radiochemical 
yields with a vast amount of derivatives in short reaction times, especially when 
trimethylammonium triflate is used as leaving group57. Subsequently the aldehyde group 
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can be transferred to the carboacid, to the benzyl alcohol and benzyl halide and others as 
displayed in Figure 2.6. [18F]Fluorobenzylethers and –amines can hereby easily be 
generated.  
 
Figure 2.6: Sample of important build-up syntheses starting from 4-[18F]fluorobenzaldehyde 
(adapted with changes from82). 
2.2.4.2 Iodonium salts in fluorine-18 chemistry 
Diaryl iodonium salts have recently proven excellent precursors for aromatic 
radiofluorination. They consist of a iodo(III) species covalently bound to two aryl groups 
and carrying a positive charge. The corresponding anion mostly is a halide, triflate or 
tosylate. Since their first application in fluorine chemistry85 they proved as highly potent 
precursors especially to introduce [18F]fluoride in electron rich aryls which is otherwise 
not possible. Despite its high relevance, the mechanism of this fluorination is not totally 
understood. Three different processes are involved and controversially discussed. First 
consideration is an analogous mechanism to standard SN(Ar) fluorination. Here, the 
iodo(III) moiety acts as activating and leaving group concurrently. In a first step the 
nucleophile ([18F]F-) attacks the onium iodine to bind covalently. Due to the two lone 
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electron pairs (phantom ligands) a trigonal bipyramidal intermediate state is composed as 
displayed in Figure 2.8 (A). 
 
Figure 2.7: Nucleophilic fluorination of an unsymmetrical iodonium salt. 
 
Subsequently the complex undergoes intramolecular aromatic nucleophilic 
substitution. In this model a bulkier aryl group would occupy the less encumbered 
equatorial position with two near and two far neighbours. Thus, the bulkier ligand is 
closer to the attacking nucleophile when “collapsing”. Such an ortho-effect in fact is 
observed84-86 also in corresponding radiofluorination reactions via diaryliodonium 
salts87,88. It is an explanation why normally desactivating methyl groups in ortho-position 
lead to higher yields. Nevertheless, this model cannot explain the influence of the counter 
anion and the fact that the ortho-effect even with four methyl-substitutes is 
comparatively small. Furthermore, studies with phosphorous pentahydride showed that 
apical-equatorial interactions in a trigonal bipyramidal structure are symmetry 
forbidden89. By Berry pseudo rotation tetragonal pyramidal constitutions can be reached 
in which an interaction between the nucleophile and an aryl ligand would be symmetry 
allowed90. A resulting reductive elimination, similar to a metal catalyzed coupling, would 
be effected by the counter anion. Here the two aryls now are equidistant to the 
nucleophile (B).  
The ortho-effect needs to be explained with kinetic effects during elimination, since 
elimination of the bulkier ligand leads to a faster decrease of tension. Otherwise the 
extreme softness of iodine could possibly reduce the grade of forbiddance. 
So far, an influence of radical reactions can also be discussed. On the one hand a 
radical mechanism cannot stand on its own because above described influences, e.g. the 
ortho-effect would not be explainable. On the other hand the use of radical scavengers 
like 2,2,6,6-tetramethylpiperidinoxyl (TEMPO) improve radiochemical yields or 
reproducability91,92. Furthermore, side products which can only be explained with 
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radicals, like biaryls are observed. Therefore, it is probably that a radical mechanism only 
takes place in decomposition of the iodonium salt in absence of a nucleophile. 
 
Figure 2.8: Comparison of the two assumed mechanisms of nucleophilic reaction on iodonium 
salts93.  
 
A further characteristic of iodonium reactions is the bad use of DMSO as solvent94-96. 
The semipolar character of the S=O “lance” of DMSO leads to S+-O- which strongly 
solvates cations97. Solvation of the iodine(III) moiety would reduce its activity. Otherwise, 
use of DMSO sometimes is described when phase transfer catalysts other than Kryptofix 
are used98. All other standard solvents can be used but without a clear preference.  
Up to now the 18F-labelled product of a iodonium precursor is generally used as a 
synthon for build up syntheses. The reason is that in the case of more complex molecules 
past studies led to very low RCY or failed completely or the iodonium salts were not 
achievable. 
2.2.4.3 Palladium-mediated cross-coupling reactions in 18F-radiosyntheses 
The role of transition metals in radiochemistry especially with fluorine-18 has 
increased in recent years. One of the most upcoming reactions is the copper-mediated 
[3+2] cycloaddition from Huisgen et. al99, often called click-chemistry100,101. It is mainly 
used to introduce 18F-labelled linkers in large molecules like peptides and proteins but 
meanwhile also in smaller ones102. Furthermore, Pd- and Rh-mediated decarbonylation is 
sometimes used for removing aldehyde groups. 
Cross-coupling reactions using Pd(0) complexes and specific designed ligands to form 
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carbon-carbon or carbon-heteroatom bonds, starting from the corresponding arylhalids 
have distinctly enhanced organic chemistry syntheses in recent years by gaining access to 
challenging structures in single-step routes with high yields103,104. This is confirmed by 
awarding Richard F. Heck, Ei-ichi Negishi, and Akira Suzuki the Nobel Prize in 2010. 
Advantages like high reaction rates and yields and a comparable easy handling make it 
very interesting for syntheses with short-lived positron emitters. Nevertheless, only some 
applications of palladium in fluorine-18 chemistry were released until now. Several 
problems can cause this fact. On the one hand slight or different solubility of reactants 
can complicate an automated synthesis. Furthermore, the high number of reactands 
together with the standard usage of unpolar solvents complicates isolation and 
separation procedures of n.c.a. products. On the other hand for the most palladium 
catalysed syntheses with aromatics, arylhalides are required. [18F]Fluoroarylhalides can 
only conveniently be obtained suitable from iodonium precursors. Former reaction routs, 
starting from a trimethylammonium salt precursor resulted in poor radiochemical 
yields105. This nihilates advantages of following reaction steps. But often also iodonium 
precursors result in low reproducability of radiochemical yields. 
 
Tab. 2.2: Previous applications of Pd-mediated cross-coupling reactions with fluorine-18 labelled 
synthons (Ph = C6H5). 
 
Type 
 
Entry 
 
18F-coupling synthon 
 
RCY 
 
Lit. 
Stille Ph-SnBu3 [18F]F-Ph-Br 70-90 % 106 
Stille H2C=CH- SnBu3 [18F]F-Ph-I 56-53 % 107 
Stille CHRI=CRII-SnBu3 [18F]F-Ph-Br 56-74 % 108 
Stille Nucleoside-SnBu3 [18F]F-Ph-I 50-70 % 109 
Sonogashira HO-CR2CCH [18F]F-Ph-I 34-88 % 110 
Hartwig-
Buchwald 
R2NH [18F]F-Ph-Br ~60 % 111 
Hartwig-
Buchwald 
Indole-NH [18F]F-Ph-I 36-70 % 112 
Suzuki Ph-B(OH)2 [18F]F-Ph-I ~90 % 113 
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Nevertheless, described cross-coupling reactions generally resulted in high yield (Tab. 
2.2). This underlines the potential of these reaction types for fluorine-18 chemistry. The 
Pd-catalyzed cross-coupling amination (Hartwig-Buchwald) directly leads to 
arylamines114,115. These structures exhibit a central structural motif in many drugs and 
other biologically active compounds such as neuroligands. The reaction mechanism is 
very similar to those of other cross-coupling reactions and displayed in Figure 2.9.  
 
 
 
Figure 2.9: Mechanism of the Hartwig-Buchwald N-arylation with 4-[18F]fluorohalobenzene as 
example for a palladium-mediated cross-coupling reaction circle (adapted with changes from204). 
 
In order to find the optimal parameters for the chosen entries there are many 
possibilities for variation. As precatalysts, Pd2(dba)3 and Pd(OAc)2 are the most common 
ones but many other exist. The selection of the Pd source impacts the efficient formation 
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 (2.4) 
 
With the radioligand the dissociation constant (KD) and the number of receptors (Bmax) 
can directly be measured. Cells exposing the specific receptor (preferently overexpressed) 
are treated with different concentrations of the radioligand, washed and subsequently 
measured. The expected graph obtained by plotting bound radioactive ligand (RL or B) 
versus the concentration of free ligand (cf. Fig. 2.10) should come to saturation when all 
receptors are occupied, resulting [RL]max = [R]total = Bmax (saturation experiment). Due to 
(2.5) and (2.6) the KD value can be determined directly. 
 (2.5) 
 
(2.6) 
However, the obtained total binding always contains a non- and unspecific binding 
fraction (s. chapter 2.4) due to all other bindings of the radioligand apart from the desired 
one. These binding parts ideally lead to a linear growth after saturation of the specific 
binding. Non- and unspecific binding can be determined and subtracted subsequently by 
a further measurement at high concentrations of the radioligand. Since unspecific binding 
often results in a deviation from linear growth normally a second experiment is 
conducted instead with involve concurrent receptor saturation with an excess of a 
different highly affine ligand. The inactive standard compound cannot be used because it 
would also saturate unspecific binding. 
 
Chapter 2: Basics and Methods 21 
 
Figure 2.10: Generalized example of a saturation experiment to determine the dissociation 
constant (KD) of a radioligand. The specific binding curve (blue) is obtained by subtracting the 
measured non/unspecific binding (red) from the total binding (black). Measured bound 
radioactivity (B) of radioligand to the receptors [RL] is plotted against its concentration (c). 
 
Are inactive ligands available only, it is possible to determine binding affinities 
indirectly. For this purpose a radioligand (mostly tritiated) with known KD for the specific 
receptor is applied in a fixed concentration and mixed with different concentrations of 
the determining inactive ligand (competition study) similar to the above described 
experiment. At low concentrations a plateau shows the total binding until beginning of 
competition. The curve ends in a second plateau which displays the nonspecific binding 
content. The inflexion point of the curve marks the concentration where half of the 
receptor is ocuppied (IC50) which is correlated with the ligand-receptor affinity. 
Dependent on the KD of the used radioligand and its concentration Cheng and Prusoff 
established the following correlation116: 
 (2.7) 
 
This equation results from enzyme kinetics. For an enzyme [E] and its substrate [S] 
transformation to the product [P] is determined by its reaction constants k. 
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radioligand instead of [S] this is the Cheng-Prusoff equation (2.7). 
 
 
 
Figure 2.11: Generalized example of a competition experiment to determine the affinity of an 
inactive ligand by substituting an active one. Measured bound radioactivity (B) of radioligand to 
the receptors [RL*] is plotted against the logarithmic concentration of the inactive ligand. 
 
Theoretically, the inhibitory constant (Ki) should be identical with the dissociation 
constant (KD) from saturation experiments but it is generally higher due to the fact that 
the nonspecific (but not unspecific) binding fraction can be measured by this method. 
Unspecific binding of the radioligand is also occupied by the cold ligand but in an 
unpredictable way because of different and unknown nature and affinity of the involved 
binding sites from different receptors. 
Binding affinities, although of particular interest, are not the only criterion of suitability 
of ligands. Further criteria can only be determined with the n.c.a. labelled product. In 
vitro autoradiography studies are conducted with brain slices of small animals containing 
the relevant parts of the brain where the receptor of interest is expressed. By blocking 
with an excess of inactive standard compounds nonspecific binding in brain tissue can be 
estimated. Very high values above 70 % mark a “knock-out” criterion for most 
radioligands. Is the distribution of the determined receptor significant and its density 
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high, a higher non-specific binding content can be tolerated. If nonspecific binding is low 
enough, the obtained autoradiographic images should represent regions of high receptor 
concentration and can be compared with references. In case of a non-existence of such a 
reference receptor localisation has to be determined or narrowed down by laborious 
genetic methods. Results from such methods like RNA hybridisation studies or special 
antigenes can be used for comparison but often give unsure conclusions.  
If the tracer show low non-specific binding and an expected brain distribution in vitro, 
ex vivo studies lead to biodistribution and pharmacokinetics. For CNS radiotracers 
especially brain uptake and metabolites in this organ are of special interest. For 
identification of observed metabolites standard compounds of assumed metabolic 
products have to be synthesized. For a future modelling and therefore quantification 
knowledge about pharmacokinetics is necessary for subsequent preclinical studies with 
small animal PET scanners. 
It has to be considered that the behaviour of tracers in small animal tissue can 
decisively differ to that in humans. On the one hand this can lead to a failure in later (at 
least clinical) steps but more problematic is the reverse case when a radioligand suitable 
for human application fails in animal experiments. 
2.3 Dopamine receptors and ligands 
2.3.1 Subtypes of dopamine receptors – the D4 receptor 
All fife known subreceptors of the dopaminergic system are G-protein coupled ones. 
That means after binding of a ligand the induced signal from the activated receptor is 
transmitted inside the cell by a second messenger cascade starting with coupling of 
receptor parts to a guanine nucleotide (G-protein), the effector. For further signal 
transduction subunits of the G-protein affect either adenylate cyclase (Gs, Gi) or 
phospholipase C (Gq). Dopamine receptors affect the adenylate cyclase and therefore the 
production of cyclic AMP117.  
At first two different types of dopamine receptors could be differentiated. The one 
activates the adenylate cyclase (D1), the other inhibits it (D2). These two receptors 
account for nearly the whole contingent of dopamine receptors in the brain and were 
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therefore considered as the only ones for a long time118. Not until the late 80th further 
subtypes were identified with a significantly lower occurrence. They could be allocated by 
their pharmacologic behaviour to one of the two types119, or now families. On the one 
hand the D5 receptor120 (or D1B in mice and rats) which belongs to the D1 family and on 
the other hand the D3121 and D4122 receptors which belong to the D2 family. That they all 
are different is directly represented by the fact that although they all represent dopamine 
receptors their affinity to dopamine is different. Dopamine affinity follows the order D3 > 
D5 > D2 > D4 > D1123. 
 
 
Figure 2.12: Sketch of the structure of a dopamine receptor as a typical G protein coupled 
receptor (GPCR). The membrane spanning helices (1-7) are displayed as tubes. D2-like receptors 
(D2, D3, D4) have a shorter C-terminus and a longer third intracellular loop (red circle). They also 
defer from the D2-like receptors in a different number of glycosylation sites at the N-terminus. E = 
Extracellular loop; I = Intracellular loop 
 
Like all G protein coupled receptors thouse for dopamine consist of seven 
transmembrane helices (TM), connected with three intracellular and three extracellular 
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loops (Fig. 2.12). The similarity of the helices within the family of D1-like receptors is 
about 80 %. In contrast the D2 receptor shares 75 % of homology with the D3 receptor and 
only 53 % with D4124-126. Meanwhile for all subtypes a various number of polymorphisms is 
known, mostly represented by single nucleotide polymorphisms or located in uncoding 
regions of the corresponding gene (UTR). From the D2 receptor two phenotypes (D2short 
and D2long) exist with a different length of the third intracellular loop (I3). The importance 
of this loop is based on its function to bind to the G protein effector upon receptor 
activation. A characteristic of the D4 receptor is its hypervariability of this region by a high 
number (2-11) of tandem repeat (VNTR). Therefore, this receptor is normally written as 
D4.x, where x is the number of repeats. Data of the dopamine receptor subtypes are 
summerized in Table 2.5. 
 
Table 2.5: Some molecular characteristics of the dopamine receptors.127,238 
Family D1-like D2-like 
Subreceptor D1 D5 D2 D3 D4 
Chromosomal 
location 
5q35.1 4p16.1 11q23 3q13.3 11p15.5 
Amino acids 446 477 414-443 400 387-515 
Polymorphisms 12 17 18 8 over 30 
Splice variants   D2s; D2L  10 (VNTR) 
G protein Gs (stimulatory) Gi (inhibitory) Go (other) 
Effect activates cAMP inhibits cAMP 
Main localisation 
in human brain 
Nucleus 
acumbens, 
Basal 
ganglia 
Limpic 
system 
Corpus 
striatum 
Cerebellum, 
Nucleus 
acumbens 
Prefrontal 
cortex, 
Limbic 
system, 
 
The D4 receptor is attributed to an extremely low density in brain128,129. Therefore, 
there is still ambiguity about physiological and pathophysiological functions as well as 
exact local density of this subtype130,131, although the dopamine D4 receptor was already 
first cloned in 1991132. Immunohistochemistry and in vitro hybridization led to 
contradicting findings and differences between species, but revealed an expected higher 
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expression of D4 in the prefrontal cortex and the limbic system and also in the temporal 
cortex, parts of tectum and cerebellum130,131,133-135. 
The D4 receptor became of more interest since it had emerged that the atypical 
neuroleptic clozapine showed a tenfold higher affinity for D4 than for D2 receptor132. 
Therefore, the higher efficacy of clozapine to non-responders as well as to therapy of 
negative symptomatology was discussed as a consequence of D4 binding. The fact that 
further studies did not reproducibly evidence a direct relation between schizophrenia and 
the D4 receptor density136,137, which could also be a result of a lack of true D4 antagonists, 
its role in psychiatric diseases remains unclear. 
It is assumed that differences in haplotypes of the D4 receptor (tandem repeats) which 
are described above, are responsible for libido dysfunctions as well as for other 
neurobehavioural disorders like attention deficit hyperactivity disorder138,139, novelty 
seeking140,141 and substance abuse142. 
2.3.2 Dopamine D4 receptor subtype-selective ligands 
Due to the low brain density of D4 receptors requirements of affinity and selectivity for 
new subtype-selective radioligands are high. Up to now various selective ligands were 
developed for the D4 receptor143-145. It attracts attention that they all share definite 
structure similarities. The basic structure consists of a nitrogen containing backbone 
flanked with two aromatic rings, one of them being an aryl amine (s. Fig. 2.13). From one 
of the first selective D4 agonist PD-168077, developed by Glase146 in 1997, up to the more 
novel developments, such as the benzoimidazole A-381393147, these molecule parts are 
fix components. The most important is the arylamine moiety. It is necessary for a suitable 
selectivity for the D2 receptor. As main representative D2 has statistically the highest 
binding probability within its family. Pharmacologically similar but underrepresented 
receptors D3 and D4 are therefore definitely discriminated. Simpson et al.148 could show 
that one side of the binding crevice is more hindered in D2 than in D4. From the 
transmembrane helices (TM) 2, 3 and 7 of the D2 receptor bulky aromatic amino acids 
extend into the crevice. In contrast, at the D4 receptor they are replaced by small aliphatic 
ones (valine and leucine). The arylamine moiety of a ligand should retard D2 binding due 
to its bulky character. N-aryls are in a planar and not tetrahedral orientation like other 
amines, since the free electron pair of the nitrogen overlaps with the ∏-system. 
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Therefore, the aromatic moiety cannot avoid the clash with bulky amino acids in the D2 
receptor. Replacing nitrogen against carbon decreases the selectivity significantly. In this 
case the aryl moiety of the ligand can be oriented away by rotating. 
 
 
Figure 2.13: Basic components of a D4 selective ligand influencing its affinity and selectivity. 
 
 
Figure 2.14: Simplified model of a D4 selective ligand in a D2 (left) and D4 (right) binding crevice. 
Bulky aromatic amino acids in D2 (red) hinder binding of sterically demanding ligand moieties at 
this part of the crevice. In D4 the same space of the helices is occupied by amino acids with small 
residues (green). Here the ligand fits. Also shown is the interaction with the basic amine and with 
the second aromatic ring. Serine(TM5)-hydrogen bridge interaction is not displayed. TM = 
Transmembrane helix; Trp = Tryptophane; Tyr = Tyrosine; Phe = Phenylalanine; Val = Valine; Leu = 
Leucine; Asp = Aspartic acid; ArC = Microdomain of aromatic amino acids. 
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The influence and necessity of other parts of a selective D4 ligand is discussed more 
controversially. Although most D4 ligands consist of a piperazine, substitution by 
piperidine seems to be sufficient as long as the above described N-aryl remains 
untouched. While the basicity of the N-aryl is decreased it suffices for interaction with 
aspartic acid at TM3 (Asp114). The carbon linker in D4 ligands mostly consists of a CH2 
group but some exceptions are known as well. CoMFA (comparative molecular field 
analysis) studies show that the ideal distance between the two aromatic moieties lies 
within 8 Å. Longer linkers often decrease D4 selectivity but can lead to other selectivities. 
Introduction of an N-butylcarboxamide chain as linker can cause D3 selectivity as 
observed at azaindoles149-151. It is not proven that the second aromatic moiety is essential 
but probably facilitates affinity to G protein coupled receptors by interacting with several 
aromatic amino acids at TM6 (Trp386, Phe389, Phe390). Groups on this aromatic ring 
which can form hydrogen bridges (N, NH, OH), as it is known for dopamine itself, can also 
assist binding by interacting with serine residues at TM5 (Ser193, Ser194, Ser197). 
Since all this assumptions are collected with statistical, computanal and cloning studies 
using known selective ligands, one can consider ligand development from this point. 
 
 
Figure 2.15: Change of D4 affinity and selectivity by substituation of the basic 1-phenyl-4-
benzylpiperazine backbone151. 
 
The easiest structure which fulfils minimal requirements of the above mentioned 
points is 1-phenyl-4-benzylpiperazine. The fact that this structure is very unselective and 
even more affine for D2 shows the differences between known theory and reality. A 
problem of aryl-aryl interaction is the balance between steric hindrance on the one hand 
and ∏-∏ interaction on the other hand. The latter can possibly lead to a higher D2 binding 
of this ligand. But a hydroxyl substitution in 4-position of the N-aryl moiety lowers D2 and 
increases D4 affinity. Further substitution by a methoxy group at this position leads to a 
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compound with shows the same moderate D4 affinity but now is inactive at the D2 and D3 
receptor152. 
 
 
Figure 2.16: A high promising class of D4 selective ligands starts from 2- or 3-substituted indole. 
Different variations lead to ligands with high D4 affinity and high selectivity within the D2 family152-
155. 
 
It can be expected that further developments would extend substitution at the N-aryl. 
Nevertheless, most of the selective D4 ligands developed until now contain only a small N-
aryl moiety with less variation (e.g. OMe, F, Cl, I). Instead, the main variation part 
presents the other aromatic side beyond the spacer carbon. A wide group of subtype-
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selective D4 ligands exhibit N-heteroaromatics of indene with a spacer linkage in 2- or 3-
position. Starting from the unsubstituted indole linked in 3-position (Fig. 2.16; A) it shows 
good affinity but moderate selectivity. A 4-chloro substitution of the N-aryl ring increases 
all measured affinities without clear priority but results in a 3-fold higher selectivity for 
D4. The insertion of a second nitrogen in the aromatic system increases selectivity 
dramatically. It leads to a higher activity at D4 with exception of the benzoimidazoles (Fig. 
2.16; B and B1) in all cases153-156. Thereby also a higher affinity of the 4-chloro derivatives 
can be observed as described for indole. Instead of a second heteroatom, the 
introduction of a strong electron-withdrawing group like nitrile can also be successful. 
Here the best values for both affinity and selectivity are obtained with the fluorine 
derivative157. 
The above mentioned expansion of the N-aryl moiety is strived by Hodgetts et al.158, 
who enlarged the N-aryl side by adding a heterocyclic moiety. As a continuation of the 
promising methoxy substituent they used oxygen as heteroatoms. On the other hand the 
linked aromatic side was derivatised by methoxy or halo substituents. Using benzodioxine 
as N-aryl moiety resulted in very high selectivities and affinities for the D4 receptor for 
nearly all determined structures. Most of them represent antagonists of D4 which are 
clearly underrepresented in the total pool of D4 ligands. Ligands with a true D4 
antagonism are useful in determining the D4 hypothesis of schizophrenia as mentioned in 
chapter 2.4.1.  
 
 
Figure 2.17: Different D4 agonists from the class of benzodioxinpiperazines158. 
 
The fact that the residues used for variation are mostly methoxy or halo groups is 
obliged for radiochemical development. Therefore, fluorine or iodine are more often 
components of a promising ligand than usual. Furthermore, besides the authentic 
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labelling of methoxy with 11C, this group could also be displaced by a [18F]fluoroethoxy 
moiety. Thus for radiochemists possibilities exist to choose from the pool of known and 
characterized ligands such compounds, which can be labelled without strong 
pharmacological alterations.  
2.4 Lipophilicity – A key property for radioligands 
The International Union of Pure and Applied Chemistry (IUPAC) defines lipophilicity as 
the affinity of a molecule or moiety for a non-polar environment159,160. Besides the dipole 
characteristics of compound parts the lipophilicity of a molecule is influenced by 
molecular size and weight, hydrogen binding capacity, resonance contributions and 3-D 
structure. As a physicochemical property it can be assessed theoretically or measured 
experimentally by different methods. The most common experimental measurement is 
partitioning of a compound between an octanol and an aqueous buffer. This is also 
referred to as “shake flask” method. The ratio of the compound concentration in the two 
layers is defined as the measure for lipophilicity. It is measured by HPLC or in case of a 
radiotracer by determination of the radioactivity distribution. Octanol is mostly used to 
mimic the bilipid layer of a cell membrane but it is not agreed as best choice161-163. Other 
used organic solvents include hexane, decane and several branched alcohols164,165. As an 
advantage the measured value contains the lipophilicity of all species in solution 
(Log D)166. Another method is the liquid / solid partitioning on a HPLC column with a 
buffered solvent. In this case the obtained retention times can be compared with 
standard compounds where the Log P values are well known167-169. It is a very fast method 
but only one species in solution is measured (Log P) and unforeseen interactions with 
mobile and stationary phase can create a variance from actual distribution coefficients. 
The buffers commonly used are adjusted at pH 7.4, since this represents the physiological 
pH value of blood serum. With computational methods electronic and resonance 
contributions of the whole molecule are difficult to calculate adequately. This leads often 
to higher values than obtained by experimental methods.  
For drug development of radioactive and as well non-radioactive pharmaceuticals, 
lipophilicity exhibits a pivotal role, since it is important for all four essential parameters in 
pharmacokinetics: adsorption, distribution, metabolism, and elimination (ADME). In the 
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following some of these effects are discussed in more detail. 
 
Plasma protein binding 
In most cases an administered pharmaceutical does not exist in a free form but is 
bound reversibly to proteins in plasma170. An equilibrium between bound and unbound 
condition exists, similar to that described for a receptor and a ligand. The higher the 
lipophilicity of a compound, the more is bound. Albumin is the first plasma protein to 
mention for this interaction, especially for acidic drugs like aspirin or diazepam171,172. 
Several other proteins like α1-glycoprotein for basic molecules like propranolol or 
quinidine are also relevant. In the majority of therapeutic drugs the bound allotment is 
nearly steady and displays a reservoir. The large protein-drug complex can neither reach 
its pharmacological target nor be eliminated. Due to the very rapid equilibration, 
removed free molecules are delivered directly from bound ones. The distinct lower 
concentration of radiotracers can lead to a total absorption of high lipophilic 
pharmaceuticals due to protein binding. This is one reason why radiotracer concentration 
beyond cell membranes like the blood brain barrier (BBB) decreases with high tracer 
lipophilicity. 
 
Permeation of blood-brain barrier (BBB) 
The BBB consists of a layer of endothelial cells which protects the sensitive organ from 
harmful polar substances173,174. Its endothelic cells lay closer than in other tissue. Besides 
the tight junctions the presence of efflux pumps and specific enzymes within the 
endothelic cells efficiently isolate the brain from the periphery. The barrier is 
impermeable for all hydrophilic molecules bigger than urea (M = 60 g/mol; Ø ≈ 0.2 nm). 
To facilitate passage of essential hydrophilic molecules like amino acids and glucose there 
are different carriers175,176. Some pharmaceuticals can use those carriers to penetrate 
without regard of their lipophilicity. Otherwise pharmaceuticals can also be affine to 
efflux pumps (for instance p-glycoprotein (PGP)) or functional metabolic enzymes177,178. 
For all other molecules a higher lipophilicity should lead to a higher permeation rate and 
result in a linear connection. In reality high lipophilic compounds show a distinct lower 
brain uptake. A higher non-specific binding to efflux pumps and enzymes can be a 
reason179,180. Together with a higher affinity also to metabolic enzymes in the periphery 
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such as P450181, an increased liver and spleen uptake and a higher lung deposition will 
cause that nothing of the pharmaceutical will reach the brain. For very lipophilic 
molecules these mechanisms, as well as the above described plasma protein binding 
become dominant, especially for n.c.a. radiotracers. Otherwise for the latter the rival 
hypothesis exists, due to which non-specifically bound drugs can also enter the brain by 
approach of the plasma proteins to the cell membrane182. This could be an explanation 
why some radiotracers with an extremely high plasma protein binding over 90 % still 
present an adequate penetration of blood-brain barrier. Nevertheless, in total the 
relationship between drug lipophilicity and brain uptake is most often a negative 
parabola. The “window” of expedient lipophilicity lies between a Log P or Log D of around 
2, provided that no specific affinity for membrane proteins (PGP or other) can be 
expected183,184. 
 
The problem of non-specific binding 
Besides an adequate brain uptake for neurotracer imaging studies another extremely 
important aspect associated with lipophilicity is the subsequent non-specific binding in 
the brain. While the former is very much considered during drug development, the latter 
is often ignored. Therefore, non-specific binding of radioligands, both in vitro and in vivo, 
is poorly understood. For radiopharmaceutical development this is an essential problem, 
since many promising radiotracers for PET or SPECT which target the CNS fail due to an 
inappropriate non-specific binding to the brain tissue185.  
Lipophilic radiotracers generally exhibit high non-specific binding in lipid-rich tissues 
like the brain. About 60 % of the human brain consist of lipids, especially myelin-rich parts 
which are therefore named white matter. Due to this fact radiotracers with higher Log P 
or Log D values than 3 are often characterized by high non-specific membrane binding 
which hence displays a limiting factor for central nervous system imaging tracers. 
Nevertheless, many molecules within the optimal range of lipophilicity exhibit high non-
specific binding or such with very high lipophilicity do not. Non-specific binding therefore 
displays a major confounding factor in the development of new radioligands for receptor 
imaging. 
When dealing with protein binding three kinds of “specificity” are to differentiate. 
Specific binding generally describes the desired or expected protein binding of a ligand, 
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unspecific binding its interaction with active binding-sites of other proteins. Both kinds 
are of the same type (only differentiated by the meaning of the experimentalist) and 
therefore reversible and saturable. In contrast, non-specific binding is unknown but 
different. Nevertheless, terms of un- and non-specific binding are often not strictly 
distinguished and used synonymously.  
The most widely used operational definition for non-specific binding describes a 
binding that is not displaceable by an excess of unlabelled ligand and therefore 
unsaturable186. Although this model seems to be useful for many studies there are some 
findings known for long time which contest this definition. Many working groups found a 
displaceable binding situation of labelled molecules and membranes devoid of 
receptors187-190. It could also be shown that the relationship between non-specific binding 
and free ligand concentration is not linear at high ligand concentrations191. In some cases 
very high free ligand concentrations led to a distinct displaceability. Instead of an 
irreversible binding, non-specific binding can therefore be seen as reversible binding to 
low affine binding sites of very high concentration. Recent studies give advice that small 
molecules affect the spacing between adjacent membrane bilayers to produce its own 
binding sites as shown with spiperone and haloperidol192. The ability of this process (the 
rate of catalysis) would be structure dependent, the pre-condition (membrane 
interaction) lipophilicity dependent. This could be an explanation why the non-specific 
binding behaviour of two pharmacologically different molecules cannot be compared in 
general. 

 3. Aims and Scope 
The knowledge about functional interactions in the human brain is significantly limited 
by the understanding of the function of our neuroreceptors which is still fragmentary. 
Receptor subtype selective radioligands may help to close gaps of understanding. This 
becomes more and more difficult, if only a low density of the investigated receptors is 
prevalent, since every binding apart from the specific one may be exceeded. A faintly 
represented but important neuroreceptor is the dopamine D4 receptor which shows an 
extremely low distribution density in the central nervous system. Although many 
neurological effects are attributed to this receptor subtype so far there is no possibility of 
its measurement in vivo by positron emission tomography due to the absence of a 
suitable radioligand.  
This work should make a contribution to alter this situation. So far the only concrete 
indication for a selection of a suitable candidate to be radiolabelled is the D4-affinity of 
known ligands as well as their selectivity over similar receptor types. Thus, the aim of this 
work was to label recently published ligands with such binding profiles with cyclotron 
produced no-carrier-added [18F]fluoride. The compound FAUC 316 was selected due to its 
excellent affinity and selectivity for D4 receptors. Furthermore, as an alternative the 
likewise highly selective 6-(4-[4-fluorobenzyl]piperazine-1-yl)benzodioxine exhibited a 
convenient modifiability. 
The first objective was the development of an effective strategy for the radiosynthesis 
and the preparation of according precursors and reference compounds. In the case of 
FAUC 316 a concept for the basic 2-substituted cyanoindole structure was to develop by 
chosing a suitable indole synthesis for 5-cyanoindole-2-carbaldehyde. The key step of the 
radiosynthesis of [18F]FAUC 316 was the preparation of the 4-[18F]fluorophenylpiperazine 
moiety. For this purpose, special interest laid in the application of a palladium catalyzed 
cross-coupling reaction which should be examined for an n.c.a. 18F-labelling procedure. 
Previously, n.c.a. 4-[18F]fluorohalobenzenes had directly be obtained from 18F-labelling by 
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nucleophilic substitution (SNAr) on adequate iodonium salts. Beside comparing the 4-
[18F]fluorohalobenzenes for their suitability as coupling partners for a Hartwig-Buchwald 
coupling (HBC), the focus of optimization studies on this coupling reaction was 
particularly on the solvent system, precursor concentration, and reaction temperature.  
In order to prepare n.c.a. 6-(4-[4-[18F]fluorobenzyl]piperazine-1-yl)benzodioxine 
different synthetic strategies like direct nucleophilic substitution of an aromatic 
compound (SNAr) as well as a multi-step synthesis using a reductive amination reaction on 
corresponding n.c.a. [18F]fluorobenzaldehydes appears attractive to investigate. For this, 
different precursors and reference compounds for identification of n.c.a. products of each 
radioactive reaction step has to be synthesized as well. Special emphasis should be laid on 
every single reaction step regarding of reaction conditions in order to compare their 
efficiency. The best labelling strategy should be used to generate n.c.a. 18F-labelled 
derivatives of 6-(4-[4-[18F]fluorobenzyl]piperazine-1-yl)benzodioxine with different 
pharmacological properties. This required modification of precursors, reference 
compounds, radiochemistry and separation. With regard to the known lipophilicity and 
expected high non-specific binding of the benzodioxine ligand new planned derivatives of 
6-(4-[4-[18F]fluorobenzyl]piperazine-1-yl)benzodioxine should be more hydrophilic. 
Considering a narrow frame of variation due to the necessity of sufficient membrane 
penetration and therefore brain uptake, such a modification must then be examined with 
regard to avoid the loss of specificity for D4 receptors. 
For identification and determination of the radiochemical yield and purity of the 
labelled compounds a suitable radio HPLC and in some cases radio TLC systems had to be 
developed. In addition, a major concern was the development of suitable separation and 
purification methods especially using solid phase extraction and radio HPLC in order to 
enable an evaluation of the compounds pharmacologically. A major aim of this work 
should be the determination of the actual binding behaviour in the tissue of the central 
nervous system with special regard to non-specific membrane binding. This property 
presents the major “knock-out” criteria for putative D4 ligands when applied as 
radiolabelled ligands in vivo. 
Finally, the most promising radioligand should be further evaluated in ex vivo animal 
experiments for its qualification as an in vivo imaging tracer. For this, all n.c.a. 18F-labelled 
derivatives are to examine in order to obtain first preclinical data. 
 4. Synthesis and 18F-labelling of FAUC 316 
In order to create a suitable radioligand for the D4 receptor the cyanoindole FAUC 316 
(1) was elected since it exhibits excellent values for affinity (Ki(D4) = 1 nM) and selectivity 
against a lot of dopamine receptors and subreceptors known as pharmacologically 
similar, especially D2.  
 
 
Figure 4.1: Ki-values of the highly affine and selective D4 ligand FAUC 316 (1) and its fluoroethyl 
derivative which can be used as tracer analogue but shows a distinct inferior binding profile156. 
 
Displacement of the fluorine substituent with fluorine-18 should leave the excellent 
binding profile untouched. On the other hand the nature of the molecule does not admit 
an easy nucleophilic n.c.a. 18F-fluorination procedure. A common alternative is the use of 
a [18F]fluoroethyl or -ethoxy group instead of authentic aromatic fluorine-18. The resulted 
aliphatic fluourination is much easier but decreases affinity and selectivity of the ligand 
dramatically by a factor of 45 to 70 (Fig. 4.1). Due to the lack of D4 radioligands and 
therefore its high requirements it makes sense to go for an authentic labelling, even if this 
is more difficult to achieve. Difficulties lay in the fluorine carrying aromatic moiety which 
is directly bound to the amine. An adequate activation for nucleophilic fluorination is 
therefore only possible by insertion of a formyl group in ortho-position. However, the 
subsequent cleavage of this group has to take place with one of the heterogenous 
catalysts tris(triphenylphosphine)rhodium(I)chloride under harsh conditions193 or 
palladium on charcoal with estimated low yields194. All alternatives include radiochemical 
built-up of the basic structure. [18F]Fluoroaniline as intermediate can be used for a Prelog 
ring closure. However, the amine has to be synthesised itself by two previous steps and 
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results of the ring closure reaction in radiochemistry are described as very poor195.  
Since the radiosynthesis of [18F]fluorohalobenzenes by labelling of iodonium 
precursors is an established method, the transition metal catalyzed coupling of amine and 
halobenzene displays an adequate option to achieve N,N-dialkyl[18F]fluoroanilines. With 
three radioactive reaction steps the Hartwig-Buchwald coupling (HBC; Fig. 4.2, B) is 
comparable with direct labelling of an ortho-aldehyde (Fig. 4.2, C) and also includes the 
same disadvantage in using totally or partly heterogenous compounds. HBC is chosen due 
to the easier synthesis of according inactive compounds and more extensive possibilities 
in varying the reaction conditions. 
 
 
Figure 4.2: Three main possibilities of retrosyntheses for the radiosynthesis of 
[18F]FAUC 316 ([18F]1).  
4.1 Syntheses of standard and precursor compounds 
All syntheses of FAUC 316 and its analogues described in the literature for distribution 
of the binding profile started from 2-(hydroxymethyl)indole-5-carbonitrile (7) which 
synthesis was not described. For the synthesis of 2-substituted indole derivatives it is not 
possible to start reactions from the heterocycle, conducting a substitution or addition 
procedure. In contrast to pyrrol, furan, and benzofuran, the 3-position of indole is 
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distinctly more activated then the 2-position. A direct aminomethylation of indoles, 
analogue to a Mannich reaction using formaldehyde, leads to an indole-3-aldehyde as 
well as does an electrophilic substitution by Vilsmeier-Haack with DMF and POCl3. It is 
therefore necessary to build-up the indole-heterocycle. From sigmatropic rearrangements 
like the Fischer synthesis over radical mechanisms up to more complex reactions using 
alkines, arynes or azirines, a lot of different indole syntheses exist196.  
4.1.1 Formation of 2-carboxylic indole via palladium mediated 
intramolecular coupling 
An elegant method to obtain 2-substituted indolecarbonyles in only one reaction step 
is provided by a palladium catalyzed coupling starting from ortho-iodoaniline described by 
Chen et al.197 It is very similar to the better known Larock198 synthesis but using ketones 
instead of alkines.  
 
Figure 4.3: Palladium mediated indole coupling which is possible with the acid but not with its 
corresponding ester due to a self-condensation under basic conditions (left side). In case of the 
acid, electronic condition of the unprotonated state prevents from aldolic reactions (right side). 
Reaction conditions: Pd(OAc)2, DABCO, DMF, 100 °C, 4h. 
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The reaction proceeds by formation of an enamine and subsequent intramolecular 
annulation by Heck-coupling of the en- and the aryliodide-moiety. In order to achieve the 
primary alcohol (7) the most obvious procedure was the reaction of ethyle pyruvate with 
5-cyano-3-iodoaniline leading to the ethylester as intermediate product. Unfortunately, 
this is not possible in general, presumable due to a rapid self-condensation of the ethyl 
pyruvate under basic conditions. This way it is described for similar reaction conditions 
and substances199. With free pyruvic acid this decomposition is not observed although an 
aldol-addition is also conceivable in this case. An explanation includes the preceeding 
deprotonation of the more acidic carboacid moiety which leads to an excellent electron-
donating group directly adjacent to the carbonyl. As a result, the acidity of the β-carbon-
hydrogen bond is lowered. This explanation is in accordance with the finding that an 
excess of minimum four equivalents of diazabicyclo[2.2.2]octane (DABCO) as amine base 
was essential for achieving the synthesis.  
A further disadvantage is the presence of the nitrile group. As a good electron-
withdrawing substituent nitrile lowers basicity of the aniline lone-pair for an enamine 
building as well as coordination of the aromatic during the Heck-coupling. Thus, the yields 
decrease distinctly from 60 % to 40 % when changing to the nitrile derivative (Tab. 4.1).  
 
Table 4.1: Influence of the cyano group of indole-2-carboxylic acids with cyclization on yield, 
stability and solubility. 
Molecule 
 
 
 
 
Yield 60 % 40 % 
Melting Point 202-206 °C 331 °C (decomposition) 
Solubility CH2Cl2, CHCl3, DMF, DMSO, 
ethylacetate, diethylether 
(slightly), tetrahydrofurane 
DMSO 
 
Due to this electronic situation of 5-cyanoindole-2-carboxylic acid (4) and its low 
solubility in most common reaction solvents, its reactivity for further reaction steps is 
low. Thus, it was not successful to esterify the molecule with methanol, ethanol and even 
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methyliodide. While the unsubstituted indolecarboxylic acid (3) can be easily transferred 
to the acid chloride by oxalyle chloride in methylene chloride, this is only possible with 3 
by using very harsh conditions or reactands like PCl5. A subsequent direct reduction to the 
alcohol showed no reaction with mild reduction agents like NaBH3 and led to 
decomposition with LiAlH4. Otherwise the conversion of the acid chloride to the amide 
was conducted in high yields independent of the nitrile, but which could not be reduced 
to the amine in any way. In conclusion this procedure proved not practicable for 
generating 7. 
4.1.2 Formation of 2-carboxylic indole by intramolecular reductive 
amination 
An alternative which should lead to the ester ethyl-5-cyano-1H-indole-2-carboxylate 
(5) in two steps is the classic indole synthesis by Reissert et al.200 Starting from an o-
nitrotoluene, ethoxy condensation takes place with ethyl oxalate and a strong ethanolate 
base to form an o-nitrophenylpyruvate (6). Due to the harsh basic conditions electronic 
influences of further substituents like the nitrile group are nearly negligible.  
 
Figure 4.4: Mechanism of the first step of the Reissert indole synthesis to generate o-
nitrophenylpyruvate (6). 
 
With 6 a subsequent reductive amination cyclisation results in the ester 5. For this 
procedure powder of elemental zinc in glacial acetic acid is typically used. Usually high 
yields are obtained with these substrates but with the disadvantage of poor 
Chapter 4: Synthesis and 18F-labelling of FAUC 316 44 
reproducibility. Therefore palladium on charcoal as reduction agent was used with 
decaborane (B10H14) as H-donor. The use of cyclohexene instead of decaborane showed 
no results.  
 
Figure 4.5: Intramolecular reductive coupling of the 5-cyano-o-nitrophenylpyruvate to the 
corresponding indole ester. 
4.1.3 Reduction of 5-cyano-2-carboxyindole ester 
The ester was then reduced to the primary alcohol 7, which is a key intermediate 
compound. Although reduction sensibility of esters is described as high, no conversion 
could be obtained with the borohydride reduction agents NaBH3, LiBH3 and Ca(BH3)2 
which were used as commercially available as well as produced in situ. The nitrile 
substituent as a further reduction sensitive group complicates the application of stronger 
reduction agents. Nevertheless, the ester group can be totally reduced to the alcohol in 
presence of the cyano group with LiAlH4 in diethylether at very low temperatures (-78 °C) 
and subsequent cautious thawing. Replacing diethylether by tetrahydrofuran leads to a 
decomposition of the starting material under identical reaction conditions. 
 
 
Figure 4.6: Different reductive procedures of the cyanoindole ester. 
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On the other hand, the use of THF is possible for a direct reductive amination reaction 
of the ester to the methylenepiperazines 8 and 9. Saving reaction steps in this case, 
however, is bought by very poor yields. Higher yields of reductive amination are obtained 
in the classical way starting from the aldehyde (10) as it is displayed in Figure 4.7. The 
nearly quantitatively selective oxidation of the alcohol with Dess-Martin periodinane 
results in the most suitable route via the alcohol 7. A direct selective reduction from the 
ester to the aldehyde with sodium bis(2-methoxyethoxy)aluminiumhydride (SMEAH) and 
pyrrolidine is possible but with a yield of about 25 % it can also not compete with the two 
step route. 
 
Figure 4.7: Reaction paths starting from 5-cyanoindole-2-methanol to the standards 1 and 
12 and the precursor 14. 
 
All further reaction steps which led to the precursor 14 and the reference compounds 
1 and 12 display standard reactions and resulted in yields from 50 to 99 %. The selective 
cleavage of the Boc protection group in presence of the benzyl protection group was 
Chapter 4: Synthesis and 18F-labelling of FAUC 316 46 
conducted on the basis of an investigation of F. Cavelier and C. Enjalbal201. It was taken 
advantage of the small difference in the acid sensitivity of the both groups. Dry HCl gas 
was dissolved in ethyl acetate and used as agent for cleavage. After 48 h a nearly 
quantitative and selective conversation was observed. A longer reaction time led to an 
additional cleavage of the benzyloxy moiety. 
4.1.4 Syntheses of iodonium precursors 
For the radiosynthesis of [18F]fluorobromobenzene and [18F]fluoroiodobenzene the 
labelling procedure by iodonium salts was chosen as most reasonable. Symmetric 
iodonium precursors were of special interest due to estimated higher yields and a 
decreased number of different side products (chapter 2.2.4.2).  
The synthesis of bis(4-bromophenyl)iodonium trifluoromethansulfonate (16) was 
conducted by the common method developed by McKillop et al.202 For this at first iodide 
was oxidised in presence of glacial acetic acid to iodine(III). A subsequent ligand 
replacement led to an overall yield of 56 %. Due to the easy oxidability of iodine (iodide) 
in contrast to bromine (bromide) the second substituent remained untouched during the 
whole reaction as well as no autooxidation processes were estimated. This was in 
contrast to the diiodo species bis(4-iodophenyl)iodonium trifluoromethansulfonate (20) 
which is displayed in Figure 4.9. Therefore, it was necessary to produce a reactive 
intermediate. 2-(Hydroxy(tosyloxy)iodotoluene (18) was formed by oxidation and ligand 
replacement. Such iodine(III) compounds with a hydroxy and a tosylate ligand are named 
“Koser’s reagents”203.  
 
Figure 4.8: Two-step synthesis of the symmetric iodonium precursor bis(4-bromophenyl)iodonium 
trifluoromethansulfonate (16). 
 
The critical step was the oxidative substitution reaction with o-diiodobenzene which 
resulted in poor yields. Due to the fact that both product and educt have the possibility 
for oxidation and replacement, the existence of an equilibrium was conceivable. This 
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postulate would explain the low yield. However an explanation for the higher stability of 
2-(hydroxy(tosyloxy)iodotoluene (18) was owing up to now. 
 
 
Figure 4.9: Four-step synthesis of the symmetric iodonium precursor bis(4-
iodophenyl)iodonium trifluoromethansulfonate (20). 
 
In a last step a ligand replacement similar to the bromo analogue led to the desired 
precursor with an overall yield of 3.5 %. It has to be noted that in principle an oxidative 
substitution analogue to the previous reaction step is conceivable as competing reaction. 
In fact this seems to proceed mainly when the reaction velocity is low as it is in the case 
when weaker acids than trifluoromethanesulfonic acid are used. 
4.2 Radiosynthesis of [18F]FAUC 316 
4.2.1 Synthesis of 4-[18F]fluorobromobenzene and 4-[18F]fluoroiodo-
benzene 
The synthesis of both [18F]fluorohalobenzenes as secondary labelling agents was 
conducted in DMF at high temperatures of 130 °C. The well known aminopolyether 
Kryptofix 2.2.2 and potassium carbonate were used as base system for radiofluorination. 
Due to the popularity of the iodonium precursors no comprehensive process optimization 
was done here. Thus by thermical decomposition of 30 μmol of the iodonium precursors 
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16 and 20 in presence of n.c.a. [18F]fluoride, radiochemical yields of 50 ± 5 % of 4-
[18F]fluorobromobenzene ([18F]21) and 60 ± 9 % of 4-[18F]fluoroiodobenzene ([18F]22) 
were obtained. Lower precursor concentrations led to a dramatically decrease of yield. 
Half of the concentration (15 μmol in 0.8 mL DMF) results in radiochemical yields of only 
about 20 %. The necessity of abnormal high precursor concentration is a general 
phenomenon of iodonium salts and presumably this is due to their rapid degradation 
which includes radical procedures. A scavenger like 2,2,6,6-tetramethylpiperidine-N-oxyl 
(TEMPO) is sometimes added for prevention92,93. Due to the high number of different 
reagents in subsequent reaction steps and the high number of unavoidable side products 
this was not considered as an option in this work.  
 
 
Figure 4.10: Scheme of solid phase extraction (SPE) route for the separation of 4-
[18F]fluoroiodobenzene ([18F]22). 
 
The latter mentioned side products as well as a free choice of solvent for the 
subsequent cross-coupling reaction necessitate a solid phase extraction procedure for 
which the moderately unpolar silica phase Sep-Pak RP18 was chosen. The procedure was 
unproblematic using bis(4-bromophenyl)iodonium trifluoromethansulfonate 16, but 
decomposition products of bis(4-iodophenyl)iodonium trifluoromethansulfonate 20 
produced a colloidal precipitate with water which obstructed cartridges and passed filter 
frits (3μ). An adequate filtration can be reached by previous addition of 100 mL of the 
Chapter 4: Synthesis and 18F-labelling of FAUC 316 49 
diatomaceous earth Celite®503 to water and filtration through a 10μ PTFE filter. The 
obtained slightly milky solution passed every cartridge without objection. Due to the fact 
that a palladium mediated cross-coupling reaction should be free of moisture an 
elaborate drying had to follow. The whole procedure is graphically displayed in Figure 
4.10 and resulted in a product loss of up to 15 %. 
4.2.2 Piperidine and 1-methylpiperazine as model compounds for a 
radioactive palladium-catalyzed Buchwald-Hartwig cross-coupling 
Test syntheses with small cyclic amines were performed as a proof of principle of the 
Hartwig-Buchwald coupling under the present n.c.a. conditions. Due to the high number 
of different combinations of parameters (catalyst, ligand, base and solvent) as well as the 
fact that no evidence for process optimization existed204 parameters were initially carried 
over from the only existing reference in radiochemistry205. As test systems piperidine as 
simplest and 1-methylpiperazine as more similar to the target structure 1 were used and 
coupled with 4-[18F]fluorobromobenzene ([18F]21) and 4-[18F]fluoroiodobenzene ([18F]22) 
using Pd2(dba)3, 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (DavePhos) 
and NaOtBu in toluene at 100 °C. Coupling results are displayed for two reaction times in 
Figure 4.11.  
 
Figure 4.11 A: Radiochemical yield (RCY) of the Hartwig-Buchald coupling (HBC) of 4-
[18F]fluorobromobenzene ([18F]21) and 4-[18F]fluoroiodobenzene ([18F]22) with piperidine. 
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Figure 4.11 B: Radiochemical yield (RCY) of the Hartwig-Buchald coupling (HBC) of 4-
[18F]fluorobromobenzene ([18F]21) and 4-[18F]fluoroiodobenzene ([18F]22) with 1-
methylpiperazine. 
 
It is obvious that iodobenzene is more suitable offering higher yields, which is a 
confirmation of a known fact for inactive organic compounds206-208. Direct comparison of 
both test systems did not show distinct differences. Thus, introduction of further tertiary 
amines were not supposed to exert an influence on the reaction. 
 
Solvent dependence 
While the alteration of the used HB-reactants (especially catalyst and ligand) would 
“only” influence the conversion rate which is already high, the choice of solvent has more 
expansive consequences. Therefore, the yield of conversion of 4-[18F]fluoroiodobenzene 
([18F]22) with 1-methylpiperazine was compared in three different solvents. Beside m-
xylene, toluene is the most used solvent for HBC with high yields but with a few 
disadvantages. It is not mixable with water due to its unpolarity. This is a problem for an 
easy, rapid and preferably lossless solid phase extraction subsequently to the coupling 
reaction. It is therefore suitable to use a water-soluble solvent from which separation and 
purification is assuaged. Moreover, the dipolar, aprotic N,N-dimethylformamide (DMF) 
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would provide the opportunity of a one-pot synthesis without an intermediate separation 
step. In addition to the simplified procedure, especially for the iodo-derivative, and the 
time savings this would minimize losses due to adsorption processes and incomplete 
fixation and elution. A further advantage is the relatively high boiling point of 150 °C of 
DMF which allows a wide range of temperature variation. Otherwise its physicochemical 
parameters are very different to toluene and xylene. Therefore, 1,4-dioxane was used as 
an alternative which is also dipolar and aprotic but should behave more like toluene due 
to a very similar dipole moment and dielectric constant (Tab. 4.2). 
 
Tab. 4.2: Solvent dependence of the radiochemical yield of HBC209 related to [18F]22. 
 
 
solvent dipole moment μ dielctricity constant ε RCY 
toluene 1.23 10-30 Cm 2.4 70 % 
1,4-dioxane 1.5 10-30 Cm 2.2 40 % 
DMF 13.1 10-30 Cm 37.8 0 % 
DMF/toluene - - 0 % 
 
In order to guarantee the comparability of solvent influences the HBC was carried out 
at constant reaction parameters and analysed by radio-HPLC and if possible radio-TLC. 
Thereby no conversion to the desired arylamine product was observed in DMF. Instead of 
the side product could be identified as the dehalogenated product [18F]fluorobenzene. 
Identification and especially quantitation of this product was difficult due to its high 
volatility. A mixture of DMF and toluene proved also unsuitable and led to the same 
results as the use of pure DMF. Thus, a subsequent addition of toluene after the labelling 
step for HBC proved not an alternative. 
The HBC in 1,4-dioxane results in moderate yields of 40 % but with a high amount of 
different radioactive side products which were not identified in detail. Toluene was 
maintained as solvent of choice due to the distinct better yield. In addition in toluene no 
radioactive side products were observed and this solvent showed a more complete 
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elution of 4-[18]fluoroiodobenzene ([18F]22) from the solid phase cartridge than 1,4-
dioxane and DMF.  
Reasons for the failure of a cross-coupling in DMF can be attributed to a complexation 
of DMF by palladium. A steric hinderance leads to a preference of the β-hydrid 
elimination which results in the dehalogenated product and an imine210. This is in 
accordance to Beletskaya et al.211 who showed that the reduction of the arylhalide is 
favoured when the deprotonation of the amine is slow. 
 
 
Figure 4.12: Part of the cross-coupling cycle of the Hartwig-Buchwald reaction. When 
deprotonation is quick the typical reductive elimination procedure is occur (A), if it is slow, due to 
a steric hinderance, β-hydrid elimination becomes predominant (B). 
4.2.3 Direct Buchwald-Hartwig coupling with 1-benzyl-2-(piperazine-1-yl-
methyl)-1H-indole-5-carbonitrile 
The cross-coupling to the benzyl-protected ligand Bn[18F]FAUC 316 ([18F]12) was the 
next step. As a consequence of the preliminary determinations in the previous chapter 
the reaction was also conducted in toluene at 100 °C with 4-[18F]fluoroiodobenzene 
([18F]22), Pd2(dba)3, 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (DavePhos) 
and NaOtBu. No conversion could be observed, even after a reaction time of one hour. A 
possible explanation for the failure of the radiosynthetic cross-coupling with 14  is the 
presence of the cyano-group which is known as well-coordinating, possibly better than 
the amine group, to build strong complexes. Furthermore, the extent of the bigger 
coupling partner potentially causes a restriction of complexation and decreases the 
reaction velocity.  
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Figure 4.13: Direct cross-coupling of 4-[18F]fluoroiodobenzene ([18F]22) with the benzylprotected 
indolepiperazine with (14) and without (25) a cyano-substituent. The presence of the cyano group 
seems to hamper coupling reaction under the chosen conditions as obvious from radiochemical 
yields.  
 
The former assumption is supported by the fact that in absence of the cyano-group a 
conversion proceeds. On the other hand the dehalogenation product [18F]fluorobenzene 
was not found as major by-product. The low yields of 10-15 % obtained with the 
unsubstituted but benzylprotected 1-benzyl-2-(piperazine-1-ylmethyl)-1H-indole (25) 
confirm the thesis of an influence of the bulky character of the amine substituent. Due to 
the high distant between the two moieties, electronic influences of the cyano group 
should be excluded in this process. 
4.2.4 Synthesis of [18F]FAUC 316 via 4-[18F]fluorophenylpiperazine 
The failure of a direct coupling of 4-[18F]fluoroiodobenzene ([18F]22) with piperazine-1-
ylmethyl-1-H-indoles necessitated an alternative procedure. In chapter 4.2.2 
preexaminatins showed a high yield conversation of small cyclic amines. Therefore, the 
synthesis of 4-[18F]fluorophenylpiperazine as intermediate product was attempted. In 
accordance with the inactive syntheses a subsequent reductive amination with 5-
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cyanoindole-2-aldehyde (10) should follow. Due to the unsensitivity of the reductive 
amination procedure the indole must not be protected. 
  
 
Figure 4.14: Successful reaction pathway to [18F]FAUC 316 [18F]1 starting from 4-
[18F]fluoroiodobenzene [18F]22. Protection of one piperazine side and therefore a later cleavage of 
the Boc-group is not necessary for the HB coupling reaction.  
 
First examinations started from coupling of tert-butyl-piperazine-1-carboxylate and 
subsequent cleavage of the Boc-group as a typical reaction path due to literature 
procedures. The cross-coupling yielded about 70 % radiochemical yield (RCY) after 25 min. 
Although the carbamat moiety of the Boc-group showed similarities to DMF, RCY of the 
successful Hartwig-Buchwad coupling to tert-butyl-4-(4-[18F]fluorophenyl)piperazine-1-
carboxylate ([18F]27) was in the same range like to 1-(4-[18F]fluorophenyl)piperidine 
([18F]23) and to 1-(4-[18F]fluorophenyl)-4-methylpiperazine ([18F]24). The subsequent 
cleavage of the Boc-group was finished with concentrated HCl after 15 min and with 
trifluoroacetic acid after 5 min. The coupling reaction was also performed with the 
unprotected piperazine due to the problems using strong acids during radiosyntheses and 
in condiseration of saving one reaction step. Inactive preexaminations showed that even 
with an excess of the aryl componend double N-arylation is disfavoured. Furthermore, 
Christensen et al.210 could show that the arylpiperazine is less reactive for a cross-
coupling than piperazine. In the radiosynthesis 4-[18F]fluoroiodobenzene is the 
substoichiometric partner but reactions with inactive haloaryl side products from the 
iodonium decomposition are conceivable.  
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Figure 4.15: Temperature dependence of the radiochemical yield (RCY) of the HBC to [18F]27 (A) 
and [18F]27 (B). In case of the free piperazine temperature sensitivity of the reaction is 
lower than when using the N-Boc precursor. 
 
It is shown that the maximum yields of both reactions did not differ distinctly, thus, the 
use of the unprotected piperazine is favoured. In fact, direct comparison of the 
temperature dependence displays a lower sensibility to temperature fluctuations of the 
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piperazine coupling which maintain its yield even with a temperature decrease of 20 °C. 
The latter reaction seems to run faster reacting saturation already after about 15 min, 
which is probably due to the two reaction centers. Otherwise, in accordance to the 
equimolar examinations, a multiple aryl-coupling of piperazine could be ruled out by 
using inactive standards. Thus, after prepurification of 4-[18F]fluorophenylpiperazine 
([18F]28) and reductive amination the overall sum of steps do not differ from the original 
pathway. The elaborated extraction procedure of the arylpiperazine intermediate is 
described in detail in the next chapter. 
 
Tab. 4.3: Different catalyst systems for radio-HBC in toluene and DMF at 100 °C. 
 
 
 
catalyst ligand base solvent time  
(min) 
RCY 
Pd-cinnamyl BrettPhos NaOtBu toluene 30 25 % 
Pd2(dba)3 RuPhos NaOtBu toluene 30 73 % 
Pd2(dba)3 DavePhos NaOtBu toluene 20 70 % 
[P(t-Bu)3PdBr]2 - K2CO3 DMF 30 0 % 
[P(t-Bu)3PdBr]2 
Pd(OAc)2 
Pd(OAc)2 
- 
RuPhos 
RuPhos 
K3PO4 
NaOtBu 
NaOtBu 
DMF 
toluene 
toluene 
30 
5 
10 
0 % 
60 % 
74 % 
Pd(OAc)2 RuPhos NaOtBu DMF 30 0 % 
 
Due to the high number of elaborate purification steps often with substantial loss of 
radioactivity, under the chosen conditions and reactands other coupling systems were 
tested with piperazine in order to use other solvents than toluene (chapter 4.2.2) or even 
to get higher yields. With some examples the use of polar, aprotic solvents such as DMSO, 
DMF and DMAA has been described for the inactive Hartwig-Buchwald syntheses212-215 
and in some cases even an aqueous solution has been used216,217. Thus, solvent 
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dependence seems to be associated with the Pd-source and ligand system. Catalysts like 
the Pd(I)-dimer [P(t-Bu)3PdBr]2, the polar PdOAc2 as well as the Pd2(dba)3/2-
(dicyclohexylphosphino)3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1’-biphenyl (BrettPhos)/KOH 
system were used for which general good yields in polar solvents are described. 2-
Dicyclohexylphosphino-2’,6’-diisopropoxybiphenyl (RuPhos) was also tested in this 
context due to its known high potency in conversation of secondary amines203. All tested 
systems are listed in Table 4.3. Nevertheless, none of these showed any sign of 
conversion to the desired 4-[18F]fluorophenylpiperazine ([18F]28) when DMF was used as 
solvent and [18F]fluorobenzene as main side product did not appear generally. Otherwise 
a very rapid reaction rate was observed using PdOAc2/RuPhos/NaOtBu in toluene which 
resulted in a considerable saving of reaction time. 
The subsequent reductive amination with 5-cyanoindole-2-aldehyde (10) was 
performed with NaBH3CN in DMSO and toluene and previously tested with the 
commercially available indole-2-aldehyde. No distinct differences were observed 
between both reactants so that the substituent does not seem to influence this reaction.  
 
Figure 4.16: Time dependence of the radiochemical yield of the reductive amination reaction of 4-
[18F]flourophenylpiperazine with 5-cyanoindole-2-aldehyde (10) to FAUC 316 ([18F]1) (red) and 
with indole-2-aldehyde to 2-((4-(4-[18F]fluorophenyl)piperazine-1-yl)methyl-1H-indole ([18F]29) 
(black).  
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4.2.5 Purification and isolation of [18F]FAUC 316 
The good radiochemical yields (measured by radio-HPLC) of every single reaction step 
show good practicability of the HBC in radiosyntheses with n.c.a. 18F-labelled compounds. 
Otherwise the overall radiochemical yield at the end of synthesis is with about 10 % 
relatively low and the total reaction time of about 120 min represents more than one half 
life of fluorine-18. Limitations of total yield and reaction time are dependent on the 
intricate purification methods following every reaction step. Purification of the arylhalide 
by solid phase extraction after the labelling procedure depends on the iodonium salt used 
as precursor and is described there in detail (chapter 4.2.1). 
4.2.5.1 Prepurification of 4-[18F]fluorophenylpiperazine ([18F]28) 
The influences of reactants and byproducts on the following reaction steps are not 
sure due to the large amount of impurities which are present after the cross-coupling 
reaction in the reaction mixture. A preliminary purification of the product is therefore 
essential following the Buchwald-Hartwig coupling. Furthermore, the free amine of the 
piperazine moiety allows a unique purification by acid extraction at this point of the 
reaction sequence. Two options appear attractive: liquid-liquid extraction as well as solid-
liquid extraction. 
The liquid-liquid extraction of the coupled product [18F]28 with hydrochloric acid (2 
mol/L) allowed a selective separation of the reaction mixture containing amines as well as 
water soluble substances. The development of progress extraction could be traced very 
well by the distribution of radioactivity between the two phases. After repeated 
extraction of the toluene reaction mixture with hydrochloric acid, the aqueous phase was 
made basic with sodium hydroxide for conversion of the product into the water-insoluble 
amine form. Subsequent adsorption of the organic ingredients on a Sep Pack C18 solid 
phase cartridge allows a change of solvent and removed all water-soluble compounds. 
For the elution of the amine from the cartridge the appropriate solvent of the following 
reaction may be used (here DMSO); in the case of 4-[18F]fluorophenylpiperazine ([18F]28) 
a suitable solvent for the semi-preparative HPLC separation. Acetonitrile was used for the 
elution before application to HPLC. HPL chromatographic analysis showed a significant 
purification of the substance by liquid-liquid extraction and allowed the isolation by a 
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semi-preparative HPLC separation. The liquid-liquid extraction was almost quantitative 
without substantial losses of [18F]28. 
For solid phase extraction Strata X-CW were used as cation exchanger cartridges. The 
reaction mixture was diluted with methanol and applied directly to the ion exchanger 
previously conditioned with methanol and water. Subsequently, the cartridge was 
washed with an ammonium formate buffer (pH 6.3) and methanol and the product was 
eluted with methanolic sodiumacetoborhydrid solution from the cartridge. The HPLC 
analysis showed, as in case of the liquid-liqid extraction, a clear purification of [18F]28. The 
process procedure provides a product yield of [18F]28 of 20 ± 4% which is distinctly lower 
than from the former method. Otherwise the solid phase extraction allows an easier 
practicability. 
 
Pharmacoceutical relevance of 4-[18F]fluorophenylpiperazine ([18F]28) 
4-Fluorophenylpiperazine (4-FPP, 28) or “fluoperazin” is a not yet listed (2010) 
psychoactive substance that is used as a substitute for amphetamines (NMDA, ecstasy, 
etc.) like a few other phenylpiperazines, due to their better commercial availability. Their 
effect is usually attributed to their 5-HT agonism (Ki(5-HT1A) = 302 nM; Ki(5-HT1B) = 794 
nM; Ki(5-HT2A) = 3236 nM; Ki(α1) = 776 nM; Ki(D2/H1/mAch) > 100.000nM)218, at least with 
4-FPP its euphoric and stimulating effect can not be explained sufficiently this way. Thus 
an effect as SRI and NARI is suspected. An effect on the norepinephrine receptor 
(agonistic) may be causative; an analogous mechanism to the amphetamines as an 
indirect sympathomimetic is also conceivable due to the only moderate affinity. This is 
confirmed by the advisement that an euphoric effect (dopamine) may not be triggered 
directly. As an indirect sympathomimetic it would release norepinephrine non-exocytotic 
from the axoplasm and simulate this way the effect of NA agonists. For this purpose there 
are two requirements: First, penetration of the BBB is necessary for a CNS effect. The 
existence of a carrier is likely due to the low lipophilicity of 4-FPP. Furthermore, 4-FPP has 
to be able to use the corresponding transmitter-carrier (with cotransport of Na+) in 
Axolemn (intake inhibition by competition) and the inclusion of the transmitter in the 
synaptic vesicles and/or prevent its degradation by monoamine oxidases (MAO). 4-FPP 
has no corresponding structural similarity to such compounds (phenylethylamine), but 
there are also similar compounds which show these effects, e.g. Amezinium. 
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4.2.5.2 HPLC purification of final products 
For a final purification semipreparative radio-HPLC had to be used in order to arrange 
pharmacological evaluations. This regards not only the final product [18F]FAUC 316 
([18F]12), since a HPLC-purification of the intermediate 4-[18F]fluorophenylpiperazine 
([18F]28) was aspired as well for future applications due to its pharmaceutical relevance.  
Large quantities of iodobenzene were acieved by decomposition of the iodonium salt 
during the production of the secondary labelling precursor (Chapter 4.2.1) beside the 
desired 4-[18F]fluoroiodobenzene [18F]22. The inactive iodobenzene is implemented in the 
Hartwig Buchwald coupling analogous to [18F]22 to produce N-arylpiperazine which pass 
all following extraction steps and reacts in the reductive amination reaction as well. The 
compounds only differ by a fluorine atom, which represents a very similar molecule also 
for most chromatographic columns. This places special requirements on the used HPLC 
system. 
 
Figure 4.17: Generating of the unsubstituted derivates (22a, 28a, 1a) during all reaction steps with 
very similar properties. The amphiphilicity of the phenylpiperazines (28, 28a) is marked by a blue 
circle for a hydrophilic and a red circle for a lipophilic area. Generation of the iodo derivatives is 
also conceivable but without strong impact due to its very different Log P and therefore retention 
time. All cLog P values were calculated by Marvin Sketch 5.1.4.239 
Reaction conditions: (a) K2.2.2, Na2CO3, DMF; (b) Pd2(dba)3, DavePhos, NaOtBu, toluene, 100 °C 
(c) 10, NaBH3CN, AcOH, DMSO 
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There is a further problem for the chromatographic purification of the 4-
[18F]fluorophenylpiperazine due to its nearly amphiphilic character. This effects that the 
orientation of the molecule between stationary and mobile phase can depend on the 
polarity of the eluent. In Figure 4.18 this phenomenon is shown using a MultoHigh 100 
RP18 HPLC column for the separation 4-fluorophenylpiperazine and 1-phenylpiperazine.  
 
Figure 4.18: Characteristic of the retention time of 4-FPP (28) and 1-phenylpiperazine (28a) on the 
water/acetonitrile proportion of the HPLC solvent. Column: CS Service, Multo High 100 RP18 5μ, 
250×4.6 mm. 
 
Figure 4.19: Dependence of the retention time of 4-FPP (28) and 1-phenylpiperazine (28a) on the 
water/acetonitrile proportion of the HPLC solvent. ΔtR of the phenylpiperazines are compared 
between the column Multo High 5 μm 100 RP18 250×4.6 mm (left) from Cs Service and the 
column Luna 5 μm PFP(2) 100 Å 250×4.6 mm (right) from Phenomenex. Solvent: MeCN/H2O (v/v), 
1 mL/min.  
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The retention time (tR) is plottet as a function of the water/acetonitril proportion. With 
high fractions of organic solvent the in general lipophilic compounds (Log P(4-
fluorophenylpiperazine) = 1.5; Log P(1-phenylpiperazine) = 1.43)239 show low to moderate 
retention times on the RP phase. Their lipophilic aryl moiety seems mostly orientated to 
the mobile phase. Interaction variation of eluent composition only causes very little 
effects. Molecule orientation changes at higher water contents. Now unpolar groups 
show a strong interaction and the molecule acts like a normal lipophilic compound. Only 
now a clear separation is possible. That the retention time dramatically decreases at very 
high proportions of water is possible due to an effect of the stationary phase material. It 
is known from a few C18-phases (e.g. Prontosil®) that a high amount of water causes a 
reversible retraction of the C18-chains so that unpolar interaction is inhibited. 
 
Figure 4.20: Comparison of semipreparative HPLC separation of [18F]FAUC 316 ([18F]1) with a 
“normal” C18 phase (A) and a pentafluorophenylphase (B). Solvent: (A) MeCN/H2O/TEA 
60/40/0.03 (v/v/v) pH 9; (B) MeCN/H2O/TEA 50/50/0.01 (v/v/v) pH 7.8. HPLC column: (A) 
Phenomenex Luna 5 μm C18(2) 100 Å 250×10 mm, 4 mL/min; (B) Phenomenex Luna 5 μm PFP(2) 
100 Å 250×10 mm, 4 mL/min.  
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As shown in Fig. 4.18/19 a high amount of water is necessary for a significant 
separation of the two compounds which limits the available HPLC columns especially as 
semipreparative ones. Some RP materials are sensitive for high amounts of water or 
cause an improper counter-pressure due to the higher viscosity of water (η20 °C(MeCN) = 
0.39 mPa s; η20 °C(H2O) = 0.95 mPa s)219. While normal phases or NH phases show now 
separation, a column material which is optimized for the present separation problem 
(slightly different halogenated aromatics) is the pentafluorophenyl phase. In Figure 4.19 
differences are displayed as moderate but distinct. This phase was used for the final 
purification of [18F]FAUC 316. In this case a better separation is due to a higher time 
resolution as shown in Figure 4.20 while this is not that definite with the free amine. 
The obtained molar activity (AM) of about 90 GBq/μmol is very high and allows in 
general for a specific accumulation as radioligand in pharmacological evaluations. 
4.3 Pharmacological evaluation of [18F]FAUC 316 
For evaluation of the pharmacological qualification of the high affine D4 radioligand 
[18F]FAUC 316 for later in vivo applications its accumulation behaviour on rat brain slices 
was examined by in vitro autoradiography in close cooperation with the 
radiopharmaceutical working group of the INM-5. Thereby the binding of the radioligand 
was competed with different inactive ligands.  
Beside the inactive FAUC 316, competing was done with the unselective but high affine 
dopaminergic ligand spiperone due to the fact that no applicable gold standard for D4 
exists. Thereby no considerable competition was achieved in any brain area (Tab. 4.3). At 
a later date experiments were repeated by competing with three of the ligands described 
in chapter 5. With these substances also no significant blocking of [18F]FAUC 316 was 
observed. 
Reasons are due to the comparatively high lipophilicity of FAUC 316. It causes an 
extremely high non-specific membrane bindig which is unlike more intensive than specific 
D4 binding sites, especially due to the low distribution of D4 receptors in brain. In spite of 
the excellent affinity and selectivity of the inactive ligand [18F]FAUC 316, appears 
therefore not suited for in vivo applications. 
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Table 4.3: Percentage of non-specific binding content in cortex (Cx) and cerebellum (Cbl) of 
[18F]FAUC 316 ([18F]1) on rat brain slices by competing with different substances. No distinct 
competing was observed in any case. 
 Non-specific binding [%] 
 Global 
binding 
10 μM 
FAUC 316 
10 μM 
Spiperone 
6 μM 
33a 
6 μM 
33d 
10 μM 
33e 
 
   
   
Cx / 95 82 96 91 93 
Cbl / 97 79 87 92 88 
4.4 Interim summary 
Application of the Hartwig-Buchwald N-arylation in radiochemistry is an adequate 
method to generate n.c.a. [18F]fluoroarylamines and therefore a possibility for the 
production of D4 selective structures of this which are 18F-labelled at the arylamine 
moiety. Nevertheless, the procedure is intricate, especially due to its many time- and 
yield-consuming purification steps. Due to the fact that the replacable moiety indole-2-
aldehyde is introduced by an unproblematic reductive amination step, further 
optimization will refer to the synthesis of 4-[18F]fluorophenylpiperazine ([18F]28), a definit 
compound. 
However, [18F]FAUC 316 is unsuitable for in vivo imaging methods due to its very high 
non-specific binding. The logical next step for optimizing of a D4-radioligand of this class 
of compounds needs a derivatization of the structure in order to alter properties 
especially the lipophilicity. But this seems not feasible in this case without worsening its 
improve binding behaviour. Every derivatization of FAUC 316 would impair its excellent 
affinity and selectivity values with high probability. Then the complex radiosynthetic 
procedure would not be worthwhile any longer and it would be better to chose 
alternative structures with simplier radiosynthetic pathways. Furthermore, a loss complex 
synthetic procedure is desireable with regard to a possible future implementation in an 
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automated synthesis device. 
 5. Synthesis, 18F-labelling and preclinical evaluation of 
benzodioxine derivatives 
Since the results of pharmaceutical evaluation with the highly promising [18F]FAUC 316 
ligand demonstrated its uselessness for in vivo imaging, the strategies for a development 
of a D4 selective radioligand had to be changed. Although the D4 affinity and the 
selectivity against the receptors is still an important feature, it became obvious for the 
choice of prospective lead structures that they had to fulfil further prerequisites. As 
important property the lipophilicity of FAUC 316 should be regarded as upper limit for 
further developments. Nevertheless, since the structural backbone of a D4 ligand is nearly 
always the same (chapter 2.3) the range of lipohilicity for these ligands is in general small 
and therefore rarely much different from FAUC 316. Furthermore, the non-specific 
binding behaviour of a new lead structure cannot be foreseen. It is therefore important to 
have comparative simple possibilities of functionalization without strong influences on 
labelling processes.  
The benzodioxine 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4-fluorobenzyl)piper-
azine (33a) seemed to comply with these requirements. It was developed and patented 
by Hodgetts and Thurkauf158 for selective blocking of D4 receptors as a prospective 
antipsychotic for the treatment of schizophrenia. Published values for affinity and 
selectivity are excellent but so far only and roughly determined within the D2 family 
(Ki(D4) = 4 nM, Ki(D3) = >5000 nM, Ki(D2) = >5000 nM). Affinity values to receptors with 
known pharmacological similar behaviour like α1 and 5-HT1A remain unknown as well as 
no differentiation in haplotypes of the D2 and the D4 receptor was examined. It was 
therefore necessary to determine thoese properties just like for every new derivative 
(chapter 5.2). The calculated lipophilicity of this new lead structure with a cLog P value of 
3.35 lay already beneath that of FAUC 316 (cLog P = 3.70). Due to the 4-fluorobenzyl 
group of 33a many different labelling strategies appeared suitable including possibilities 
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for direct labelling. This moiety also offered a derivatisation which is discussed in more 
detail together with the lipophilicity properties of all considered ligands in chapter 5.4.1. 
5.1 Synthesis of benzodioxine standard and precursor 
compounds for 18F-labelling 
The synthesis of the non-radioactive standard compounds of derivatives of 32 and 33 
was performed for the in vitro determination of affinity values (Ki) and in vivo evaluation 
studies on rodents as well as of appropriate analytical conditions for the identification of 
n.c.a. radiolabelled compounds. The intermediate product 1-(1,4-benzodioxine-6-
yl)piperazine (30) was synthesized by a Prelog-cyclisation220,221 of the commercially 
available aminodioxine 2,3-dihydrobenzo[b][1,4]dioxin-6-amine with bis(2-
chloroethyl)amine hydrochloride in diethylene glycol or diethylene glycol monomethyl 
ether analogously to the description of Liu et al.222. Thereby higher yields were found 
while also saving one reaction step when compared to the palladium catalyzed coupling 
as described by Hodgetts et al.158 The Prelog annulations displays the easiest method to 
generate arylpiperazines when suitable anilines are available. This includes not only yield 
and reaction time, but also the purchase and costs of compounds as well as product 
purification. 
 
Figure 5.1: Comparison of synthesis routes for the preparation of the important intermediate 30. 
Reaction conditions: (a) Pd2(dba)3, P(o-tolyl)3, NaOtBu, 1-boc-piperazine, toluene, 100 °C; (b) TFA, 
CH2Cl2, rt; (c) C4H9NCl HCl, C2H6O2, 150 °C, 12 h; (d) Na2CO3  
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The intermediate product 30, obtained by both ways, was the common lead structure 
for all radioactive and inactive analogues of the lead structures 32 and 33; with exception 
of those for direct labelling syntheses. Isolating the hydrochloride product by 
precipitating the salt from methanol and liberation of the free base with Na2CO3 resulted 
in a pure white solid, directly useful for further synthetic steps. Alternatively the product 
30 was obtained from the supernatant by flash chromatography yielding a light yellowish 
solid which showed no differences neither in analytical properties nor in its reaction 
behaviour. 
 
Figure 5.2: Synthesis of the precursor for direct radiolabelling 32b and its reference compound 
32a and alternative synthesis of title compound 33e via 32c. 
Reaction conditions: (a) C2O2Cl2, DMF, CH2Cl2, 50 °C, 2h; (b) 30, CH3Cl, (CH3)3N o. C5H5N, rt, 3-24 h; 
(c) BH3THF, C4H8O, reflux, 24 h. 
 
Scheme 5.3: General synthesis schemes of title structures and reference compounds. 
Reaction conditions: (a) 30, K2CO3, KI, CH3CN, reflux, 18 h; (b) 30, CH3OH, CH3COOH, NaBH3CN, 
60 °C, 24 h   
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The nitro-benzylamid 32b and its corresponding fluorine-analogue 32a, as used 
standard were synthesized from the carboxylic acids by formation of acid chlorides as 
displayed in Figure 5.2. Due to the high yields of about 70 % of those coupling reactions 
the fluoropyridine-analogue (4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)(6-
fluoropyridin-3-yl)-methanone was also synthesized that way with the intention of 
subsequent reduction and therefore easy production of the pyridine standard compound 
33e. Problems of reduction, however, occurred as are described below. 
The coupling reaction of the starting intermediate 30 to the benzylamines 33a-f could 
be performed with corresponding benzylhalides, which led in case of 4-
fluorobenzylbromide to good yields of up to 55 % of 33a. Reductive amination with the 
appropriate aldehydes 32a-f, however, was selected as the preferred method, because 
due to better reproducibility and also easier synthesis of the aldehydes (cf. Scheme 5.3). 
Thus, a series of new 3-substituted 6-(4-[4-fluorobenzyl]piperazine-1-yl)benzodioxine 
derivatives were obtained in 20-85 % yield. They all represent standard reference 
compounds with exception of the pyridine compound 33e’ which is the precursor for 
direct labelling to [18F]33e. 
For the preparation of the pyridine reference compounds 33e and 33e’ 2-
fluoronicotinic acid or 2-chloronicotinic acid were used as starting material, respectively. 
While the chloro compound was commercially available, the fluoro-analogue was 
obtained by oxidation of 2-fluoro-5-methylpyridine to 2-fluoronicotinic acid which was 
converted to the nicotinic acid chloride, coupled to the amide, and subsequently reduced 
to the amine (cf. Fig. 5.2 and 5.4). Alternatively, the acid chloride was reduced to the 
alcohol, oxidized with Dess-Martin periodinane to the corresponding aldehyde (cf. Fig. 
5.4) and coupled by reductive amination as described above. The latter method resulted 
in higher yields because the conversion of the pyridineamide 32c to the corresponding 
amine by reduction with BH3THF or LiAlH4 proceeded very poorly.  
The precursors for direct radiofluorination by nucleophilic substitution with n.c.a. 
[18F]fluoride, the aldehydes (4-formyl-phenyl)-trimethylammonium triflate (40a) and (4-
formyl-3-methoxyphenyl)trimethylammonium triflate (40b), were synthesized by the well 
known amination of the corresponding fluorine compounds (commercially available) with 
dimethylamine hydrochloride and subsequent quaternization with methyltrifluoro- 
methane sulfonate223,224. 
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Figure 5.4: Synthesis of 5-nicotinic aldehyde (34e) as standard for labelling as well as intermediate 
to title compound 33e.  
Reaction conditions: (a) KMnO4, H2O, 100 °C; (b) C2O2Cl2, DMF, DCM, rt; (c) NaBH3, THF, 60 °C; (d) 
Dess-Martin periodinane, DCM, rt; (e) 1. sec-BuLi, C4H10O, -78 °C, 45 min; 2. DMF, rt 
 
The benzyl protected precursor (3-benzyloxy-4-formylphenyl)trimethylammonium 
triflate (40c) was synthesized by a 6-step reaction procedure starting from 4-bromo-N,N-
dimethylaniline (Fig. 5.5). The key step was the formation of the aldehyde group from the 
bromo compound with DMF and sec-butyllithium. The nitro precursors 40a’ and 40b’ 
were commercially available while 40c’ was synthesized by a benzylation of 4-nitro-3-
hydroxybenzaldehyde at a temperature of 110 °C following a procedure described by 
Langer et al.225. All aldehyde precursors (40a-e) are listed in Figure 5.9 (see below Chapt. 
5.3.2). A 4-step route starting from 4-fluoro-3-methoxybenzaldehyde by a Lewis acid 
assisted cleavage of the methyl group was utilized to prepare the corresponding hydroxy 
and benzyloxy reference compounds (33c, 33d) of the according radiolabelled 
compounds. Thus, the obtained series of compounds included the reference compounds 
of the desired radiolabelled analogs (33a, 33b, 33d and 33e), the precursors for aromatic 
18F-for-Cl or 18F-for-NO2 substitution (33f and 32b), and the precursor compounds 40a-e 
suitable for a two-step radiosynthesis of [18F]33a-e by reductive amination with 
intermediate 30. 
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Figure 5.5: Scheme of the 6-step reaction route to the precursor compound (3-benzyloxy-4-
formylphenyl)-trimethylammonium triflate 40c. 
Reaction conditions: (a) H2O2 (30 %), C4H6O3, -78 °C, 2 h (b) C4H6O3, 0 °C, 2 h (c) KOH, MeOH, 70 °C, 
2 h; (d) C7H7Br, K2CO3, acetone, reflux, 3 h; (e) 1. sec-BuLi, C4H10O, -78 °C, 45 min; 2. DMF, rt, 1 h; 
(f) CF3SO3CH3, CH2Cl2, 40 °C, 7 h 
5.2 Receptor binding and intrinsic affinities 
The 3-position of the 4-fluorobenzyl moiety was selected as derivatisation place to 
avoid the distress of problems with the molecule adjustment in the binding crevice. As 
shown in chapter 2.3.2 three OH-groups from different serines can interact with ligand 
moieties which are able to undergo hydrogen bridges. 
 All receptor binding assays were performed in the institute of pharmaceutical 
chemistry of the Friedrich-Alexander Universität Erlangen-Nürnberg (direction of Prof. Dr. 
P. Gmeiner) by Dr. H. Hübner. The results are discussed in this work, because the values 
found are basic facts for modelling of new ligands and evaluation of the radiotracers. Due 
to the necessity of this cooperationship binding affinities could only be determined with 
the inactive standard compounds which results in inhibitory constant (Ki) values as 
explained in chapter 2.2.5. Then main reason for determination of affinities is the obvious 
problem of an unpredictable alteration of affinity and selectivity of the original lead 
structure 33a due to derivatization. Therefore, the lead compound 33a and its derivatives 
33b, 33d and 33e were subjected to receptor binding studies for testing their ability to 
displace [3H]spiperone from the cloned human dopamine receptors D2long, D2short,226 D3,227 
Chapter 5: Synthesis, 18F-labelling and preclinical evaluation of benzodioxine derivatives 72 
and the most common D4 polymorphism D4.4,228 being stably expressed in Chinese 
hamster ovary (CHO) cells.229 33a was tested itself because different displacement studies 
often show differences.  
Additionally, the metabotropic receptors 5-HT1A, 5-HT2A and α1, from which it is known 
that they could reveal competing binding affinity for putative D4 ligands, were measured 
utilizing porcine cortical membranes and the selective radioligands [3H]WAY600135, 
[3H]ketanserin and [3H]prazosin, respectively.230 The in human brain highly expressed but 
structurally and functionally different dopaminergic receptor D1 was measured using 
porcine striatal membranes and the radioligand [3H]SCH23990. The results of the receptor 
binding studies are presented in Table 5.1. 
 
Table 5.1: Binding affinities of the derivatives 33a, 33b, 33d and 33e to the human dopamine 
receptor subtypes D2long, D2short, D3, and D4.4, the porcine D1 receptor, as well as the porcine 5-HT1A, 
5-HT2, and α1 receptors  
 
 
compound Ki values ± SD [nM]a 
 R hD2longb hD2shortb hD3b hD4.4b pD1c p5-HT1Ad p5-HT2e pα1f 
33a H 
7600 ± 
570 
5700 ± 
1300 
3900 ± 
71  
1.1 ± 
0.56 
19000 
 ± 11000 
5200 ± 
2200 
7000 ± 
5700 
4000 ± 
780 
33b OMe 
17000 ± 
1400 
16000 ± 
2100 
5900 ± 
640  
4.2 ± 
0.071 
23000 
 ± 4200 
5600 ± 
2100 
4200 ± 
2100 
3300 ± 
350 
33d OH 
9000 
± 1100 
6100 
± 71 
4200 
± 1300  
7.3 ± 
2.6 
15000 
 ± 3600 
6200 ± 
710 
2300 ± 
640 
3000 ± 
210 
33e - 
29000 ± 
20000 
45000 ± 
710 
17000 ± 
710  
15 ± 
0.71 
35000 
 ± 4200 
21000 ± 
2100 
5800 ± 
2100 
11000 ± 
710 
a Ki-Values [nm] are mean values of two independent experiments each done in triplicate. 
b [3H]spiperone. c [3H]SCH 23990. d [3H]WAY600135. e [3H]ketanserin. f [3H]prazosin. 
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All ligands showed a good affinity to the D4 receptor in the low nanomolar range and 
weak affinities to all other tested receptors (Tab. 5.1). Among the series of compounds, 
the lead compound 33a showed the highest affinity to the D4 receptor combined with an 
exceptional D4 subtype selectivity (Tab. 5.2). Higher values were found here when 
compared with the earlier measured affinities within the D2-familiy described by Hodgetts 
at al.158 Nevertheless, the introduction of a methoxy or hydroxy group into the 
fluorophenyl moiety (see 33b, 33d) led to a minor decrease in D4 affinity of these 
compounds. This is astonishing due to an estimated increase of affinities with insertion of 
moieties with the ability to form hydrogen bridges. The displacement of the fluorophenyl 
group by the fluoropyridinyl substituent (33e) induced a decrease in D4 affinity by a factor 
of about 10. However, the D4 subtype selectivity of >1000 (D4/D3) and >2000 (D4/D2) for 
33e appears still adequate for in vivo imaging.  
In general, the subtype selectivity was high for all derivatives (Tab. 5.2), but highest for 
33a, followed by 33b, 33e and 33d. Remarkably, selectivities of 33a measured in this 
study displayed a Ki ratio of more than 5000 for D2 (D4/D2) and 3500 for D3 (D4/D3), which 
is one of the highest selectivities for D4 over D3 reported up to now.  
 
Table 5.2: D4 subtype selectivity within the family of D2-like receptors 
compound 
hD4.4 ratio of Ki(D2 or D3) / Ki(D4.4) 
Ki [nM] hD2long / hD4.4 hD2short / hD4.4 hD3 / hD4.4 
33a 1.1 6666 5000 3571 
33b 4.2 4000 3846 1408 
33d 7.3 1250 833 588 
33e 15 2000 3030 1136 
 
The original lead structure 33a is described as an antagonist at the D4 receptor. Data 
on receptor affinities were extended by functional data using a previously described 
mitogenesis assay to confirm this data and to determine the intrinsic activity of the other 
derivatives 231. The agonist activation of dopamine receptors is known to increase 
mitogenesis in heterologously transfected cell lines, measuring the rate of proliferation in 
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growing cells232. Full and partial agonist ligands preferentially bind to the active GPCR 
conformation (high-affinity state), inverse agonists favour binding to the inactive 
receptor, and antagonists have equal affinity for the active and inactive state. Since in 
general the inactive GPCR conformation is predominant, differences in binding kinetics 
are estimated for agonists and antagonists. It is important to determine the intrinsic 
activity for a putative radioligand helping to interpret these differences in the in vivo 
behaviour of radioligands. The intrinsic activity of the series of title compounds was 
investigated by measuring the [3H]thymidine incorporation into growing CHO cells stably 
expressing the dopamine D4 receptor233. As shown in Figure 5.6, a neutral antagonism 
was determined for all title compounds under investigation when compared to the 
reference quinpirole. 
 
Figure 5.6: Measurement of [3H]thymidine incorporation in D4 expressing cells as an assay for 
functional activity; dose-dependent increase of incorporation of radioactivity as a matter of 
activation of the human dopamine D4.4 receptor stably transfected in CHO cells compared to the 
effect of the full agonist quinpirole (= 100 %). 
 
In summary, the radiosyntheses of the corresponding 18F-labelled antagonistic 
radioligands 33a, 33b, 33d and 33e was aspired due to their promising high D4 receptor 
affinity and distinct D4 receptor subtype-selectivity. 
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5.3 Radiosynthesis of benzodioxine derivatives 
5.3.1 Direct n.c.a. 18F-labelling of benzodioxine derivatives 
For direct labelling with n.c.a. [18F]fluoride by nucleophilic substitution on arenes the 
presence of an electron withdrawing group is necessary as previously described in 
chapter 2.2.3. Therefore, the synthesis of n.c.a. 4-[18F]fluorophenylpiperazines is only 
suitably practicable by labelling of the corresponding amides and subsequent reduction as 
described for inactive compounds above. The nitro group was selected as the best 
adaptable leaving group for the SNAr reaction. Trimethylammonium triflat cannot be 
generated in these compounds due to the rivalry of the two tertiary arylamines 
(dimethyl- and arylpiperazine-group) with very similar pKa values. Kryptofix 2.2.2 was 
used as anion activator and DMSO and DMF as solvents. In DMSO substitution of the nitro 
group resulted in radiochemical yields of up to 50 % after 15 min. As a typical character of 
direct labelling adequate yields are only obtained with very high reaction temperatures of 
at least 160 °C. Therefore, DMF cannot be used due to its lower boiling point although it 
displays considerably higher radiochemical yields at equal temperatures (Fig. 5.8). 
However, a reproducibility of radiochemical yields cannot be guaranteed using DMF at 
higher temperatures than 140 °C. 
 
 
Figure 5.7: Radiosynthesis of [18F]33a and [18F]33e by direct nucleophilic substitution.  
Reaction conditions: (a) [18F]F-, K 2.2.2, K2CO3, DMSO, 160 °C, 15 min; (b) BH3THF, THF, 65 °C, 15 
min; (c) [18F]F-, K 2.2.2, K2CO3, DMSO, 160 °C, 20 min 
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The reduction of the amide [18F]32a was at first conducted with the strong reduction 
system LiAlH4/AlCl3 in diethylether or THF due to the absence of further substituents for 
sensitive reduction. Nevertheless, yields of the reduction with LiAlH4 switched from 100 % 
to zero after 5 min reaction time and no reproducibility could be reached. Furthermore, 
rapid hydrogen evolution hampers the working conditions. Using the BH3/THF complex as 
reducing agent led to a conversion of 42 ± 4 %, but requires 65 °C and 15 min reaction 
time. Despite a theoretical overall yield of about 20 %, after separation with a semi-
preparative HPLC column (Gemini C18, Phenomenex 250×10 mm) the radiochemical 
yields of [18F]33a were only marginally above 1 % at the end of synthesis (EOS). The 
reason for this is the high number of solid phase extraction steps (3), where each time a 
loss of yield can be observed as well as losses during subsequent HPLC separation. These 
poor yields initiated renunciation of direct labelling to build-up radiosynthesis methods 
which are described in the next chapter.   
 
Figure 5.8: Time dependence of radiochemical yield (RCY) of [18F]32a at different reaction 
temperatures in DMSO (red) and DMF (black) by direct 18F-substitution on 32b. 
Reaction conditions: n.c.a. [18F]F-, [32b] = 40 mmol/L, [K 2.2.2] = 40 mmol/L, [K2CO3] = 20 
mmol/L, solvent = 0.5 mL 
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The situation is different with the pyridine derivative 33e due to the fact that pyridines 
itself led, however, to an aromatic activation for nucleophilic substitution in ortho- and 
para-position. Only poor radiochemical yields up to 5 % of [18F]33e  were obtained at 
160 °C in DMSO after 30 min despite this fact and high radiochemical yields of 2-
[18F]fluoropyridine described in literature77.  
5.3.2 Build-up synthesis of benzodioxine derivatives by reductive 
amination 
Since the first utilization of reductive amination of 18F-labelled aldehydes by Wilson et 
al.223, the method has proven convenient to produce corresponding no-carrier-added 
benzylamines with fluorine-18 in aryl position. The labelling conditions comprise a 
temperature range of about 130-150 °C, DMSO as solvent and (K 2.2.2)/carbonate as 
anion activator234. The normal procedure includs the separation of the labelled aldehyde 
by solid phase extraction or the HPLC purification and performing the amination reaction 
in a mixture of MeOH and CH3CO2H and temperatures of about 60 °C. As a variation of the 
Leuckart-Wallach reaction235,236 sodium cyanoborohydride is commonly chosen as 
reducing agent instead of an excess of formic acid. Hai-Bin et al. showed that reductive 
amination reactions can also be performed in the presence of DMSO and Kryptofix 
2.2.2237. Thus, labelling and reductive amination could be performed as a one-pot 
reaction using DMSO at the same temperature of 110° C.  
 
 
Figure 5.9: Radiosynthesis of [18F]33a-c and  [18F]33e by a two-step, one-pot reaction.  
Reaction conditions: (a) [18F]F-, K 2.2.2, K2CO3, DMSO, 110 °C; (b) 30, NaBH3CN, DMSO, 110 °C; 
(c) Pd(black), HCOONH4, MeOH, 60 °C, 10 min 
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For the reductive aminations performed here the addition of methanol to the reaction 
mixture was found unnecessary in contrast to acetic acid which is an essential reagent for 
the rapid formation of the immonium ion. 
Furthermore, less radioactive side products were found by using DMSO instead of 
methanol. In DMSO a nearly quantitative conversion of the 18F-labelled aldehyde to the 
tertiary amine could be observed by radio-HPLC analysis. Performing the one-pot reaction 
with DMF, which is also a suitable solvent for radiofluorination of aldehydes, or using 
lower temperatures, however, led to an extreme loss of the radiochemical yield. A 
general disadvantage of the one-pot synthesis, however, is the accumulation of inactive 
reactants and unidentified side products in the final reaction solution. Therefore, HPLC 
purification can severely be obstructed depending on the respective product. 
 
Figure 5.10: Time dependence of radiochemical yield of 18F-labelling of benzaldehyde derivatives. 
For comparison nitro precursors (34a’-c’) are displayed in blue and with dashed lines while 
benzaldehyde trimethylammonium triflates are shown in red. 6-[18F]Fluoropyridinealdehyde 
(34e), also displayed in red, shows the highest yields at short time but followed by rapid 
degradation. 
Reaction conditions: n.c.a. [18F]F-, [34a-e] = 20-60 mmol/L, [K 2.2.2] = 40 mmol/L, [K2CO3] = 20 
mmol/L, DMSO = 0.5 mL, 110 °C  
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The unsubstituted and the methoxy compounds ([18F]33a, [18F]33b) could be 
generated as described above in radiochemical yields of about 60 % and with a molar 
activitiy of about 60 GBq/μmol, when starting with about 500-1000 MBq of [18F]fluoride. 
By 18F-fluorination of the extremely activated ortho-position of 6-chloronicotinaldehyde 
40e defluorination of [18F]34e occurred after a very short reaction time after about 2 min 
depending on the precursor concentration. A higher amount of precursor acted as a 
pseudo carrier and diminished the rate of decomposition to some extend. The influence 
of both activating systems (aldehyde and pyridine) seems to polarize C-F binding that 
strong that even weaker nucleophiles (every halide, hydride or hydroxy) in low 
concentrations can displace [18F]fluoride. Despite these findings no comparable 
observation is described in the literature for similar compounds like 6-chloronicotinic acid 
dietylamide during its 18F-fluorination76. Back reaction with chloride as nucleophile, which 
is also conceivable would lead to an equilibrium which is not observed during the 
fluorination procedure (Fig. 5.13 A). Nevertheless, after reductive amination (Fig. 5.13 B) 
the chloro derivative 33e’ is observed as a main inactive side product. The unsubstituted 
derivative 33f was also determined after reductive amination and confirmed the 
hypothesis of a defluorination (Fig. 5.11). 
 
Figure 5.11: Chromatogram of semi-preparative HPLC-purification of the pyridine analogue 
[18F]33e. The black line shows the output from the γ-counter while the blue line describes the UV-
absorption. Main inactive side products are the chloro analogue 33e’ as well as the unsubstituted 
derivative 33f. In the front inactive side products are supposed to consist of reactands, aldehydes 
and decomposition products but were not all identified.  
HPLC-column: Gemini 5 μm C18 110Å, 250×10 mm, Phenomenex. Eluent: 40/60/0.1 
MeCN/H2O/TEA (v/v/v); 4 mL/min  
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Figure 5.12: Time dependence of the total radiochemical yield of the amination reaction related 
to [18F]F- (blue) as well as the radiochemical yield of the products ([18F]33a,b,c,e) related to the 
intermediate aldehyde compounds ([18F]34a,b,c,e) (red).  
Reaction conditions: [30] = 46 mmol/L, NaBH3CN = 64 μmol, DMSO = 0.6 mL, AcOH = 40 μL, 110 °C 
 
Defluorination was also the critical side reaction when the reductive amination 
reaction on [18F]34e was performed. Any change of reaction parameters, however, such 
as reaction time, lowering the amine concentration or reaction temperature or using 
weaker reduction systems resulted in very poor radiochemical yields.  
For pre-purification of [18F]33c SepPac C18 cartridge were used. Problems with large 
amounts of persisting inactive lipophilic impurities which overly the product peak in HPLC 
could be removed by using the weaker, more hydrophilic eluent ethanol/water instead of 
acetonitrile, but the higher purity was only attained on the account of total yield. 
For the production of the 18F-labelled hydroxy derivative [18F]33d 18F-fluorination and 
amination with the benzyl protected aldehyde compound [18F]33c were performed as 
described above. This intermediate product was easier separated from the reaction 
solution by adsorption on an EN cartridge since the benzyl group led to a considerable 
higher lipophilicity. Thus, the above described problems with final HPLC purification are 
not valid for the hydroxy derivative. Despite that, the obtained radiochemical yield after 
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semi-preparative radio HPLC separation was lower than for all others. 
 
 
Figure 5.13: Time dependence of RCY of [18F]34e (A) and of subsequent amination to [18F]33e 
related to [18F]34e (B) according to precursor and amine concentration, respectively. In both cases 
a lower concentration leads to a rapid degradation of [18F]34e.  
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Losses during the synthesis of [18F]33d can occur due to the additional reaction 
(cleavage) and therefore extraction step and adsorption processes during this cleaving 
step. The cleavage of the benzyl protection group was succeeded in methanol with 
ammonium formate and palladium black at 60 °C under inert conditions. Previously a 
complete drying of the benzyl-intermediate by a stream of argon and elution through an 
AluminaN® cartridge is necessary. An acid cleavage with strong acids like trifluoroacetic 
acid, which could possibly be performed without further separation, is not suitable 
because of a rapid degradation of the dioxine component and of enhancing more 
preferred side reactions. Similar degradations can be observed when cleavage of the 
methoxy substituent from [18F]33b with BBr3 is performed. 
All radiosyntheses result in molar activities (AM) of about 30-60 GBq/μmol (cf. Tab. 5.3) 
which are high enough to guarantee the possibility of a specific accumulation of every 
radioligand far from levels of saturation. 
5.3.3 Comparison of 18F-labelling methods for benzodioxine derivatives 
While direct labelling is normally the method of choice and build-up synthesis is 
normally reserved for cases when the former fails, in direct comparison of both methods, 
here the latter lead to better results. In both cases of direct labelling only a radiochemical 
yield of about 1-5 % as achieved at the end of synthesis while the build-up syntheses lead 
to radiochemical yields of 9-35 %. The required reaction time of 120 min in case of 
[18F]33a, exemplarily for [18F]33b and [18F]33c as well, could not keep up with the two-
step amination reaction. This is due to the high 18F-labelling yields with the 
trimethylammonium triflate benzaldehydes and the fact that the applicable one-pot 
operation demonstrates the advantage of a single step with respect to effort, product 
loss, and synthesis time. Further reasons include the insensitivity and therefore 
reproducability of the reductive amination reaction and its high conversion rates which 
make this reaction type remarkable appropriate for n.c.a. 18F-chemistry.  
An exception displays the pyridine derivative because generating the 18F-labelled 
product [18F]33e could be done in a single step. However, 18F-fluorination of the 6-
chloronicotinic aldehyde led to many inactive side products which complicate product 
separation processes and gave lower yields. On the other hand, the extremely poor yield 
obtained from direct labelling of the chloropyridine-methylpiperazine 33e’ compound 
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was surprising when compared to the normally good results of nucleophilic substitution 
at the ortho- or para-position of pyridines. Therefore, it seems worthwhile for further 
experiments to examine other leaving groups with this compound like the nitro 
substituent. Using microwave irradiation as it is described in many 18F-labelling 
procedures of pyridines before would be another reasonable option for possible 
improvement. 
 
Table 5.3: Radiochemical yields of radiofluorination and amination steps to yield [18F]33a-b and 
[18F]33d-e in a one-pot reaction according to figure 5.9. 
precursor time  
(min) 
[18F]fluoro-
aldehyde 
RCY 
(%) 
total 
time 
(min) 
final 
product 
RCY at 
EOS (%)   
AM 
(GBq/μmol) 
40a 10 
[18F]34a 
75 ± 5 
~90 [18F]33a 35 ± 5 60 
40a’ 12 38 ± 1.5 
40b 10 
[18F]34b 
72 ± 5 
~90 [18F]33b 20 ± 5 50 
40b’ 15 30 ± 5 
40c 5 
[18F]34c 
80 ± 2 
~120 [18F]33d 9 ± 4 27 
40c’ 10 48 ± 7 
40e 2 [18F]34e 80 ± 6 ~80 [18F]33e 15 ± 5 40 
EOS = end of synthesis. 
 
Table 5.4: Radiochemical yields of [18F]33a and [18F]33e by direct labelling in DMSO at 160 °C. 
precursor final 
product 
total synth. 
time (min) 
RCY at EOS 
(%) 
32b [18F]33a 120 5 ± 2 
33e’ [18F]33e 50 1 ± 0.5 
EOS = end of synthesis. 
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5.4 Pharmacological evaluation of 18F-labelled benzodioxine 
derivatives as D4 ligands 
5.4.1 Lipophilicity 
As an adequate estimation of this physicochemical property the MarvinSketch 5.1.4 
software239 and the ALOGPS 2.1 software240 were used to calculate Log P values of 
compounds 33a-b and 33d-e which were estimated between 2.3 and 3.4 (Tab. 5.5). The 
two different algorithms showed very similar results. However, experimental lipophilicity 
values (Log P and Log D), ranging from 1.7 to 2.7, were again rather close to each other 
but clearly lower than the theoretical ones. Experimental values were obtained by two 
different methods at pH 7.4, i.e. shake flask and HPLC method, according to the OECD 
guidelines for the testing of chemicals241. As explained in chapter 2.5 the values obtained 
by the shake flask method include all species in solution (Log D7.4) and is more real to the 
situation at biomembranes. Otherwise this method was not trusted at higher lipophilicity 
due to the easy contamination of the two phases. The obtained Log P and Log D values 
were determined to be between 1.7 to 2.4, a range that is proposed for ligands to 
penetrate the blood brain barrier, suggesting sufficient brain uptake of the corresponding 
radioligands. 
 
Table 5.5: Calculated and experimental log P7.4 values of the derivatives 33a-33e 
Ligand 33a 33b 33d 33e 
cLog P (Marvin) 3.35 3.09 2.87 2.49 
cLog P (ALOGPS) 3.23 ± 0.27 3.11 ± 0.45 2.81 ± 0.37 2.26 ± 0.32 
Log P7.4  2.71 ± 0.03 2.44 ± 0.07 1.70 ± 0.15 2.02 ± 0.17 
Log D7.4  n.d. 2.33 ± 0.09 1.78 ± 0.01 1.81 ± 0.05 
 
Differences between calculated and experimental lipophilicity values of ΔLog P values 
of about 0.6 and 0.7, respectively, are very similar for the unsubstituted compound 33a 
and its methoxy derivative 33b. The highest difference with ΔLog P of about 1.1 is shown 
by the hydroxyl derivative 33d. A possible reason can lay in the nature of the OH group 
which can form hydrogen bonds both as donor and acceptor and therefore lead to an 
unclear protonated state, 3D structure and solvent interaction of this molecule, which is 
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not comprised by the algorithms of the used programmes. The fact that differences in 
results within both experimental methods are small let presume that despite this, nearly 
only one species exists at pH 7.4. With ΔLog P of about 0.45 the difference between 
calculated and experimental values of the pyridine derivative 33e is the smallest but lays 
in the range of 33a/b. For the more hydrophilic compounds the trend observed with 
experimental values is reversely to that of the calculated ones. It is estimated that this 
observation is more due to the hydroxyl derivative which is assured by the linear slope 
(cp. Fig. 5.14). It is regarded that in case of plotting the lipophilicity against the non-
specific binding, calculated cLog P values show the more definite trend. 
5.4.2 Autoradiography 
In vitro and ex vivo autoradiography as well as biodistribution and metabolization 
studies were performed in close cooperation with the radiopharmacology group of the 
INM-5.  
As explained in detail in chapter 2.5, non-specific binding, the binding which remains 
after an addition of an access of inactive specific ligands, often leads to a disqualification 
of selective radioligands. In the majority this is related to lipophilic structures. Lesser 
known is, that the assumption non-specific binding would be totally unsaturable is 
wrong184. Therefore, the non-specific binding of two structures with a different 
pharmacological profile is not comparable and does not necessarily depend on their 
lipophilicity.  
After determination of suitable affinity and subtype selectivity of all tested substances 
to the D4 receptor, in vitro autoradiography studies on horizontal rat brain slices were 
performed with those ligands labelled with fluorine-18 in order to compare the non-
specific binding pattern and the lipophilicity. For this, 18F-labelled compounds were 
competed with an excess of the inactive standards 33a-33b and 33d-33e. No differences 
in competition behaviour could be found between competition with the original identical 
standard compound or with another ligand. Thereby a confirmation of the postulated 
relationship185,192,242 between non-specific binding and lipophilicity (Fig. 5.14) was found. 
The more lipophilic radioligands [18F]33a and [18F]33b showed inacceptable high non-
specific binding of 96 % and 79 %, respectively, and seem therefore unsuitable as 
potential radiotracers. In contrast, non-specific binding of [18F]33d was only 33 %, and 
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[18F]33e showed even a lower non-specific binding of only 7 %. Although [18F]33e 
exhibited a lower D4 affinity than the other ligands, it therefor lends itself for further ex 
vivo studies due to its high selectivity and low non-specific binding.  
In vitro autoradiography studies of the more hydrophilic compounds [18F]33d and 
[18F]33e showed generally a specific binding within the whole rat brain. Both compounds 
displayed a distinct high accumulation in the colliculus and in the medial nuclei of the 
cerebellum. As presented in Figure 5.15 there is no marked higher accumulation in 
hippocampus, frontal cortex and striatum. 
 
Figure 5.14: Relation of experimentaly determined Log P7.4 values (red) and calculated cLog P 
values (blue) of the derivatives 33a, 33b and 33d, 33e and of non-specific binding of the 18F-
labelled compounds received by competition studies with reference compounds on Wistar rat 
brain slices in vitro. 
 
By contrast, in ex vivo autoradiography studies with NMRI mice high binding was 
observed in the cortex and hippocampus. In comparison with the cresyl violet stained 
image of the same slice the good contrast allows differentiating between the outer layers 
of cortex with high binding and lower binding in middle layers of cortex. In the 
hippocampus high binding uptake was observed in dentate gyrus (GD) and cornu 
ammonis 3 (CA3). This is in agreement with findings of Prante et al.243 who described a 
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significant higher uptake in the gyrus dentate of rat brain slices with a 18F-labelled 
pyrazolo[1,5-α]pyridine D4 ligand but not in the other regions of hippocampus. High 
uptake in vitro and ex vivo was observed in regions of the colliculus. This brain region, 
responsible for sorting out of optical and acoustical information, was described as a part 
of brain, where D4 receptors should be found130, but which often is not mentioned as 
region of interest. Otherwise the high accumulation of the radioligand in the cerebellum 
is controversial to the estimated D4 distribution in brain, although there is information in 
the literature on D4R expressing genes which are also found in this tissue130. However, no 
uptake in striatum was observed which is in accordance to the literature130,131,133-135.  
 
 
 
Figure 5.15: In vitro autoradiography of a rat brain (A) with 5 nmol/L [18F]33e and after blocking 
with 10 μM 33e (B) to show low non-specific binding. Sagittal slices of in vitro (C) and ex vivo (D) 
autoradiography studies of mouse brain with [18F]33e are displayed for comparison. 
 
In order to exclude that different binding in vitro and in vivo might be due to 
differences of species, in vitro autoradiography of NMRI mouse brain slices was also 
performed. Even though a slightly higher binding in cortex was recognized here, the 
contrast of radioligand accumulation was worse in comparison to the ex vivo 
autoradiograms. Possible reasons for that finding could be a metabolisation by a 
unforeseen significance of enzymes in vitro or by the used incubation buffer; however, 
both explanations were falsified by experiment. Thus, it was assumed, that a notable 
binding in intracellular compounds which are only accessibly in vitro may result in a 
higher non-specific background. For a comparison with an autoradiography of the rare 
Chapter 5: Synthesis, 18F-labelling and preclinical evaluation of benzodioxine derivatives 88 
literature showing results with D4 ligands, sagittal mouse brain slices were chosen and the 
ex vivo binding distribution compared with rat brain slices of the 131I-labelled ligand 
FAUC113 (Ki = 2.6 nM)244. In both studies similar binding was found in cortex and 
thalamus, which affirms binding in the limbic system. Also cerebellar binding was in 
accordance with the previous work. 
 
 
 
Figure 5.16: Ex vivo autoradiography (left) of horizontal planes of a mouse brain 15 min after 
injection of [18F]33e and the corresponding histological image stained with cresyl violet (right). 
 
5.4.3 Biodistribution and in vivo stability 
For preliminary biodistribution studies of [18F]33e each three NMRI mice were 
sacrificed at 5, 10, 15 and 30 min p.i.. Due to the low lipophilicity of the ligand there was a 
rapid accumulation in the kidney. As expected the hepatic uptake was lower. A high 
penetration of the blood brain barrier was observed in spite of the rather low log P of 1.8 
with a brain uptake of about 5 % ID/g tissue after 5 min. After 30 min there was still more 
than 1 % ID/g in the brain. The data show a continuous decrease (Fig. 5.17) thus no 
compartment-trapping seems to be responsible for the high uptake.  
In vivo stability of the radioligand [18F]33e was checked by thin layer chromatography 
(TLC) on aluminium oxid layers. For thos, the whole blood activity and plasma activity as 
well as plasma activity and activity of plasma extracts was compared to ensure that all 
potential metabolites are analyzed.  
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Figure 5.17: Time dependence of uptake of [18F]33e as %ID/g in the brain of NMRI mice. 
 
There was a loss of about 27 % of radioactivity in the plasma after centrifugation of the 
blood. This was lower than the hematocrit of mouse (35 - 49 %) why it is assumed that all 
losses were due to adsorbtion and that no binding to blood cells occurred. Similarly, there 
was no significant loss of radioactivity after deproteination of the plasma (< 2 %), so that 
all generated metabolites are analyzed. All observed metabolites did not move on the 
silica gel plates with the chosen solvent (ethyl acetate/methanol/diethyl amine 96:2:2), 
thus they were all hydrophilic. Furthermore, it is suggested, that defluorination did not 
take place to a considerable extend because of the very low bone uptake (< 2.7 %ID/g 
tissue) at all p.i. time points (Tab. 5.6). An increasing defluorination would lead to a rise of 
[18F]fluoride accumulating bones, which is not observed. The half life of in vivo stability in 
blood of 38-39 °C (NMRI mouse) was about 5 min indicating fast metabolisation according 
to the fast metabolism of mice.  
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Figure 5.18: In vivo stability of [18F]33e in NMRI mice determined by radio-TLC. In the plasma 
ectract (A) beside the ligand a single spot at the base line can be observed over the whole time 
which can be due to metabolites or “artifacts” or both.  
To ensure that all active products are captured, recovery (r) of blood, plasma and plasma extract 
is determined. In vivo stability in plasma extract at a higher dilution with buffer and acetonitrile is 
compared to that in the brain (B). In the brain nearly no metabolites can be observed. B = blood; P 
= plasma; E = plasma extract; Ht = hematocrit; r = recovery; TLC = thin layer chromatography; EA = 
ethylacetate; DEA = diethylamine 
 
Tests for metabolization in the brain were performed after 10 min in the same way but 
using a higher dilution during the extraction steps feasible by using higher amounts of 
radioactivity. There was only found an extremely slight sign of metabolization after 10 
min in the mouse brain. Analysing the blood plasma of the same animals and also using a 
high dilution during extraction led to comparable findings of rapid metabolisation to 
those before.  
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Table 5.6: Biodistribution data of [18F]33e in NMRI mice (n = 3) 
 % ID / g tissue 
5 min 10 min 15 min 30 min 
Brain 4.93 ± 
1.58 
 
2.85 ± 
0.14 
 
2.27 ± 
0.17 
 
1.47 ± 
0.15 
 
Heart 1.80 ± 
1.00 
 
0.52 ± 
0.04 
 
0.58 ± 
0.31 
 
1.13 ± 
0.35 
 
Lung 12.99 ± 
2.53 
 
4.84 ± 
1.21 
 
4.79 ± 
0.68 
 
2.68 ± 
0.80 
 
Liver 4.13 ± 
1.76 
 
6.78 ± 
0.28 
 
5.67 ± 
0.30 
 
7.79 ± 
0.39 
 
Kidney 8.23 ± 
2.85 
 
5.86 ± 
0.62 
 
4.67 ± 
0.40 
 
6.03 ± 
0.61 
 
Spleen 4.42 ± 
1.62 
 
3.60 ± 
0.15 
 
3.19 ± 
0.20 
 
3.13 ± 
0.18 
 
Intestine 2.16 ± 
0.70 
 
2.68 ± 
0.19 
 
2.51 ± 
0.39 
 
4.47 ± 
0.20 
 
Pancreas 8.36 ± 
3.55 
 
11.10 ± 
0.37 
 
6.88 ± 
1.44 
 
7.43 ± 
0.56 
 
Bone 2.03 ± 
0.51 
 
2.54 ± 
0.33 
 
2.70 ± 
0.89 
 
0.93 ± 
1.05 
 
Blood 
final 
1.62 ± 
0.14 
 
1.29 ± 
0.16 
 
1.23 ± 
0.33 
 
0.53 ± 
0.21 
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Therefore, it is expected that the obtained in vivo stability curve of [18F]33e (Fig. 5.19) 
does only contain a small amount of “pseudo-metabolites” (artifacts) which may occur by 
retaining of the radioligand by remaining dried proteins.  
It can be assumed that the different metabolization rate indicated were due to a 
degeneration of the ligand on thin layer plates, which only occurs under n.c.a. conditions 
and which is rapid on silica but moderate on alox plates. 
 
Figure 5.19: In vivo stability of [18F]33e in blood plasma of NMRI mice measured by radio-TLC. The 
open circle point shows the result of the experiment with a higher dilution of analysed plasma 
extract from which was known that all measured activity except from the radioligand-spot were 
true metabolites and no artifacts. 
5.5 Interim summary 
The reductive amination reaction for the coupling of 18F-labelled aldehydes with 
secondary amines proved very useful in radiochemistry also in this study here. Since this 
reaction tolerates water and requires relatively mild reaction conditions like 60-110 °C, a 
weak acid and mild reduction agents, the reproducibility of this method is high also with 
n.c.a. radiochemistry. Furthermore, the toleration of a lot of different solvents offers the 
possibility of performing a two step synthesis without interim separation. From all four 
examined derivatives here, only the fluoronicotine aldehyde [18F]34e appeared a little 
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problematic due to its rapid decomposition during the first labelling step. 
The alternative labelling concept by a direct nucleophilic substitution of phenyl-
piperazinebenzodioxine precursors was possible but resulted in lower radiochemical 
yields for all derivatives tested. With the pyridine derivative [18F]33e a direct labelling of 
corresponding precursors with other leaving groups (e.g. the nitro group) appears 
suitable offering the radiosynthesis by a single step reaction. 
When plotting the non-specific binding on rat brain slices of all derivatives against its 
lipophilicity, an almost linear relation is recognized. The original ligand [18F]33a, with a 
calculated lipophilicity similar to that of [18F]FAUC 316, shows also a very high non-
specific binding. The influence and binding behaviour to lipid membranes is therefore 
estimated as similar (cp. 2.4). In contrast, the two less lipophilic derivatives [18F]33d and 
[18F]33e with less non-specific binding appear suitable for in vivo imaging methods. 
Especially [18F]33e which shows a good affinity and selectivity and a non-specific binding 
of only 7 %, appears as excellent candidate for D4 receptor imaging. Its high brain uptake, 
adequate metabolisation (almost no metabolites in brain) and high-contrast brain 
distribution in the mouse model underline this assumption and encourage further 
preclinical examination. 
 

 6. Experimental 
6.1 Materials, chromatographic and spectrometric 
procedures 
All reagents and anhydrous solvents were purchased from Aldrich (Steinheim, 
Germany) or Fluka (Buchs, Switzerland) and used without further purification. Other 
compounds were synthesized according to literature methods. 
Sep-Pak C-18 plus-cartridges were purchased from Waters (Eschborn, Germany), EN 
cartridges and Li-Chrolut glass columns (65 x 10 mm) from Merck (Darmstadt, Germany). 
Thin layer chromatography (TLC) was run on precoated plates of silica gel 60F254 (Merck) 
or Alumina N (Macherey-Nagel). The compounds were detected at 256 nm. HPLC was 
performed on the following system from Dionex (Idstein, Germany): an Ultimate 3000 
LPG-3400A HPLC pump, an Ultimate 3000 VWD-3100 UV/VIS-detector (272 nm), a UCI-50 
chromatography interface, an injection valve P/N 8215. Reversed-phase HPLC was carried 
out using a Gemini 5 mm C18 110A column, for analytical separations with a dimension of 
250mm × 4.6mm (flow 1 mL/min) and for semi-preparative applications 250mm × 10mm 
(flow 5 mL/min) from Phenomenex (Aschaffenburg, Germany). Radio TLC chromatograms 
were detected on a Packard Instant Imager. 1H, 13C and 19F NMR spectra were recorded 
on a Bruker DPX Avance 200 spectrometer with samples dissolved in CDCl3 or d6-DMSO. 
All shifts are given in δ ppm using the signals of the appropriate solvent as a reference. 
Mass spectra were obtained from a Finnigan Automass Multi mass spectrometer with an 
electron beam energy of 70 eV. High resolution electron spray mass spectra were 
recorded on an LTQ FT Ultra (Thermo Fischer). Melting points are uncorrected and were 
determined on a Mettler FP-61 apparatus in open capillaries. 
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6.2 Synthesis of [18F]FAUC 316 
6.2.1 Syntheses of precursor and standard compounds 
6.2.1.1 Indole syntheses by intramolecular coupling 
4-Amino-3-iodobenzonitrile (2) 
In a 1-L one-neck flask 16.05 g (63.3 mmol) of I2 and 19.74 g (63.3 mmol) 
of silver sulphate were dissolved in 500 mL of absolute ethanol and 7.47 g (63.3 mmol) of 
4-aminobenzo-nitrile was added. The flask was covered with aluminium foil and the 
solution was stirred for 20 h. The beige suspension was filtered from silver salts and the 
solution was evaporated to dryness in vacuo. The crude product was recrystallized from 
chloroform, washed twice with 100 mL of 5 % NaOH and once with 150 mL of water and 
dried over sodium sulphate. After evaporation the obtained slight red solid (9.69 g, 40 
mmol, 63 %) could be used in the further reaction step without additional purification. 
Mp 109-110 °C (Lit.: 110-112 °C). TLC (CHCl3): Rf = 0.4. 1H NMR (200.13 MHz, DMSO-d6): δ 
4.67 (br, 2H), 6.73 (d, J = 8.4 Hz, 1H), 7.41 (dd, 3J = 8.4 Hz, 4J = 1.8 Hz, 1H), 7.91 (d, 4J = 1.8 
Hz 1H) ppm. FT-MS (ESI): m/z 244.81 [M+H]+. 
 
General procedure of Pd-catalysed indole synthesis (3, 4) 
 In a well baked out flask with reflux condenser 4.4 g 
(40 mmol) of 1,4-diazabicyclo[2.2.2]octane, 1.32 g (15 mmol) of pyruvic acid and 10 mmol 
of the corresponding ortho-iodoaniline were dissolved under a stream of argon in 40 mL 
of dry DMF. The mixture was further degassed by the stream of argon through the 
solution by a hollow needle for 10 min and, after the addition of 115 mg (0.5 mmol, 5 
mol%) of tris(dibenzylideneacetone)dipalladium(0), for another 15 min. The solution was 
heated for 2 h at 105 °C to complete the reaction and than cooled to room temperature. 
The mixture was concentrated to about 6 mL and 150 mL of ethyl acetate and 50 mL of 2 
N HCl solution was added. The ethyl acetate phase was washed with another 50 mL of 2 N 
HCl solution, dried over sodium sulphate and 0.35 g of activated carbon (Darco G60) was 
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added for decolouring and then the suspension was stirred for 20 min. The mixture was 
filtered and concentrated to ~20 mL, 20 mL of n-heptane was added slowly obtaining a 
slurry. After filtration the crude product was dried in vacuo and purified by flash 
chromatography (chloroform/methanol 5:1). 
 
1H-Indole-2-carboxylic acid (3) was obtained from 2-iodoaniline (2.19 g, 10 mmol) as a 
slight yellow solid (1.0 g, 6 mmol, 60 %). TLC (chloroform/methanol 5:1): Rf = 0.62. 1H 
NMR (200.13 MHz, CDCL3) δ 7.07 (dd, J = 7.51 Hz, J = 8.0 Hz, 2H), 7.25 (t, J = 7.58 Hz, 1H), 
7.47 (d, J = 7.58 Hz, 1H), 7.66 (d, J = 7.95 Hz, 1 H), 7.97 (s, 1H), 11.75 (s, 1H) ppm. 13C NMR 
(50.33 MHz, CDCL3) δ 107.96, 113.34, 120.76, 122.76, 125.02, 127.78, 129.69, 138.06, 
163.51 ppm. FT-MS (ESI): 310.15 m/z (100) [M+H]+. 
5-Cyano-1H-indole-2-carboxylic acid (4) was obtained from 4-amino-3-
iodobenzonitrile (2) (2.44 g, 10 mmol) as a beige solid (500 mg, 2.7 mmol, 27 %). Mp. 
331 °C (degradation). TLC (chloroform/methanol 2:1): Rf = 0.30. 1H NMR (200.13 MHz, 
CDCL3) 7.23 (s, 1H), 7.59 (d, 2H), 8.25 (s, 1H), 12.37 (s, 1H), 13.73 (br, 1H) δ ppm. FT-MS 
(ESI): 186.85 m/z (100) [M+H]+ 
 
2-((4-(4-Fluorophenyl)piperazine-1-yl)methyl)-1H-indole (29).  
Method A: Under an atmosphere of argon 0.74 mmol of the 
corresponding amide was dissolved in 25 mL of dry THF and cooled at 0 °C. 0.74 mmol of 
lithium aluminium hydride (1 M in diethyl ether) was added dropwise and the reaction 
mixture was stirred for 4 h. After an addition of 40 mL of water the solution was extracted 
three times with 50 mL of chloroform, the organic phase was dried over sodium sulphate, 
evaporated in vacuo and purified by flash chromatography to obtain 117 mg (0.36 mmol, 
50 %) of the product. 
Method B: Under an atmosphere of argon 1 mmol of borane solution (1 M in THF) was 
cooled at 0 °C. 0.5 mmol of the corresponding amide was dissolved in dry THF and added 
all at once. The ice bath was removed and the solution was refluxed over night. After a 
second addition of 1 mmol of borane solution the mixture was stirred for a further night, 
then quenched with 10 mL of acetic acid and extracted with chloroform. The organic 
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phase was dried over sodium sulphate, evaporated in vacuo and purified by flash 
chromatography to obtain 63 mg (0.2 mmol, 41 %) of the product. 
 TLC (chloroform/methanol 20:1): Rf = 0.66. 1H NMR (200.13 MHz, CDCL3) δ 2.74 (m, 
4H), 3.19 (m, 4H), 3.86 (s, 1H), 6.49 (s, 1H), 6.88 (m, 4H), 7.21-7.78 (m, 4H) ppm. FT-MS 
(ESI): 310.12 m/z (100) [M+H]+. 
 
6.2.1.2 Cyanoindole syntheses by intramolecular reductive amination 
 
Ethyl 3-(5-cyano-2-nitrophenyl)-2-oxopropanoate or potassium (E)-1-(5-cyano-2-
nitrophenyl)-3-ethoxy-3-oxoprop-1-en-2-olate (6) 
 In a 250-mL two-neck flask with silicone septum 5 g (30.8 mmol) 
of 3-methyl-4-nitrobenzonitrile and 8 mL (8.64 g; 60 mmol) of diethyl oxalate were 
dissolved in 85 mL of dry ethanol, slightly cooled and 12.3 mL (30.9 mmol) of cooled (~ 
4 °C) potassium ethanolate solution (24 wt% in ethanol) were added. After stirring for 20 
min the solution was moderately heated to 40 °C and slowly stirred for 20 h. To quench 
the reaction and redissolve the red precipitate 150 mL of water and 100 mL of HCl 
solution (14 %) were added and the solution stored at 4 °C for crystallisation. The 
precipitate was filtrated, dissolved with chloroform, dried over sodium sulphate and 
evaporated to dryness. The crude product was purified by flash chromatography (n-
hexane/ethyl acetate 2:1) to obtain 3.2 g (12.2 mmol, 40 %) of a sticky solid which is 
yellow in acid and red in base media. Mp. 98 °C. TLC (chloroform): Rf = 0.36. 1H NMR 
(200.13 MHz, DMSO-d6) δ 1.32 (td, J = 7.11 Hz, J = 1.81 Hz, 3H), 4.32 (qd, J = 7.12 Hz, J = 
2.56 Hz, 2H), 4.66 (s, 2H), 7.95-8.33 (m, 3H) ppm. FT-MS (ESI): 263.03 m/z (30) [M+H]+, 
302.75 m/z (100) [M+K]+ (poorly ionisable under ESI conditions). 
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Ethyl 5-cyano-1H-indole-2-carboxylate (5) 
Under an atmosphere of argon 100 mg (0.38 mmol) of ethyl 3-(5-
cyano-2-nitrophenyl)-2-oxopropanoate and 20 mg (0.19 mmol) of palladium on carbon 
were dissolved in 5 mL of dry methanol and 13.92 mg (0.114 mmol) of decaborane were 
added in portions. The reaction mixture was heated at 40 °C for 1.5 h until the starting 
material has disappeared completely. The reaction mixture was quenched with 50 mL of 
water, extracted with diethyl ether, washed with brine and dried over sodium sulphate. 
After evaporation in vacuo the crude product was purified by flash chromatography (n-
hexane/ethyl acetate 2:1), and 57 mg (0.27 mmol, 70 %) of product was obtained as a 
with solid.  TLC (chloroform/methanol 25:1): Rf = 0.66. 1H NMR (200.13 MHz, DMSO-d6) δ 
1.36 (t, J = 7.11 Hz, 3H), 4.38 (q, J = 7.11 Hz, 2H), 7.27 (d, J = 2.0 Hz, 1H), 7.60 (s, 2H), 8.25 
(s, 1H), 12.46 (s, 1H) ppm. 13C NMR (50.32 MHz, DMSO-d6) δ 15.06, 61.78, 103.35, 109.17, 
114.80, 120.96, 127.38, 129.17, 130.68, 139.57, 161.63 ppm. FT-MS (ESI): 214.84 m/z (35) 
[M+H]+, 429.27 m/z (100) [2M+H]+ (poorly ionisable under ESI conditions). 
 
2-(Hydroxymethyl)-1H-indole-5-carbonitrile (7) 
 Under an atmosphere of argon a solution of 4.2 mL (4.2 mmol) of 
lithium aluminium hydride (1 M in THF) and 10 mL of dry diethyl ether were cooled to 
about -60 °C in a carbon dioxide / acetone bath. Subsequently 660 mg (3.1 mmol) of ethyl 
5-cyano-1H-indole-2-carboxylate suspended in 30 mL of dry diethyl ether were added and 
the suspension was warmed to room temperature under stirring over night. The reaction 
was quenched with 10 mL of water, extracted twice with diethyl ether, washed with brine 
and dried over sodium sulphate. After evaporation in vacuo the crude product was 
purified by flash chromatography (n-hexane/ethyl acetate 2:1) to obtain 257 mg (1.5 
mmol, 48 %) of a brownish crystalline product. TLC (chloroform/methanol 25:1): Rf = 0.66. 
1H NMR (200.13 MHz, DMSO-d6) δ 2.06 (s, 2H), 6.08 (s, br, 1H), 6.68 (m, 1H), 7.32 (m, 1H), 
7.47 (m, J = 4.96 Hz, 2H), 9.58 (s, 1H) ppm. FT-MS (ESI): 173.01 m/z (20) [M+H]+, 194.90 
m/z (30) [M+Na]+, 345.18 m/z (20) [2M+H]+, 367.18 m/z (100) [2M+Na]+. 
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2-Formyl-1H-indole-5-carbonitrile (10) 
Method A: In a one-neck flask 230 mg (1.313 mmol) of 2-
(hydroxymethyl)-1H-indole-5-carbonitrile (7) were dissolved in 5 mL of dry 
tetrahydrofurane and 656 mg (1.44 mmol, 1.1 eq) of Dess-Martin periodinane were 
added in portions. The suspension was stirred at room temperature for 45 min and 
quenched with 15 mL of a mixture of sodium thiosulphate solution and sodium 
bicarbonate solution (1:1). The solution was extracted with ethyl acetate, washed with 
brine and dried over sodium sulphate to obtain 220 mg (1.3 mmol, 99 %) of a slightly 
yellow product. 
Method B: 0.43 mL (1.38 μmol) sodium bis(2-methoxyethoxy)aluminum hydride 
solution (65w% in toluol) in 0.3 mL of dry tetrahydrofurane was cooled at -10 °C and 
122 μL (1.5 μmol) of pyrrolidine in 0.9 mL of dry tetrahydrofurane were added. The 
solution was warmed to room temperature, stirred for 1 h and 21.5 mg (0.2 mmol) of 
potasasium tert-butoxid were added. Under an atmosphere of argon the whole solution 
was added dropwise to 150 mg (0.7 mmol) of ethyl 5-cyano-1H-indole-2-carboxylate (5) 
dissolved in 0.8 mL of dry tetrahydrofurane. After stirring for 10 min 5 mL of 1 N HCl 
solution was added, the mixture was extracted with ethyl acetate, washed with brine, 
dried over sodium sulphate and evaporated in vacuo. The crude product was purified by 
flash chromatography (n-hexane/ethyl acetate 2:1) to obtain 30 mg (25 %) of product. 
Mp. 220 °C (decomposition). TLC (dichloromethane/methanol 95:5): Rf = 0.73. 1H NMR 
(200.13 MHz, CDCL3-d6) δ 7.46-7.80 (m, 3H), 8.38 (s, 1H), 19.20 (s, 1H), 12.53 (s, br, 1H) 
ppm. 13C NMR (50.32 MHz, CDCL3) δ 103.25, 114.75, 114.78, 120.43, 126.85, 126.90, 
128.51, 129.88, 138.52, 184.11 ppm. FT-MS (ESI): no ionisation with ESI possible. 
 
2-((4-(4-Fluorophenyl)piperazine-1-yl)methyl)-1H-indole-5-carbonitrile, FAUC 316 (1) 
Method A: Under an atmosphere of argon 0.5 mL (0.5 
mmol) of lithium aluminium hydride (1 M in THF) were added to 91 mg (0.5 mmol) of 1-
(4-fluorophenyl)piperazine in 10 mL of dry tetrahydrofurane and stirred at 60 °C for 
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30 min. Subsequently 171 mg (0.8 mml) of ethyl 5-cyano-1H-indole-2-carboxylate (5) in 
4 mL of dry tetrahydrofurane were added dropwise over a period of about 20 min. The 
solution was stirred for 20 min and quenched with saturated sodium bicarbonate 
solution. After extracted with dichloromethane and washed with brine the organic phases 
were dried over sodium sulphate, evaporated in vacuo and purified via flash 
chromatography (chloroform/methanol 20:1) to obtain 18 mg (53.9 μmol, 10 %) of 1. 
Method B: 200 mg (1.18 mmol) of 2-formyl-1H-indole-5-carbonitrile (10), 318 mg (1.76 
mmol) of 1-(4-fluorophenyl)piperazine, 1 g (4.72 mmol) of sodium cyanoborohydride and 
280 μL (4.72 mmol) of acetic acid were dissolved in 12 mL of methanol and heated at 
60 °C for 20 h. After cooling to room temperature the solution was extracted with ethyl 
acetate, washed with brine and dried over sodium sulphate. Upon evaporation in vacuo 
the product was purified by flash chromatography (n-hexane/ethyl acetate 2:1) to obtain 
190 mg (0.57 mmol, 49 %) of 1. 
Mp. 200 °C (decomposition). TLC (dichloromethane/methanol 95:5): Rf = 0.73. 1H NMR 
(200.13 MHz, DMSO-d6) δ 2.58 (t, br, J = 4.16 Hz, J = 5.1 Hz, 4H), 3.12 (t, br, J = 5.22 Hz, J = 
4.12 Hz, 4H), 3.73 (s, 2H), 6.50 (s, 1H), 6.95-7.05 (m, 4H), 7.40 (dd, J = 8.42, J = 1.56, 1H), 
7.51 (d, J = 8.46, 1H), 8.01 (s, 1H), 11.67 (s, 1H) ppm. 13C NMR (50.32 MHz, DMSO-d6) δ 
49.42, 53.09, 55.25, 60.22, 101.25, 102.10, 112.73, 115.48, 115.91, 117.49, 117.64, 
121.32, 123.96, 125.50, 128.14, 138.64, 139.38, 148.37, 170.78 ppm. 19F NMR (188.28 
MHz, DMSO-d6) δ -125.61 ppm. FT-MS (ESI): 335.11 m/z (100) [M+H]+. 
 
1-Benzyl-2-formyl-1H-indole-5-carbonitrile (11) 
 Under an atmosphere of argon 330 mg (1.94 mmol) of 2-formyl-1H-
indole-5-carbonitrile (5) was suspended in 12 mL of anhydrous tetrahydrofuran (THF) and 
400 mg (2.91 mmol, 1.5 eq) of anhydrous potassium carbonate  was added. After addition 
of 0.46 mL (660 mg, 3.88 mmol) of benzylbromide the orange reaction mixture was 
refluxed and stirred over night. Upon cooling the reaction solution was quenched with 
40 mL of water and the solution was extracted with ethyl acetate, washed with water and 
saturated sodium chloride solution and dried over sodium sulphate. After evaporation of 
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the solvent in vacuo the residue was purified by flash chromatography (n-hexan/ethyl 
acetat 2:1) to obtain 360 mg (1.4 mmol, 72 %) of 11 as a slight yellow solid. TLC (n-
hexane/ethyl acetate 2:1): Rf = 0.57. 1H NMR (200.13 MHz, DMSO-d6) δ 5.91 (s, 2H), 7.10 
(dd, J = 7.2 Hz, J = 1.54 Hz, 2H), 7.3 (m, 3H), 7.73 (s, 1H), 7.74 (dd, J = 8.6 Hz, J = 1.58 Hz, 
1H), 7.87 (d, J = 8.8 Hz, 1H), 8.45 (s, 1H), 10.04 (s, 1H) ppm. FT-MS (ESI): 260.71 m/z (100) 
[M+H]+. 
 
General preparation of indolealdehydes by reductive amination (12, 13) 
The reductive amination of the 
indolealdehydes 11 was conducted under the same conditions as described for 1 (Method 
B). 1 equivalent of the indolealdehyde, 1.5 equivalents of 1-(4-fluorophenyl)piperazine or 
tert-butyl piperazine-1-carboxylate, 4 equivalents of sodium cyanoborohydride  and 250 
μL (4.2 mmol) of acetic acid were suspended in 10-12 mL of methanol and heated at 60 °C 
for 3-4 h. The solution was extracted with ethyl acetate, washed with brine and dried 
over sodium sulphate. After evaporation in vacuo the product was purified via flash 
chromatography (n-hexane/ethyl acetate 2:1). 
1-Benzyl-2-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-1H-indole-5-carbonitrile (12) 
was obtained from 1-benzyl-2-formyl-1H-indole-5-carbonitrile (11, 150 mg, 0.577 mmol) 
as a white, crystalline solid (150 mg, 0.35 mmol, 61 %). Mp. 111 °C. TLC (n-hexane/ethyl 
acetate 2:1): Rf = 0.61. 1H NMR (200.13 MHz, CDCL3-d6) δ 2.52 (br, 2H), 2.94 (br, 4H), 3.69 
(s, 2H), 5.64 (s, 2H), 6.67 (s, 1H), 6.86-6.93 (m, 2H), 6.99-7.08 (m, 4H), 7.22-7.26 (m, 3H), 
7.45 (dd, J = 8.55, J = 1.54, 1H), 7.55 (d, J = 8.58, 1H), 8.10 (s, 1H) ppm. 13C NMR (50.32 
MHz, DMSO-d6) δ 47.11, 49.32, 52.95, 54.26, 101.90, 104.06, 111.80, 115.48, 115.92, 
117.50, 117.65, 121.05, 124.55, 125.97, 126.70, 127.37, 127.56, 129.00, 139.63, 139.91, 
148.29, 148.34 ppm. 19F NMR (188.28 MHz, DMSO-d6) δ -125.63 ppm. FT-MS (ESI): 425.66 
m/z (100) [M+H]+. 
Tert-butyl 4-((1-benzyl-5-cyano-1H-indol-2-yl)methyl)piperazine-1-carboxylate (13) 
was obtained from 1-benzyl-2-formyl-1H-indole-5-carbonitrile (231 mg, 0.89 mmol) as a 
white, crystalline solid (230 mg, 0.35 mmol, 60 %). Mp. 109 °C TLC (n-hexane/ethyl 
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acetate 2:1): Rf = 0.43. 1H NMR (200.13 MHz, DMSO-d6) δ 1.39 (s, 9H), 2.35 (t, br, J = 2.0 
Hz, 4H), 3.18 (t, br, J = 1.85 Hz, 4H), 3.63 (s, 2H), 5.62 (s, 2H), 6.64 (s, 1H), 7.01 (dd, J = 
7.77 Hz, J = 1.84 Hz, 2H), 7.30 (m, 3H), 7.45 (dd, J = 8.57 Hz, J = 1.61 Hz, 1H), 7.56 (d, J = 
8.58 Hz, 1H), 8.09 (d, J = 1.5 Hz, 1H) ppm. FT-MS (ESI): 431.29 m/z (100) [M+H]+. 
 
General procedure of selective Boc-group cleavage (14a, 14) 
With a hollow needle 30 mL of 
anhydrous ethyl acetate were treated under a constant stream of HCl gas for 30 min. 
From the ethyl acetate / HCl solution 15 mL were added under ice bath cooling to 0.5 
mmol of the corresponding Boc-protected piperazine derivative and stirred at room 
temperature for 10 h. Afterwards the solution was extracted twice with 50 mL of water 
and the combined aqueous phase neutralized with a 1 M potassium hydroxide solution to 
about pH 8. The aqueous phase was extracted with chloroform and after drying over 
sodium sulphate evaporated in vacuo. If necessary the product can be recrystalized with 
ethyl acetate. 
(1H-Indol-2-yl)(piperazin-1-yl)methanone (14a) was obtained from tert-butyl 4-(1H-
indole-2-carbonyl)piperazine-1-carboxylate (320 mg, 0.97 mmol) as a yellow foam 
(220 mg, 0.96 mmol, 99 %). TLC (n-hexane/ethyl acetate 2:1): Rf = 0.22. 1H NMR (200.13 
MHz, DMSO-d6) δ 2.76 (br, 4H), 3.69 (br, 4H), 6.77 (d, J = 1.45 Hz, 1H), 7.05 (td, J = 7.1 Hz, 
J = 0.92 Hz, 1H), 7.19 (td, J = 7.6 Hz, J = 1.22 Hz, 1H), 7.43 (d, J = 7.3 Hz, 1H), 7.61 (d, J = 
7.62 Hz, 1H), 11.57 (s, 1H) ppm. FT-MS (ESI): 319.98 m/z (100) [M+H]+. 
1-Benzyl-2-(piperazin-1-ylmethyl)-1H-indole-5-carbonitrile (14) was obtained from 
tert-butyl 4-((1-benzyl-5-cyano-1H-indol-2-yl)methyl)piperazine-1-carboxylate (230 mg, 
0.53 mmol) as a silver, crystaline solid (170 mg, 0.52 mmol, 99 %). Mp. 264 °C 
(decomposition). TLC (n-hexane/ethyl acetate 2:1): Rf = 0.22. 1H NMR (200.13 MHz, 
DMSO-d6) δ 2.53 (m, br, 4H), 2.82 (m, br, 4H), 3.67 (s, 2H), 5.62 (s, 2H), 6.69 (s, 1H), 7.0 (d, 
J = 6.94 Hz, 2H), 7.25-7.35 (m, 3H), 7.46 (dd, J = 8.58 Hz, J = 1.53 Hz, 1H), 7.58 (d, J = 8.58 
Hz, 1H), 8.11 (s, 1H) ppm. FT-MS (ESI): 331.26 m/z (100) [M+H]+. 
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6.2.1.3 Synthesis of 4-fluoroanilines 
 
1-(4-Fluorophenyl)-4-methylpiperazine (24) 
 Under an argon atmosphere 0.1 mL (1.6 mmol) of methyliodide were 
added cautiously to 300 mg (1.6 mmol) of 1-(4-fluorophenyl)piperazine dissolved in 9 mL 
of dry tetrahydrofuran and 63 mg (1.6 mmol) of sodium hydride (60 % dispersion on 
mineral oil). The solution was stirred over night at room temperature. 10 mL of water 
were added, the solution was extracted twice with 30 mL of dichloromethane, washed 
with water and dried over sodium sulphate. After evaporation in vacuo the crude product 
was purified by flash chromatography to obtain 162 mg (0.83 mmol, 52 %) of the product 
as a high viscous oil. 1H NMR (200.13 MHz, CDCL3) δ 2.66 (s, 3H), 3.04 (m, 4H), 3.40 (m, 
4H), 6.85-7.05 (m, 4H) ppm. 19F-NMR (188 MHz, CDCl3): δ -122.79 (1F, s).  13C NMR (50.32 
MHz, CDCL3-d6) δ 44.96, 48.92, 54.54, 115.58, 116.03, 118.65, 118.80, 146.91, 146.96, 
155.40, 160.17 ppm. FT-MS (ESI): 195.57 m/z (100) [M+H]+. 
 
Tert-butyl 4-(4-fluorophenyl)piperazine-1-carboxylate (27) 
To 300 mg (1.66 mmol) 4-fluorophenylpiperazine suspended in 4 mL 
of water and 1.5 mL of tetrahydrofurane 405 mg (2 mmol) of di-tert.-butyl dicarbonate 
and 350 mg (3.3 mmol) of sodium carbonate were added and the suspension was stirred 
at 100 °C for 2 h. 15 mL of water were added and the solution was extracted three times 
with ethyl acetate, the combined organic layers were washed with brine and dried over 
sodium sulphate. After evaporation in vacuo the product was recrystallized from n-
hexane/ethylacetate to obtain 460 mg (1.65 mmol, 99 %) of 27. 
1H-NMR (200.13 MHz, CDCl3): δ 1.36 (s, 9H), 3.03 (m, 4H), 3.37 (m, 4H), 7.21 (m, 4H) 
ppm. FT-MS (ESI): 180.43 m/z (100) [M+H]+. 
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1-(4-Fluorophenyl)piperidine (23) 
Under an atmosphere of argon 100 mg (0.25 mmol) of 2-
dicyclohexylphosphino-2’-(N,N-dimethylamino)biphenyl (DavePhos), 230 mg (0.25 mmol) 
of Pd2(dba)3 and 575 mg (6 mmol) of sodium tert.-butoxide were dissolved in 25 mL of 
shortly heated dry toluene and 1.1 g (5 mmol) of 1-fluoro-4-iodobenzene and 635 mg (7.5 
mmol) of piperidine were added. The reaction mixture was heated at 100 °C for 2 h and 
after cooling to room temperature washed with water. The solution was extracted 5 
times with 20 mL of 2N HCl solution and the aquaous phase adjusted to pH 8 with sodium 
hydroxide subsequently. The solution was extracted with chloroform, dried over sodium 
sulphate and evaporated in vacuo. The crude product was purified by flash 
chromatography (n-hexane/ethyl acetate 5:1) to obtain 573 mg (3.2 mmol, 64 %) of 
crystalline product.  
1H-NMR (200.13 MHz, CDCl3): δ 1.61 (m, 2H), 1.79 (m, 4H), 3.11 (t, 4H), 7.0 (d, 4H) 
ppm. 19F-NMR (188 MHz, CDCl3): δ -125.03 (1F, s) 
 
6.2.1.4 Syntheses of iodonium precursors 
 
1-Bromo-4-acetoxyiodobenzene (15) 
In a 250 mL flask 90 mL of glacial acetic acid were warmed to 40 °C, 2.83 
g (10 mmol) of 1-bromo-4-iodobenzene were added and the flask was covered with 
aluminium foil. Afterwards over a period of 30 min 16.92 g (110 mmol) of sodium borate 
tetrahydrate were added and the solution was stirred for 23 h. In a rotary evaporator 
about half of the solvent was evaporated under about 35 mbar. 150 ml of water were 
added to the suspension and extracted once with 70 mL and twice with 50 mL of 
chloroform The organic phase was washed with water, dried over sodium sulphate and 
evaporated in vacuo. The product was recrystalysed with a small amount of acetic acid 
and methanol to obtain 3.155 mg (7.9 mmol, 79 %) of 15 as white crystals. TLC 
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(chloroform/methanol 4:1): Rf = 0.71. Mp. 159-161 °C. FT-MS (ESI): 340.78 m/z (100) 
[M+H]+. 
 
Bis(4-bromophenyl)iodonium trifluoromethanesulfonate (16) 
Under an atmosphere of argon 3.07 mg (7.65 mmol) of 1-bromo-4-
acetoxyiodobenzene dissolved in 35 mL of dry dichloromethane was cooled to -15 °C and 
1.34 mL (15.15 mmol) of trifluoromethanesulfonic acid were added dropwise. After 
stirring for 1 h the dark solution turned to clear orange, 1.29 mg (8.21 mmol) of 
bromobenzene were cautiously added and the yellow suspension was stirred at 0 °C for 
an additional 3 h. The solvent was concentrated in vacuo and diethylether was added. 
Under cooling at 4 °C the desired product was obtained as slight yellow precipitate (2.8 g, 
4.76 mmol, 63 %). FT-MS (ESI): 438.95 m/z (100) [M+H]+. 
 
2-Diacetoxyiodotoluene (17) 
Under an atmosphere of argon and cooling in an ice bath 4.36 g (20 mmol) 
of 4-iodotoluene was treated with 9.12 g (48 mmol) of peracetic acid (w = 40 %) and 
stirred at 0 °C for 1.5 h. After removing of the ice bath the solution was cooled in a 
refrigerator over night. The obtained precipitate was removed, washed with water and 
dried under vacuo to obtain 6.39 g (19 mmol, 95 %) of crystalline product. 
Mp. 147 °C. 1H-NMR (200.13 MHz, DMSO-d6): δ 1.92 (s, 6H), 2.66 (s, 3H), 7.34 (m, 1H), 
7.63 (m, 2H), 8.33 (d, 1H) ppm. FT-MS (ESI): 235.16 m/z (100) [M -2OAc +OH]+ 
 
2-(Hydroxy[tosyloxy])iodotoluene (18) 
5.8 g (17.2 mmol) of 2-diacetoxyiodotoluene dissolved in 7 ml 
of hot acetonitrile and treated with 3.6 g (18.9 mmol) of p-toluenesulfonic acid dissolved 
in 3 ml of hot acetonitrile. The yellow reaction mixture was refluxed for 0.5 h and cooled 
Chapter 6: Experimental 107 
to -20 °C over night. The yellow precipitate was filtered and dried in vacuo to obtain 4.63 
g (11.4 mmol, 66 %) of 18. Mp.: 138-141 °C. 1H-NMR (200.13 MHz, CDCl3): 2.36 (s, 3H), 
2.65 (s, 3H), 6.04 (br, 1H), 7.13 (m, J = 7.82 Hz, 3H), 7.30 (m, J = 7.62 Hz, J = 6.42 Hz, 2H), 
7.57 (d, J = 8.1 Hz, 2H), 8.24 (d, J = 8.36 Hz, 1H) ppm. FT-MS (ESI): 235.18 m/z (100) [M –
OTs]+ 
 
1-Iodo-4-(hydroxy[tosyloxy])iodotoluene (19) 
5.47 g (14 mmol) 2-(Hydroxy([tosyloxy])iodotoluene and 
4.618 g (14 mmol) 1,4-diiodobenzene  were dissolved in 35 ml of dichloromethane and 
stirred at room temperature. The precipitated product was separated from the solution 
by filtration several times. The precipitate was washed with dichlorometane and 
recrystallized from acetonitrile/methanol 80:20 (v/v) to obtain 3.27 g (6.3 mmol, 45 %) of 
19. 
Mp. 141 °C. 1H-NMR (200.13 MHz, DMSO-d6): δ 2.31 (s, 3H), 7.23 (d, 2H), 7.49 (d, 2H), 
7.98 (m, 4H) ppm. FT-MS (ESI): 346.98 m/z (100) [M-OTs]+. 
 
Bis(4-iodophenyl)iodonium trifluoromethanesulfonate (20) 
1.04 g (2 mmol) of 1-Iodo-4-(hydroxy[tosyloxy])iodotoluene and 
0.408 g (2 mmol) of iodobenzene dissolved in 20 ml of dichloromethane were cooled at -
78 °C and treated with 3 g (20 mmol) of trifluoromethanesulfonic acid. The reaction 
mixture was stirred until the solution reached room temperature and subsequently the 
solvent was evaporated in vacuo. After an addition of water the solution was extracted 
with chloroform and the organic phase was treated with diethylether. The obtained white 
precipitate of 20 (651 mg, 1 mmol, 50 %) was filtered and washed with diethylether. 
Mp. 202 °C. FT-MS (ESI): 532.86 m/z (100) [M+H]+ 
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6.2.2 Radiosyntheses 
Drying of n.c.a [18F]fluoride 
N.c.a. [18F]fluoride was produced via the 18O(p,n)18F nuclear reaction by bombardment 
of an isotopically enriched [18O]water in an Ti-target245 with 17 MeV protons at the JSW 
cyclotron BC 1710 (INM-5, Research Center Jülich). The aqueous [18F]fluoride solution (10 
– 50 μL, 75 – 375 MBq) was filled into a 5 mL conical vial (Reactivial) containing 1 mL of 
acetonitrile, 10 mg of Kryptofix 2.2.2, 13 μl of an aqueous 1 M potassium carbonate 
solution [52]. The solvent was evaporated under a stream of argon at 80 °C and 600 mbar. 
This azeotropic drying was repeated twice using each time 1 mL of dry acetonitrile, 
followed by evaporation at 8-15 mbar for 5 min. 
 
General preparation of 4-[18F]fluorobromobenzene ([18F]21) and 4-[18F]fluoroiodo-
benzene ([18F]22) 
A solution of bis(4-bromophenyl)iodonium triflate (16, 17 mg, 30 μmol) or bis(4-
iodophenyl)iodonium triflate (20, 20 mg, 30 μmol) dissolved in 0.5 mL of anhydrous DMF 
was added to the vial containing the dried [18F]fluoride at 130 °C. Monitoring of the 
reaction progress was determined by radio HPLC of about 30 - 50 μL taken at regular time 
intervals aliquots (Gemini 5 μ RP18 A110, 250 · 4.6 mm, 1 mL/min, isocratic 75:25:0.5 
v/v/v CH3CN/H2O/TEA) for the determination of radiochemical yields and the optimal 
reaction time.  
In case of [18F]21 for further reaction steps after 15 min the solution was diluted with 
20 mL of water and passed through a Sep Pak C18 cartridge, previously conditioned with 
8 mL of ethanol and 8 mL of water. The cartridge was dried in a stream of argon and 
eluted through an unconditioned Alumina N cartridge with 2 mL of anhydrous toluene in 
a second reaction vial. 
In case of [18F]22 after 10 min reaction time 100 mg of Celite 503 suspended in 20 mL 
of water was added to the reaction mixture and the total solid was removed by a 
Lichrolut cartridge (Merck) with a 10 μm PTFE strainer. After washing with 1 mL of water 
the nearly clear solution was passed through a Sep Pak C18 cartridge, conditioned with 8 
mL of ethanol and 8 mL of water, previously washed with 5 mL of water dried for 5 min in 
a stream of argon. Subsequently the product was eluted through an unconditioned 
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Alumina N cartridge with 2 mL of anhydrous toluene in a second reaction vial. 
 
General procedure of N-arylation via Hartwig-Buchwald cross-coupling 
Large reaction batch: 5.5 μmol of the palladium catalyst (Pd2(dba)3 or Palladium(π-
cinnamyl) chloride dimmer or PdOAc2), 11 μmol of the biaryl phosphine ligand (2-
dicyclohexylphosphino-2’-(N,N-dimethylamino)biphenyl (DavePhos), 2-(dicyclohexyl-
phosphino)3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1’-biphenyl (BrettPhos) or 2-dicyclohexyl-
phosphino-2’,6’-diisopropoxybiphenyl (RuPhos) or 2-(dicyclohexylphosphino)3,6-
dimethoxy-2’,4’,6’-triisopropyl-1,1’-biphenyl (BrettPhos)), 100 μmol of the base (NaOtBu 
or K2CO3 or K3PO4) and 50 μmol of the amine compound were exposed under argon in a 
reaction vial. Thereafter, 4-[18F]fluoroiodobenzene ([18F]22) was added in 2 mL of toluene 
or 1,4-dioxane from the reaction step before directly by elution from the cartridge into 
the vial, and the reaction mixture was heated at 100 °C. When the reaction was 
conducted in DMF the previous separation step was omitted. Reaction progress was 
mainly monitored by radio-HPLC (Gemini 5 μ RP18 A110, 250 × 4.6 mm, 1 mL/min, 
isocratic 75:25:0.5 v/v/v CH3CN/H2O/TEA) from aliquots of about 30-50 μL diluted ten fold 
with the elution solvent and typically containing of about 37 kBq of activity were injected.  
 
Prepurification of 4-[18F]fluorophenylpiperazine ([18F]28)  
Method A: Liquid-liquid extraction of 4-[18F]fluorophenylpiperazine ([18F]28). The 
reaction mixture was extracted twice with 2 mL of hydrochloric acid (2 M) and the 
aqueous phases were treated with 4 mL of a sodium hydroxide solution (2 M). The 
solution was afterwards passed through a Sep Pak C18 cartridge, conditioned with 8 mL 
of ethanol and 8 mL of water, and dried for 2 min in a stream of argon. The product was 
then eluted with 1-2 mL of anhydrous DMSO or acetonitrile. 
Method B: Solid-liquid extraction of 4-[18F]fluorophenylpiperazine ([18F]28). The 
reaction mixture was diluted with 5 mL of methanol and passed through a Strata-X-CW 
weak cation exchanger cartridge, conditioned with 10 mL of methanol and 10 mL of 
water. The cartridge was washed with 5 mL of an ammonium acetate buffer (pH 6.3) and 
5 mL of methanol. The product was eluted with formic acid (2 %) in 1-2 mL of a mixture of 
acetonitrile and methanol 80:20 (v/v) or DMSO.  
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General preparation of reductive amination reaction ([18F]1, [18F]29) 
Sodium cyanoborohydride (4 mg, 64 μmol) in 50 μL of DMSO and 5.8 mg (40 μmol) of 
1H-indole-2-carbaldehyde or 6.8 mg (40 μmol) of 2-formyl-1H-indole-5-carbonitrile (10) in 
50 μL of DMSO and 40 μL of acetic acid were added to the reaction vial containing the 
eluted 4-[18F]fluorophenylpiperazine ([18F]28) in DMSO. For determination of reaction 
progress the aliquots were analysed by radio HPLC using different systems: (A) 
Phenomenex Luna 5 μm C18(2) 100 Å 250×4 mm, 1 mL/min, isocratic 60:40:0.03 v/v/v 
CH3CN/H2O/TEA pH 9, (B) Phenomenex Gemini 5 μm C18 100 Å 250×4.6 mm, 1 mL/min, 
isocratic 60:40:0.03 v/v/v CH3CN/H2O/TEA pH 9, (C) Phenomenex Luna 5 μm PFP(2) 100 Å 
250×4.6 mm, 1 mL/min, isocratic 50:50:0.01 v/v/v CH3CN/H2O/TEA pH 7.8. After addition of 
20 mL of water the solution was passed through a Sep Pak C18 cartridge followed by 
washing with 5 mL water and drying with air. Then the cartridge was eluted with 1 mL of 
acetonitrile and the eluate injected on a semi-preparative HPLC system (Phenomenex 
Luna 5 μm PFP(2) 100 Å 250×10 mm, 4 mL/min, isocratic 50:50:0.01 v/v/v 
CH3CN/H2O/TEA pH 7.8.). The collected fraction was diluted with 15 mL of water, passed 
through a SepPak C18 cartridge, which was then washed with water (5 mL) and dried in a 
stream of argon. The cartridge was eluted with 4 mL of diethylether, the solvent was 
evaporated in vacuo (800 up to 330 mbar) and the product was redissolved in 100-300 μL 
of ethanol. 
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6.3 Synthesis of benzodioxine derivatives 
6.3.1 Syntheses of precursor- and standard compounds 
1-(1,4-Benzodioxine-6-yl)piperazine (30) 
Under an atmosphere of dry argon a mixture of 1.27 g (8.4 mmol) of 
6-amino-1,4-benzodioxine and 1.5 g (8.4 mmol) of bis(2-chloroethyl)amine hydrochloride 
in 3 mL of dry ethylene glycol was heated at 150 °C over night. After cooling to room 
temperature methanol was added to the mixture to precipitate a white crystalline solid. 
This was treated with saturated sodium carbonate solution and extracted with ethyl 
acetate. The combined organic layers were washed with brine, dried over sodium 
sulphate and concentrated in vacuo to give a pure white solid. The mother liquor was 
concentrated in vacuo to get rid of methanol and extracted with saturated sodium 
carbonate solution as described above. The product 30 was purified by column 
chromatography (CHCl3/methanol 5:1) to obtain a slight beige solid (1.17 g, 5.3 mmol, 63 
%). Mp 169-171 °C. TLC (CHCl3/methanol, 5:1): Rf = 0.18. 1H NMR (200.13 MHz, DMSO-d6): 
δ 2.78 – 2.92 (m, 8H), 4.17 (m, 4H), 6.43 (m, 2H), 6.70 (d, 1H) ppm. FT-MS (ESI): m/z 
221.21 [M+H]+. 
 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4-fluorobenzyl)piperazine (33a) 
A mixture of 350 mg of 1 (1.6 mmol), 394 mg of 4-
fluorobenzylbromid (2.08 mmol), 443 mg of K2CO3 (3.2 mmol) and 345 mg of potassium 
iodide (2.08 mmol) was suspended in 20 mL of dry acetonitrile and heated at 85 °C for 18 
h. After cooling to room temperature the mixture was treated with 50 mL of water and 
extracted with ethyl acetate. The combined organic layers were washed with brine, dried 
over sodium sulphate and concentrated in vacuo. The product was purified by column 
chromatography (n-hexane/ethyl acetate 1:2) to obtain 33a as a white solid (240 mg, 0.73 
mmol, 46 %). Mp 120 °C. TLC (n-hexane/ethylacetat, 1:2): Rf = 0.7. 1H NMR (CHCl3, 
400 MHz) δ 2.56 (t, J = 4.8 Hz, 4H), 3.06 (t, J = 4.8 Hz, 4H), 3.50 (s, 2H), 4.19 (m, J = 4.5 Hz, 
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2H), 4.21 (m, J = 4.6 Hz, 2H), 6.43 (m, 2H), 6.75 (m, 1H), 6.98 (m, 1H), 7.29 (m, 2H) ppm. 
FT-MS (ESI): m/z 329.166 [M+H]+. 
 
4-Fluoro-3-hydroxybenzaldehyde (34d) 
Under an atmosphere of argon 4-fluoro-3-methoxybenzaldehyde (1 g, 6.49 
mmol) dissolved in 25 mL of dry dichloromethane was cooled in a dry ice/acetone bath at 
-78 °C. A solution of 1 M BBr3 in dichloromethane (19 ml, 19 mmol) was cautiously added 
dropwise, afterwards the reaction mixture was warmed to room temperature and stirred 
for 18 h. At the end of the reaction 40 - 50 mL of ice cooled water were added while 
cooling the reaction mixture in an ice bath. The organic phase was separated, washed 
with 50 mL of a solution of saturated NaHCO3 and extracted twice with a solution of 2 N 
NaOH. The brown aqueous NaOH solution was cooled in an ice bath and concentrated 
HCL was cautiously added until pH 1 - 3 was reached. Afterwards the solution was 
extracted 3 - 4 times with dichloromethane. The organic phase was washed with brine, 
dried over sodium sulphate and evaporated to dryness. The obtained light yellow solid of 
34d (563 mg, 4.02 mmol, 62 %) could be used in followed reaction steps without further 
purification. Mp. 101-103 °C. TLC (n-hexan/ethyl acetate 2:1): Rf = 0.42. 1H NMR (DMSO-
d6, 400 MHz) δ 7.35-7.49 (br, 3H); 9.89 (s,1H); 10.5 (s, 1H)) ppm. FT-MS (ESI): m/z 140.91 
(100) [M+H]+. 
 
General preparation of benzylated phenolaldehydes (34c, 40c’) 
Under an atmosphere of argon the corresponding 
hydroxyaldehyde (1.63 mmol) was dissolved in 4 mL of anhydrous N,N-dimethylformamid 
(DMF) and anhydrous potassium carbonate (243 mg, 1.76 mmol) was added. After 
addition of benzylbromide (0.34 mL, 0.49 g, 2.86 mmol) the reaction mixture was heated 
at 110 °C and stirred over night. After cooling the reaction solution was quenched with 40 
mL of water and the solution was extracted with dichloromethane, washed with water 
and saturated sodium chloride solution and dried over sodium sulphate. After 
evaporation of the solvent in vacuo the residue was purified by flash chromatography 
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(n-hexan/ethyl acetat 4:1). 
3-Benzyloxy-4-fluorobenzaldehyde (34c) was obtained from 4-fluoro-3-
hydroxybenzaldehyde (2d) (200 mg, 1.4 mmol) as a white solid (126 mg, 0.55 mmol, 50 
%). TLC (n-hexane/ethyl acetat 4:1): Rf = 0.56. (200.13 MHz, CDCL3-d6) δ 5.24 (s, 2H); 7.28-
7.62 (br, 8H); 9.93 (s, 1H) ppm. FT-MS (ESI): m/z 231.09 (100) [M+H]+. 
 
3-Benzyloxy-4-nitrobenzaldehyde (40c’) was obtained from 3-hydroxy-4-
nitrobenzaldehyde (265 mg, 1.63 mmol) as yellow solid (212 mg, 0.92 mmol, 57 %). Mp 
92 °C. TLC (n-hexane/ethyl acetat 4:1): Rf = 0.44. (200.13 MHz, DMSO-d6) δ 5.42 (s, 2H); 
7.35-7.48 (br, 5H); 7.71 (dd, J = 8.3 / 1.4 Hz, 1H); 7.92 (d, J = 1.4 Hz, 1H); 8.03 (d, J = 8.3 Hz, 
1H); 10.8 (s, 1H) ppm.  
 
4-Formyl-2-benzyloxy-N,N-dimethylaniline (9) 
Under an atmosphere of argon 4-bromo-2-benzyloxy-N,N-
dimethylaniline (500 mg, 1.65 mmol) was dissolved in 6 mL of anhydrous diethylether and 
cooled in an carbon dioxide/acetone bath at -78 °C. Carefully 1.75 mL of sec.-BuLi (2.45 
mmol, 1.4 M in cyclohexane) was added and the reaction was stirred for 45 min at -78 °C. 
Subsequently DMF (200 μL, 2.6 mmol) was added all at once and the reaction mixture 
was stirred for 1 h at room temperature. For quenching the solution was diluted with 15 
mL of water and 15 mL of saturated aqueous ammonium chloride and extracted with 
diethylether. After washing with a saturated sodium chloride solution the organic phase 
was dried over sodium sulphate, filtered and evaporated in vacuo to dryness. The crude 
product 9 was purified by flash chromatography on silica gel (n-hexane/ethyl acetate: 4:1) 
and obtained as a clear, light yellow liquid (240 mg, 0.95 mmol, 57 %). TLC (n-
hexane/ethyl acetate: 4:1): Rf = 0.44. 1H NMR (d6-DMSO, 200 MHz) δ 2.91 (s, 6H); 5.18 (s, 
2H); 6.97 (d, 1H); 7.46 (m, 7H); 9.79 (s, 1H) ppm. MS (ESI): m/z 256.21 [M+H]+. 
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General preparation of ammonium trifluoromethanesulfonates (40a, 40b, 40c) 
The corresponding fluoroanalogue (24 mmol) was 
dissolved in 130 mL of DMSO and 40 mL of water. After further addition of potassium 
carbonate (60 mmol, 2.5 eq) and dimethylamine hydrochloride (36 mmol, 1.5 eq) the 
mixture was heated at 100 °C over night. Upon complete cooling of the reaction (!) the 
solution, it was extracted three times with diethylether to obtain the crude 4-
(dimethylamino)benzaldehyde derivative which was further used without purification. 
Under an atmosphere of argon the 4-(dimethylamino)benzaldehyde derivative was 
dissolved in 60 mL of dry methylene chloride. At rt 1 eq of methyl trifluoromethane-
sulphonate was added and stirred for about 7 h. 40 mL of n-hexane were added 
subsequently and the solution cooled at 4 °C. The precipitate was filtered, washed with 
cold n-hexane and recrystalyzed from methylene chloride. 
 
4-(Trimethylammonium)benzaldehyde trifluoromethanesulfonate (40a) was 
obtained from 3 g (24 mmol) 4-fluorobenzaldehyde as a white solid (6.4 g, 20.4 mmol, 85 
%). (200.13 MHz, DMSO-d6) 3.67 (s, 9H), 8.19 (m, 4H), 10.13 (s, 1H) δ ppm. FT-MS (ESI): 
209.67 m/z (100) [M+H]+. 
 
4-(Trimethylammonium)-3-methoxybenzaldehyde trifluoromethanesulfonate (40b) 
was obtained from  3 g (19.46 mmol) 4-fluoro-3-methoxybenzaldehyde as a white solid 
(5.9 mg, 17.2 mmol, 88.4 %). (200.13 MHz, DMSO-d6) δ 3.69 (s, 9H), 3.73 (s, 3H), 7.77-7.82 
(m, 3H), 10.09 (s, 1H) ppm. FT-MS (ESI): 195.33 m/z (100) [M+H]+. 
 
4-(Trimethylammonium)-3-benzyloxybenzaldehyde trifluoromethanesulfonate (40c) 
was obtained from 100 mg (0.4 mmol) of 4-formyl-2-benzyloxy-N,N-dimethylaniline (9) as 
a white solid (154 mg, 0,37 mmol, 92 %). (200.13 MHz, DMSO-d6) δ 3.70 (s, 9H), 5.51 (s, 
2H), 7.43-7.64 (m, 5H), 7.49 (dd, J = 8.52 Hz, J = 1.72 Hz, 1H), 7.99 (d, J = 1.70 Hz, 1H), 8.19 
(d, J = 8.56 Hz, 1H), 10.11 (s, 1H) ppm. FT-MS (ESI): 270.09 m/z (50) [M+H]+. 
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6-Fluoronicotinealdehyd (34e) 
 Method A: To 2-fluoro-5-methylpyridine (9.758 g, 88.15 mmol) suspended 
in 350 mL of distilled water, KMnO4 (16.3 g, 103 mmol) was added and the reaction 
mixture was heated at 100 °C over night. Thereafter manganese dioxide was removed by 
using a filter paper circle (blue ribbon) and washed with water. After adding 20 mL of 
concentrated HCl to the clear solution the product crystallized at 4 °C and was separated 
by filtration to obtain 6-fluoronicotinic acid. 
Under an atmosphere of argon to 6-fluoronicotinic acid (500 mg, 3.55 mmol) dissolved 
in 20 mL of dichloromethane (DCM) and one drop of N,N-dimethylformamid (DMF) 
oxalylchloride (450 μL, 5.25 mmol) was added and the reaction mixture stirred at 50 °C 
until evolution of CO2 stopped (ca. 2 h). After evaporation of DCM in vacuo to dryness 
sodium borohydride (455 mg, 12.03 mmol) was added in portions at 0 °C to the acid 
chloride dissolved in 7.5 mL of dry tetrahydrofurane under an atmosphere of argon and 
the reaction mixture was stirred for 1 h at 0 °C and then 1 h at room temperature. After 
adding 60 mL of brine the solution was extracted three times with 50 mL of diethylether, 
the combined organic phase was dried over sodium sulfate and the solvent evaporated in 
vacuo. 
To the crude product 6-fluoropyridine-3-yl-methanol (230 mg, 1.81 mmol) dissolved in 
5 mL of dry tetrahydrofurane freshly produced Dess-Martin periodinane (908 mg, 2.14 
mmol) was added in portions and the suspension was stirred for 1 h at room 
temperature. Thereafter 20 mL of a mixture of saturated sodium thiosulfate and 
saturated sodium bicarbonate (1:1) was added to the suspension and the obtained 
solution was extracted with ethyl acetate. The crude product was recrystallized from n-
hexane/methanol or purified by flash chromatography (n-hexane/ethyl acetate 4:1) to 
obtain 6-fluoronicotinaldehyd as a white solid (220 mg, 1.76 mmol, 38.5 % related to 2-
fluoro-5-methylpyridine). 
Method B: A well baked out flask was evaporated and refilled with argon three times. 
After charging with 5-bromo-2-fluoropyridine (342 mg, 1.94 mmol) dissolved in 2 mL of 
absolute tetrahydrofurane (THF) isopropylmagnesium chloride (1 mL, 2 M in THF) was 
added drop wise. After stirring for 1 h at room temperature dry DMF was added all at 
once. The reaction mixture was stirred over night, quenched with 30 mL of water and 
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chloroform and extracted with chloroform. The organic phase was dried over sodium 
sulfate and evaporated in vacuo. The red oil was cooled and dried in vacuo until 
formation of crystals. The crude product was cautiously recrystallized from n-
hexane/methanol to obtain light yellow crystals (24 mg, 0.19 mmol, 10 %) of 34e. 
Mp 65-67 °C. TLC (ethyl acetate/methanol/diethyl amine 96:2:2): Rf = 0.71. (200.13 
MHz, DMSO-d6) δ 6.76 (d, J = 9.07 Hz, 1H); 7.87 (d, J = 9.01 Hz, 1H); 8.59 (s, 1H); 9.74 (s, 
1H) ppm. 
 
General preparation of amides (32a, 32b, 32c) 
The corresponding aromatic carboxylic 
acid (3.54 mmol) was dissolved in 20 mL of anhydrous DCM followed by a small amount 
of DMF (20 μL) and oxalylchloride (5.3 mmol, 1.5 equiv). The mixture was stirred at room 
temperature until evaporation of gas had stopped (2 - 3 h) and then the solvent was 
evaporated in vacuo to get the corresponding acid chloride.  
Under an argon atmosphere 1-(1,4-benzodioxine-6-yl)piperazine (30) was dissolved in 
DCM and triethylamine (2.2 mmol, 0.6 equiv) was added. The solution was cooled in an 
ice bath at 0 °C and the respective acid chloride redissolved in 5 mL of DCM was added 
dropwise. The reaction mixture was warmed to room temperature and stirred over night 
for at least 10 h. To quench the reaction 20 mL of saturated sodium bicarbonate solution 
was added. The solution was extracted with DCM, washed with water and saturated 
sodium chloride solution and dried over sodium sulphate. After evaporation of the 
solvent in vacuo the residue was purified by flash chromatography.  
 
(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)(4-fluorophenyl)methanone 
(32a) was obtained from 4-fluorobenzoic acid (286 mg, 2.04 mmol) as white foamous 
solid (460 mg, 1.34 mmol, 66 %). TLC (n-hexane/ethyl acetat 1:2): Rf = 0.56. 1H NMR 
(CHCl3, 400 MHz) δ 3.04 (b, 4H, 4CH2); 3.7 (b, 4H, 4CH2); 4.19 (m, 2H, 2CH2); 4.22 (m, 2H, 
2CH2); 6.44-6.45 (m, 2H, Ar-CH); 6.77 (m, 1H, Ar-CH); 7.08 (m, 2H, Ar-CH); 7.42 (m, 2H, Ar-
CH) ppm. FT-MS (ESI): m/z 343.19 (100) [M+H]+. 
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(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)(4-nitrophenyl)methanone 
(32b) was obtained from 4-nitrobenzoic acid (267 mg, 1.6 mmol) as a yellow solid (520 
mg, 1.41 mmol, 88 %). TLC (n-hexane/ethyl acetat 1:2): Rf = 0.49. 1H NMR (CHCl3, 
400 MHz) δ 2.92 (b, 2H); 2.97 (b, 2H); 3.13 (b, 2H); 3.45 (b, 2H); 4.19 (m, 2H); 4.22 (m, 2H) 
6.44-6.45 (m, 2H); 6.77 (d, 1H); 7.58 (dt, J = 8,7 Hz; 2H); 8.28 (dd, J = 8,3 Hz, 2H) ppm. FT-
MS (ESI): m/z 370.14 (90) [M+H]+. 
 
(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)(6-fluoropyridin-3-yl)-
methanone (32c) was obtained from 2-fluoronicotinic acid (450 mg, 3.2 mmol) as a white 
solid (680 mg, 2 mmol, 62 %). TLC (n-hexane/ethyl acetat, 1:3): Rf = 0.48. 1H NMR (CHCl3, 
400 MHz) δ 3.06 (br, 2H); 3.12 (br, 2H); 3.52 (br, 2H); 3.80 (br, 2H); 4.21 (m, 2H); 4.25 (m, 
2H); 6.52 (s, 1H); 6.53 (dd, J = 2.8 Hz / 8.6 Hz, 1H); 6.79 (d, J = 9.2 Hz, 1H); 7.36 (dd, J = 2.5 
Hz / 8.4 Hz, 1H); 8.15 (ddd, J = 2.5 Hz / 8.2 Hz / 8.2 Hz, 1H); 8.42 (d, J = 2.0 Hz, 1H) ppm. 
FT-MS (ESI): m/z 344.14030 (100) [M+H]+. 
 
 
General preparation of 3-substituted 6-(4-benzylpiperazine-1-yl)benzodioxine 
derivatives (33b, 33c, 3d, 33e, 33e’, 33f) by reductive amination 
In a 100-ml two-neck flask 1-(1,4-
benzodioxine-6-yl)piperazine (30) (1.816 mmol, 1 equiv) and the corresponding 
benzaldehyde (34b-f, 2.724 mmol, 1.5 equiv) were dissolved in 20 ml of dry methanol. 
After an addition of acetic acid (96 %, 5.45 mmol, 3 equiv) sodium cyanoborohydride 
(2.724 mmol, 1.5 equiv) was added in small portions and rinsed with methanol. The 
reaction was heated for 12-24 h at 60 °C. After cooling the reaction was quenched by 
addition of 50 ml of saturated sodium bicarbonate solution, extracted three times with 
chloroform and washed with brine. The organic layer was dried over sodium sulphate and 
evaporated to dryness after filtration. The residue was purified by chromatography over a 
silica gel column (n-hexane/ethyl acetate 1:2). 
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1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4-fluoro-3-methoxybenzyl)piperazine 
(33b). The methoxy derivative was obtained from the commercially available 4-fluoro-3-
methoxybenzaldehyde (34b) (420 mg, 2.724 mmol) as a pale yellow crystalline solid (551 
mg, 1.54 mmol, 85 %). Mp 100 °C. TLC (n-hexane/ethylacetat, 1:2): Rf = 0.44. 1H NMR 
(CHCl3, 400 MHz) δ 2.56 (t, J = 4.8 Hz, 4H), 3.06 (t, J = 4.8 Hz, 4H), 3.48 (s, 2H), 3.88 (s, 3H), 
4.18 (m, J = 1.6 Hz, 2H), 4.20 (m, J = 1.6 Hz, 2H), 6.44 (m, 1H), 6.45 (m, 1H), 6.75 (m, 1H), 
6.82 (m, 1H), 6.98 (m, 2H) ppm. FT-MS (ESI): m/z 359.176 [M+H]+. 
 
1-(3-(Benzyloxy)-4-fluorobenzyl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)piperazine 
(33c) was obtained from 3-benzyloxy-4-fluoro-benzaldehyde (34c) (160 mg, 0.7 mmol) as 
a white crystalline solid (175 mg, 0.41 mmol, 58 %). Mp 94 °C. TLC (n-hexane/ethylacetat, 
1:2): Rf = 0.74. 1H NMR (CHCl3, 400 MHz) δ 2.40 (m, 4H); 2.92 (m, 4H); 3.41 (s, 2H); 4.11 
(m, 2H); 4.14 (m, 2H); 5.14 (s, 2H); 6.36 (d, J = 2.7 Hz, 1H); 6.38 (dd, J = 2.9 Hz / 8.6 Hz; 
1H); 6.66 (d, J = 8.7 Hz, d); 6.84 (m,1H); 7.14 (m, 2H); 7.31-7.42 (m, 5H) ppm. FT-MS (ESI): 
m/z 345.20758 [M+H]+. 
 
5-((4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)methyl)-2-fluorophenol 
(33d). The hydroxyl derivative was obtained from 4-fluoro-3-hydroxybenzaldehyd (34d) 
(70 mg, 0.5 mmol) as a white crystalline solid (112 mg, 0.35 mmol, 66 %). Mp 186-187 °C. 
TLC (n-hexane/ethylacetat, 1:2): Rf = 0.35. 1H NMR (CHCl3, 400 MHz) δ 2.57 (m, 4H); 3.06 
(m, 4H); 3.45 (s, 2H); 4.18 (m, 2H); 4.20 (m, 2H); 6.44 (m, 2H); 6.74 (m, 1H); 6.79 (m, 1H); 
6.98 (m, 2H); 9.84 (br, 1H) ppm. FT-MS (ESI): m/z 345.19 (100) [M+H]+. 
 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-((6-fluoropyridin-3-yl)methyl)piperazine 
(33e). Method A: Obtained from 6-fluoronicotinaldehyde (34e) (100 mg, 0.8 mmol) as a 
white crystalline solid (35 mg, 0.11 mmol, 13.7 %). 
Method B: A 25 mL flask with a silicone septum was twice heated under vacuo after 
filled with argone. After cooling 1 mL of borane (1 M in THF) was filled into the flask and 
150 mg of 5c (0.44 mmol) dissolved in 4 mL of dry THF were added afterwards. The 
reaction mixture was heated to 65 °C for 7 h and a second portion of borane (0.7 mL, 1 M 
in THF) was added. After another 22 h the reaction was quenched by addition of small 
amounts of ice, extracted three times with chloroform and washed with brine. The 
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organic layer was dried over sodium sulphate and evaporated to dryness after filtration. 
The residue was purified over a silica gel column (chloroform/methanol 8:1) to obtain a 
white solid (43 mg, 0.132 mmol, 30 %). Mp 94 °C. TLC (chloroform/methanol 8:1): Rf = 
0.63; (ethyl acetate/methanol/diethyl amine 96:2:2): Rf = 0.78 . 1H NMR (CHCl3, 400 MHz) 
δ 2.52 (br, 4H); 3.00 (br, 4H); 3.47 (s, 2H); 4.14 (m, 2H); 4.16 (m, 2H); 6.38 (m, 2H); 6.71 
(m, 1H); 6.84 (dd, J = 2.8 Hz / 8.4 Hz, 1H); 7.74 (ddd, J = 2.3 Hz / 8.0 Hz / 8.1 Hz, 1H); 8.09 
(d, J = 1.9 Hz, 1H) ppm. FT-MS (ESI): m/z 330.16 [M+H]+. 
 
1-((6-Chloropyridin-3-yl)methyl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)piperazine 
(33e’). It was also obtained by the general amination procedure from the commercially 
available 6-chloronicotinaldehyd (34e’) (380 mg, 2.68 mmol) as a white crystalline solid 
(445 mg, 1.29 mmol, 71 %). Mp 94 °C. TLC (n-hexane/ethylacetat, 1:2): Rf = 0.53. 1H NMR 
(CHCl3, 400 MHz) δ 2.45 (m, 4H); 2.94 (m, 4H); 3.51 (s, 2H); 4.10 (m, 2H); 4.14 (m, 2H); 
6.36 (d, J = 2.5 Hz, 1H); 6.38 (dd, J = 2.7 Hz / 8.6 Hz, 1H); 6.66 (d, J = 8.6 Hz, 1H); 7.46 (d, J 
= 8.2 Hz, 1H); 7.77 (dd, J = 2.3 Hz / 8.1 Hz, 1H); 8.31 (d, J = 2.2 Hz, 1H) ppm. FT-MS (ESI): 
m/z 346.13150 [M+H]+. 
 
1-((Pyridin-3-yl)methyl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)piperazine (33f) was also 
obtained by the general amination procedure from the commercially available 
nicotinaldehyd (34f) (234 mg, 2 mmol, 1.1 eq) as a white crystalline solid (260 mg, 0.84 
mmol, 46 %). TLC (n-hexane/ethylacetat, 1:2): Rf =0.49. 1H NMR (CHCl3, 200.13 MHz) δ 
2.57 (tr, br, 4H), 3.12 (tr, br, 4H), 4.22 (m, 4H), 6.49 (m, 2H), 6.80 (d, 1H), 7.32 (m, 1H), 
7.77 (d, 1H), 8.57 (m, 2H) ppm. 13C NMR (50.32 MHz, CDCL3-d6) δ 50.14, 53.07, 60.12, 
62.62, 64.27, 64.65, 105.77, 110.48, 117.40, 123.44, 123.51, 136.95, 137.52, 143.66, 
146.32, 148.75, 148.94, 150.49 ppm. 
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6.3.2 Radiosyntheses 
N.c.a. [18F]fluoride was produced via the 18O(p,n)18F nuclear reaction by bombardment 
of isotopically enriched [18O]water in a titanium target245 with 17 MeV protons at the JSW 
cyclotron BC 1710 (INM-5, Research Center Jülich). The aqueous [18F]fluoride solution (10 
– 50 μL, 75 – 375 MBq) was filled into a 5 mL conical vial (Reactivial) containing 1 mL of 
acetonitrile, 10 mg of Kryptofix 2.2.2, 13 μl of an aquaous 1 M potassium carbonate 
solution [52]. The solvent was evaporated under a stream of argon at 80 °C and 600 mbar. 
This azeotropic drying was repeated twice using 1 mL of dry acetonitrile, followed by 
evaporation at 8-15 mbar for 5 min. 
 
6-(4-[4-[18F]Fluorobenzyl]piperazin-1-yl)benzodioxine ([18F]33a). Method A: A 
solution of precursor 32a (8 mg, 22 μmol) in 0.5 mL of anhydrous DMSO was added to the 
vial containing the dried [18F]fluoride at 160 °C. Monitoring of the reaction progress was 
determined by radio HPLC from aliquots of about 30 - 50 μL (Gemini 5 μ RP18 A110, 250 × 
4.6 mm, 1 mL/min, isocratic 60:40:0.1 v/v/v CH3CN/H2O/TEA) and by radio TLC (1:2 n-
hexane/ethyl acetate) determining the reaction time for optimal radiochemical yields. For 
reduction of the intermediate compound the reaction mixture was diluted with 20 mL of 
water, passed through a Sep Pak C18 cartridge, washed with water (5 mL) and dried with 
air. The cartridge was eluted through a drying cartridge charged with 4 Å molecular sieve 
and 270 mg dry sodium sulphate using 5 mL absolute dichloromethane. After removal of 
the solvent in vacuo (800 up to 300 mbar) at room temperature 0.2 mL of BH3THF (1M, 
0.2 mmol) solution and 0.7 mL of dry THF were added and the solution was stirred for 10 
min at 65 °C. The reaction mixture was cooled in an ice bath, carefully quenched with 20 
mL of water and passed through a second Sep Pak C18 cartridge. After washing with 
water, drying in air and eluting with 1 mL of acetonitrile the solution was injected on a 
semi-preparative HPLC system (Gemini 5μ RP18 A110, 250 × 10 mm, 4 mL/min, isocratic 
30:70:0.1 v/v/v CH3CN/H2O/TFA).  
Method B: A solution of 40a (8 mg, 25.5 μmol) in 0.5 mL of anhydrous DMSO was 
added to a reaction vial at 110 °C and the reaction was monitored via radio HPLC (Gemini 
5 μ RP18 A110, 250 × 4.6 mm, 1 mL/min, isocratic 60:40:0.1 v/v/v CH3CN/H2O/TEA). A 
solution of 30 (8.7 mg, 40 μmol) in 40 μL acetic acid and 50 μL DMSO and a solution of 
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sodium cyanoborohydride (4 mg, 64 μmol) in 50 μL DMSO were added successively. The 
reaction mixture was stirred for 15 min, diluted with water and passed through a SepPak 
C18 cartridge, washed with water (5 mL) and dried with air. The cartridge was eluted with 
1 mL of acetonitrile and injected on a semi-preparative HPLC system (Gemini 5μ RP18 
A110, 250 × 10 mm, 4 mL/min, isocratic 30:70:0.1 v/v/v CH3CN/H2O/TFA). The separated 
fraction was diluted with 15 mL of water and passed through a second SepPak C18 
cartridge. After washing with water and drying in an argon stream the cartridge was 
eluted with 5 mL of diethylether which was then evaporated in vacuo (800 up to 330 
mbar). For in vitro studies [18F]3a was formulated in 300 μL ethanol/saline (5:1).  
 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4-[18F]fluoro-3-methoxybenzyl)piper-azine 
([18F]33b). Analoguous to method B of the radiosynthesis of [18F]33a a solution of 40b 
(7 mg, 20 μmol) in 0.5 mL of anhydrous DMSO was added to the reaction vial containing 
the dried [18F]fluoride at 110 °C and the reaction progress was monitored as described 
above via radio HPLC (Gemini 5 μ RP18 A110, 250 × 4.6 mm, 1 mL/min, isocratic 60:40:0.1 
v/v/v CH3CN/H2O/TEA). Without further separation a solution of 30 (8.7 mg, 40 μmol) in 
40 μL of acetic acid and 50 μL of DMSO and a solution of sodium cyanoborohydride (4 mg, 
64 μmol) in 50 μL of DMSO were rapidly added to the reaction vial at the same 
temperature. The reaction was stirred for 15 min, diluted with water and passed through 
a SepPak C18 cartridge, washed with water (5 mL) and dried with air. The cartridge was 
eluted with 1 mL of acetonitrile and injected on a semi-preparative HPLC system (Gemini 
5μ RP18 A110, 250 × 10 mm, 4 mL/min, isocratic 30:70:0.1 v/v/v CH3CN/H2O/TFA). The 
collected fraction was diluted with 15 mL of water, passed through a SepPak C18 
cartridge again, washed with water (5 mL) and dried in a stream of argon. The cartridge 
was eluted with 4 mL of diethylether and the solvent was evaporated in vacuo (800 up to 
330 mbar). For further experimental use in in vitro autoradiography studies [18F]33b was 
formulated in 300 μL ethanol/saline (5:1).  
 
6-(4-[4-[18F]Fluoro-3-hydroxybenzyl]piperazine-1-yl)benzodioxine ([18F]33d). The 
benzyl-protected precursor 39 (3 mg, 7 μmol) dissolved in 0.5 mL of anhydrous DMSO 
added to the dried [18F]fluoride containing vial was heated at 110 °C and the reaction 
progress was determined by radio HPLC (Gemini 5 μ RP18 A110, 250 × 4.6 mm, 1 mL/min, 
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isocratic 80:20 v/v CH3CN/H2O). A solution of 30 (6.5 mg, 30 μmol) in 40 μL acetic acid and 
50 μL DMSO and a solution of sodium cyanoborohydride (4 mg, 64 μmol) in 50 μL DMSO 
were immediately added to the reaction vial and stirred for 7 min at 110 °C. Subsequently 
the solution was diluted with water (20 mL) and passed through an EN cartridge. After 
washing with water (5 mL) and drying in a stream of argon for 8 min the cartridge eluted 
through an unconditioned Alumina N cartridge with 5 mL of anhydrous diethylether in a 
second reaction vial. The ether was evaporated in vacuo and the residue was diluted with 
1 mL of anhydrous methanol. Radio HPLC analysis showed a nearly quantitative 
conversion of [18F]34c to [18F]33c. 20 mg of Pd(black) and 250 mg of ammonium formate 
were added to the solution and the resulting suspension was stirred for 8 min at 60 °C. 
The start of the reaction could be observed by a strong evolution of gas. The mixture was 
cooled in an ice bath, filtered through a small glass column with two frits (Merck: pore 
size 4) and washed with a small amount of methanol. After solvent evaporation in vacuo 
the residue was diluted with 1 mL of methanol/phosphate buffer and injected on a semi-
preparative HPLC system (Gemini 5μ RP18 A110, 250 × 10 mm, 4 mL/min, isocratic 60:40 
v/v MeOH/phosphate buffer pH 8.5). The separated fraction was diluted with 15 mL of 
water, passed through a SepPak C18 cartridge, washed with water (5 mL) and dried in a 
stream of argon. The cartridge was eluted with 4 mL of diethylether and the solvent was 
evaporated in vacuo (800 up to 330 mbar). For further experimental use in in vitro 
autoradiography studies [18F]33d was formulated in 300 μL of ethanol/saline (5:1).  
 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-((6-[18F]fluoropyridine-3-yl)methyl)- 
piperazine ([18F]33e). Method A: The precursor for direct labelling 33e’ (13.8 mg, 40 
μmol) dissolved in 0.5 mL of anhydrous DMSO was added to the vial containing the 
[18F]fluoride complex and the solution was stirred at 160 °C for 20 min. Progress of the 
reaction was monitored via radio HPLC (Gemini 5 μ RP18 A110, 250 × 4.6 mm, 1 mL/min, 
isocratic 50:50:0.1 v/v/v CH3CN/H2O/TEA). Water was added to the solution and it was 
passed through a Sep Pak C18 cartridge, washed with water and dried with air. The 
cartridge was eluted with acetonitrile (2 mL) and the solvent was evaporated in vacuo. 
The residue was diluted with 1 mL acetonitrile/water (50/50) and injected on a semi-
preparative HOLC system (Gemini 5μ RP18 A110, 250 × 10 mm, 4 mL/min, isocratic 
40:60:0.1 v/v/v CH3CN/H2O/TEA).  
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Method B: The radiochemical synthesis of [18F]33e by reductive amination was 
performed in an identical manner as described for [18F]33a, [18F]33b and [18F]33c, starting 
from 6-pyridinealdehyde (40e,5 mg, 35.5 μmol) solved in 0.5 mL of anhydrous DMSO and 
stirred for 2 min at 110 °C. The radiochemical yield of [18F]34e was measured by radio 
HPLC (Gemini 5 μ RP18 A110, 250 × 4.6 mm, 1 mL/min, isocratic 60:40:0.1 v/v/v 
CH3CN/H2O/TEA). After reaching the optimal yield at 2 min, immediately a solution of 30 
(6.5 mg, 30 μmol) in 40 μL of acetic acid and 50 μL of DMSO and a solution of sodium 
cyanoborohydride (4 mg, 64 μmol) in 50 μL of DMSO were added and the reaction 
mixture was further stirred for 8 min. After addition of 20 mL of water the solution was 
passed through a Sep Pak C18 cartridge followed by washing with 5 mL water and drying 
with air. The cartridge was eluted with 1 mL of ethanol/water (80/20) and injected on a 
semi-preparative HPLC system (Gemini 5μ RP18 A110, 250 × 10 mm, 4 mL/min, isocratic 
40:60:0.1 v/v/v CH3CN/H2O/TEA). The collected fraction was diluted with 15 mL of water, 
passed through a SepPak C18 cartridge, washed with water (5 mL) and dried in a stream 
of argon. The cartridge was eluted with 4 mL of diethylether and the solvent was 
evaporated in vacuo (800 up to 330 mbar). For further experimental use [18F]33e was 
formulated in 300 μL of saline containing 1% tween 80. 
6.3.3 Radioanalytical methods 
For identification of the labelled products and determination of their radiochemical 
yields (RCY) and purity both radio high performance liquid chromatography (radio-HPLC) 
and radio thin layer chromatography (radio-TLC) were used. All 18F-labelled compounds 
were identified by their non-radioactive standard compounds by comparison of the UV-
signals with the radioactive signals. The determination of volatile compounds like [18F]21 
and [18F]22 as well as products directly obtained from these was of course not suitable by 
radio-TLC. Therefore these compounds were only analyzed by radio-HPLC. 
6.3.3.1 Radio thin layer chromatography 
Analytical radio thin layer chromatography was carried out in order to verify that no 
radioactive species especially very polar and non-polar ones other than those detected by 
radio-HPLC were present. As an alternative chromatography method on normal silica 
phases radio-TLC was further used to exclude a casually identic retention of product and a 
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given reference compounds. Radio-TLC was performed on precoated Merck silica plates 
(F254) with different solvent systems. 1.5-3 μL of the radioactive sample solution was given 
on the TLC plates and developed in the appropriate solvent (Tab. 6.1).  
 
Table 6.1. Rf-values of the standard compounds for chromatographic identification by radio-TLC 
on silica plates. 
Compound Rf 
1-(4-Fluorophenyl)piperidine (23) 0.57 (A) 
1-(4-Fluorophenyl)piperazine (28) 0.52 (B) 
2-((4-(4-Fluorophenyl)piperazine-1-yl)methyl)-1H-indole-5-
carbonitrile, FAUC316 (1) 
0.73 (C) 
2-((4-(4-Fluorophenyl)piperazine-1-yl)methyl)-1H-indole (29) 0.66 (D) 
4-Fluorobenzaldehyde (34a) 0.61 (E) 
4-Fluoro-3-methoxybenzaldehyde (34b) 0.89 (F) 
4-Fluoro-3-benzyloxybenzaldehyde (34c) 0.56 (A) 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4- 
fluorobenzyl)piperazine (33a) 
0.70 (F) 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4-fluoro-3-
methoxybenzyl)piperazine (33b) 
0.44 (F) 
1-(3-(Benzyloxy)-4-fluorobenzyl)-4-(2,3- 
dihydrobenzo[b][1,4]dioxin-6-yl)piperazine (33c) 
0.74 (F) 
5-((4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)piperazin- 
1-yl)methyl)-2-fluorophenol (33d) 
0.35 (F) 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-((6-fluoropyridin-3-
yl)methyl)piperazine (33e) 
0.63 (G); 0.78 
(H) 
(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)(4-
fluorophenyl)methanone (32a) 
0.49 (F) 
(A) n-hexane/ethyl acetate 4:1; (B) butanol/H2O/acetic acid 4:1:1; (C) dichloromethane/methanol 
95:5; (D) chloroform/methanol 20:1; (E) n̂hexane/ethyl acetat 2:1; (F) n̂hexane/ethyl acetat 1:2; 
(G) chloroform/methanol 8:1; (H) ethyl acetate/methanol/diethyl amine 96:2:2 
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The developed TL-chromatograms were measured for radioactivity on an Instant 
ImagerTM (Packard, Canberra). Retardation factors (Rf-values) of individual standards are 
also listed in Table 6.1. 
6.3.3.2 Radio high performance liquid chromatography 
Analytical and semipreparative high performance liquid chromatography was 
performed using an Ultimate 3000 pump and variable wave length UV/Vis detector from 
Dionex. For measurement of radioactivity the outlet of the UV/Vis detector is connected 
to a Na(Tl) scintillation detector (Gabi star, raytest). The aliquots of the labelled 
compounds were analysed by different reverse phase (RP) columns as stationary phase 
and various acetonitrile/water systems with and without buffer as mobile phase. All 
measurements were performed at room temperature with a flow rate of 1 mL/min for 
analytical and 4 mL/min for semipreparative chromatography. Individual capacity factors 
(k’) of the standard compounds are given in Table 6.2. k’-values are determined by 
equation (6.1) from individual retention times (tR) and dead time (t0) of the HPLC system. 
 
 (6.1) 
 
 In practice for analytical radio-HPLC, samples were diluted with the eluent and about 
40 kBq were injected via a Rheodyne injection valve and a 200 μL loop. Subsequent to the 
completed chromatographic sequence, equal volume samples were injected three times 
directly in front of the detectors via a second injection valve bypassing the column. For 
determination of the RCY in % the radioactivity of separated compounds (100 %) were 
related to the total radioactivity of the aliquots. In case of a previously performed 
separation (e.g. solid phase extraction) aliquots can not be related to the short activity of 
[18F]fluoride and RCY are therefore related to the total radioactivity of the actual reaction 
step instead. For semipreparative radio-HPLC samples of an acetonitrile or ethanol 
solution were injected via a 1000 μL loop. The obtaind RCY at the end of synthesis (EOS) is 
not the product of all intermediate RCY but lower due to losses during extraction and 
purification. 
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Table 6.2. k’-values of the standard compounds for chromatographic identification by radio-HPLC. 
Compound k‘ 
4-Fluorobromebenzene (21) 14.74 (C) 
4-Fluoroiodobenzene (22) 7.41 (E) 
1-(4-Fluorophenyl)piperidine (23) 2.04 (C) 
1-(4-Fluorophenyl)-4-methylpiperazine (24) 2.97 (C) 
Tert-butyl 4-(4-fluorophenyl)piperazine-1-carboxylate (27) 2.23 (C) 
1-(4-Fluorophenyl)piperazine (28) 1.17 (C); 4.89 (G) 
2-((4-(4-Fluorophenyl)piperazine-1-yl)methyl)-1H-indole-5-
carbonitrile, FAUC316 (1) 
8.7 (H) 
2-((4-(4-Fluorophenyl)piperazine-1-yl)methyl)-1H-indole (29) 7.56 (D) 
4-Fluorobenzaldehyde (34a) 1.88 (D) 
4-Fluoro-3-methoxybenzaldehyde (34b) 1.65 (D) 
4-Fluoro-3-benzyloxybenzaldehyde (34c) 4.35 (F) 
6-Fluoronicotinaldehyd (34e) 1.28 (D); 2.06 (B) 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4-
fluorobenzyl)piperazine (33a) 
6.04 (D); 11.72 (C) 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4-fluoro-3-
methoxybenzyl)piperazine (33b) 
5.11 (D); 7.11 (A) 
1-(3-(Benzyloxy)-4-fluorobenzyl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-
6-yl)piperazine (33c) 
5.53 (F) 
5-((4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)methyl)-2-
fluorophenol (33d) 
6.85 (A) 
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-((6-fluoropyridin-3-
yl)methyl)piperazine (33e) 
4.19 (D); 5.87 (B) 
1-((6-Chloropyridin-3-yl)methyl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-
6-yl)piperazine (33e’) 
7.37 (B) 
1-((Pyridin-3-yl)methyl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)piperazine (33f) 
4.02 (B) 
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Table 6.2 continued  
(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)(4-
fluorophenyl)methanone (32b) 
2.97 (C); 2.28 (D) 
1-(1,4-Benzodioxine-6-yl)piperazine (30) 0.62 (D) 
Gemini 5 μ RP18 A110: (A) isocratic 30:70:0.03 v/v/v CH3CN/H2O/TEA pH 9; (B) isocratic 
40:60:0.03 v/v/v CH3CN/H2O/TEA pH 9; (C) isocratic 50:50:0.03 v/v/v CH3CN/H2O/TEA pH 9; (D) 
isocratic 60:40:0.03 v/v/v CH3CN/H2O/TEA pH 9; (E) isocratic 75:25 v/v CH3CN/H2O; (F) isocratic 
80:20:0.03 v/v/v CH3CN/H2O/TEA pH 9; 
Phenomenex Luna 5 μm PFP(2) 100 Å: (G) isocratic 50:50:0.01 v/v/v CH3CN/H2O/TEA pH 7.8; (H) 
isocratic 70:30:0.01 v/v/v CH3CN/H2O/TEA pH 7.8 
6.3.3.3 Determination of molar activities 
For all pharmacological applications the molar activity of the labelled tracers has to be 
determined previously by measuring its amount of carrier. The analysis of the molar 
activity of [18F]1, [18F]33a, [18F]33b, [18F]33d and [18F]33e was carried out by HPLC. The 
applied mass of the non-radioactive standard compounds is proportional to the integral 
of the UV-signal obtained by HPLC. Thus the measured peak areas were fitted as a 
function of varying masses of 1, 33a, 33b, 33d, and 33e, respectively. The dependences 
between UV adsorbtion and the amount of substance is displayed for all fife labelled 
ligands in Figures 6.1-6.5. With this calibrations measured radioactivities of the γ-peak 
can be related to the mass or molarity of each ligand, respectively. 
For 2-((4-(4-[18F]fluorophenyl)piperazine-1-yl)methyl)-1H-indole-5-carbonitrile, FAUC 
316 ([18F]1) highest molar activity of 90 GBq/μmol was achieved. For the benzodioxine 
derivatives [18F]33a, [18F]33b, [18F]33d, and [18F]33e molar activities of about 60 
GBq/μmol, 50 GBq/μmol, 25 GBq/μmol, and 40 GBq/μmol were achieved, respectively. 
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Figure 6.1: Dependence of the integral UV absorption (328 nm) on the amount of FAUC 316 (1) in 
HPLC chromatography. 
 
 
Figure 6.2: Dependence of the integral UV absorption (220 nm) on the amount of 1-(2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4-fluorobenzyl)piperazine (33a) in HPLC chromatography. 
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Figure 6.3: Dependence of the integral UV absorption (220 nm) on the amount of 1-(2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)-4-(4-fluoro-3-methoxybenzyl)piperazine (33b) in HPLC 
chromatography. 
 
 
Figure 6.4: Dependence of the integral UV absorption (220 nm) on the amount of 5-((4-(2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)methyl)-2-fluorophenol (33d) in HPLC 
chromatography. 
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Figure 6.5: Dependence of the integral UV absorption (220 nm) on the amount of 1-(2,3-
Dihydrobenzo[b][1,4]dioxin-6-yl)-4-((6-fluoropyridin-3-yl)methyl)piperazine (33e) in HPLC 
chromatography. 
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6.4 Pharmacology 
6.4.1 Determination of partition coefficients 
Using the HPLC method corresponding to the OECD guideline for the testing of 
chemicals241, the lipophilicity of compounds was determined using a LiChrospher 100 RP-
8 (5 mm) column (Merck). Soerensen buffer was used as eluent (methanol/phosphate 
buffer 75:25 (v/v) at a pH of 7.4). The retention time of a number of reference 
compounds (ascorbic acid, benzaldehyde, anisole, toluene, 4-bromoanisole, 4-
iodoanisole) with known log P values (ranging from -1.67 to 3.24) were determined and 
the capacity factors k´ calculated. Plotting log k´ against log P gave the reference curve 
used to determine the log P values of 3a-e via their respective retention time. 
Using the shake flask method corresponding to the OECD guideline for the testing of 
chemicals241, the lipophilicity of ligands was determined by analyzing the partitioning of 
the 18F-labelled products between a phosphate-buffer (pH 7.4) and an n-octanol phase. 
The pure n.c.a. 18F-labelled substance in 4.5 μL of absolute ethanol was added to a 
mixture of 1.5 mL of phosphate buffer and 150 μL of n-octanol. The system was shaken 
for 3 min and afterwards centrifuged for 5 min at 13000 r/min. On a silica TLC plate 2.5 μL 
of the organic phase and 5 μL of the buffer phase were stippled four times, respectively. 
Partitioning of radioactivity in both phases was determined by an Instant Imager. 
6.4.2 Animals 
4-6 month old Wistar rats (230–250 g body weight) and 2-6 month old female NMRI 
mice of 18-22 g were purchased from Charles River laboratories (Wilmington, 
Massachusetts). All animals were kept under a natural light/dark cycle and had access to 
water and food ad libitum. The local government approved all procedures according to 
the German Law on the Protection of Animals (§§7-9 TierSchG). Animal experiments were 
also approved by the Animal Research Committee of the Scientific and Technical Advisory 
Board of the Research Center Jülich. For conducting ex vivo experiments with living 
animals the number of approval was AZ 9.93.2.10.35.07.244. 
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6.4.3 In vitro autoradiography of rat and mouse brain slices 
After anesthetising and decapitation of the animals whole brains were rapidly 
removed and immediately frozen at -80 °C until use. Rat brain sections were prepared in a 
cryostat microtome (CM 3050; Leica; section thickness 20 μm) at -20 °C, thaw-mounted 
onto silica-coated object slides dried on silicagel overnight at 4 °C and stored at -80 °C 
until use. 
Incubation conditions for in vitro autoradiography of all tested substances were similar 
to those previously described by Zhang et al.246. All incubations were performed at 22°C in 
Tris-HCl buffer (50 mmol/L, pH 7.4). After preincubation in buffer for 10 min rat brain 
slices were incubated in 5 nmol/L of [18F]33a or [18F]33b or [18F]33e or 10 nmol/L of 
[18F]33d and mouse brain slices in 20 nmol/L of [18F]33e for 30 min either with 10 μmol/L 
competitor (spiperone or cold standard) or with the same amount of DMSO, respectively. 
They were washed twice for 5 min in ice-cold Tris-HCl buffer, rapidly rinsed with ice-cold 
distilled water, and placed under a stream of dry air for rapid drying. Object slides were 
exposed to a γ-sensitive film for 15-30 min and then laser scanned by a phosphor imager 
BAS 5000 (Fuji). The evaluation of receptor autoradiography was processed according to 
standard image analysis software (AIDA 2.31; Raytest Isotopenmeßgeräte, Germany). 
Nonspecific binding was defined as the residual activity in the presence of cold standard. 
Specific binding was calculated as the difference between total and nonspecific binding. 
6.4.4 Ex vivo biodistribution in mouse model  
1.1-2.6 MBq of [18F]33e in 50 μL of saline (containing 1 % tween 80) was injected to the 
tail vain of female NMRI mice. Animals were killed by cervical dislocation and organs were 
removed immediately. All organs and blood were weighted and the radioactivity 
measured in a gamma-counter (Auto-Gamma® MINAXI 5000 Packard). Brains were rapidly 
frozen at -80 °C and cut into horizontal or sagittal sections (thickness, 40 μm) at -20 °C. 
6.4.5 In vivo stability of [18F]33e 
In order to determine the stability of [18F]33e in mouse serum, removed blood (n = 3) 
was centrifuged for separation of the plasma which was deproteinated with two volumes 
of acetonitrile. Samples of 2.5 μL were taken from the extract and analyzed by radio-TLC 
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using ethyl acetate/methanol/diethyl amine (96:2:2). In order to estimate the recovery of 
[18F]33e in the extracted solution and to exclude loss of original radioligand or possible 
labelled metabolites, samples of 2.5 μL of origin blood and plasma were submitted to TLC 
analysis. 
For the determination of possible brain metabolites, mouse brains (n = 3) were 
homogenized with a Potter Elvehjem homogenizer with two volumes of Tris HCl buffer 
(0.1 M pH 7.4)  and treated like above described with two volumes of acetonitrile. 
6.4.6 Staining of brain slices by cresyl violet 
After total decay of the fluorine-18 in the brain sections, cresyl violet staining of cell 
nuclei of these sections was performed to identify the different brain regions. After 
fixation with neutral buffered formalin for 30 min at 4°C the sections were rinsed twice 
with water and thereafter incubated in cresyl violet solution (40 mM natrium acetate in 
10% glacial acetic acid) for 30 min at 60 °C. After a short water rinse the sections were 
dehydrated by 70%, 80%, 90% and 100% of ethanol followed by a xylol bath, each step for 
5 min. The staining was sealed with DPX Mountant for histology (Fluka). 

 7. Summary and Outlook 
 
Dopamine is a multifunctional neurotransmitter in the human brain which influences 
modulation of behaviour and cognition, voluntary movement, motivation, punishment 
and reward, sleep, mood, attention and learning. These effects are mediated through the 
interaction of only 5 different receptor molecules from which few are reasonably 
understood. For the D4 type of dopamine receptors, impact on sexual behaviour, 
substance abuse, attention and personality traits are postulated. However, the extremely 
low density of this receptor subtype in the brain leads to demanding requirements for 
radioligands. Therefore to a lack of appropriate ones exists for functional in vivo imaging 
which prevents from a systematic examination of this receptor type in man until now. 
Otherwise, lead structures of putative D4 ligands are known from studies of structure-
activity relationship. Mostly they are derivatives of a 1-phenyl-4-benzylpiperazine 
backbone. In this work the 18F-labelling of a couple of such putative ligands was 
developed and their preliminary pharmacological evaluation performed. 
The radiosynthesis of [18F]FAUC 316 ([18F]1), a ligand of high affinity, was not described 
before due to the requirement of a multistep and complex implementation of no-carrier-
added (n.c.a.) [18F]fluoride in the aromatic phenyl moiety. Fluoride was obtained by a 
18O(p,n)18F nuclear reaction on a [18O]H2O water target at a cyclotron. Radiosynthesis of 
[18F]1 as authentic tracer is expedient, since it exhibits extremely high values of affinity 
and selectivity which are not conserved when analogue labelling like 18F-fluoroalkylation  
is performed. Furthermore, aromatic C-F bonds are rather stable under in vivo conditions. 
In the first steps of radiosynthesis of [18F]FAUC 316 ([18F]1) the known iodonium salts 
bis(4-bromophenyl)iodonium triflate (16) and bis(4-iodophenyl)iodonium triflate (20) 
were labelled by nucleophilic substitution with n.c.a. [18F]fluoride to obtain radiochemical 
yields (RCY) of up to 60 % of 4-[18F]fluorobromobenzene ([18F]21) and 4-
[18F]fluoroiodobenzene ([18F]22). Subsequently, they were cross-coupled by a Hartwig-
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Buchwald reaction (HBC) with piperazine to yield 4-[18F]fluorophenylpiperazine ([18F]28) 
with a RCY of up to 70 %. Thereby 20 appeared as more favourable precursor with higher 
yields both with fluorination and coupling of [18F]22. Due to decomposition during 
fluorination of both precursors and the formation of colloidal by-products with 20, solid 
phase extraction for solvent exchange became rather complex and demanding. The HBC 
was primarily conducted with Pd2(dba)3 and the phosphine ligands DavePhos and RuPhos 
in toluene. The use of Pd(OAc)2 was also possible obtaining similar yields. With other 
solvents, especially DMF, no or only poor yields were obtained. 
The possibility of an acid extraction of the free amine [18F]28 resulted in a good pre-
purification. A subsequent reductive amination reaction using NaBH3CN and acetic acid 
with 5-cyanoindole-2-carbaldehyde 10 led to [18F]1 in a high conversion rate of 80-90 % 
and an overall RCY (related to starting [18F]F-) at the end of synthesis (EOS) of about 10 % 
and a molar activity of about 90 GBq/μmol. In contrast, a direct HBC of [18F]22 with the 
benzyl protected 1-benzyl-2-(piperazin-1-ylmethyl)-1H-indole-5-carbonitrile (14) was not 
successful. However, this path would not offer advantages, neither in the number of 
synthetic steps nor in reaction time, but cause disadvantages of a more complex 
precursor synthesis and abolition of the pre-purification step and therefore was not 
further persecuted. 
For its use in pharmacological evaluation radio high performance liquid 
chromatography (HPLC) purification of [18F]1 was developed using the modern 
pentafluorophenyl phase to separate from non-isotopic carrier. In addition, a 
prepurification by extraction was employed to minimise non-radioactive side products 
and to enable the subsequent radio HPLC purification, which finally resulted in a 
radiochemical purity of about 99 %. 
With [18F]28 a new “small labelling compound” was developed, which proved 
convenient for the preparation of 18F-labelled 1-(4-fluorophenyl)-4-phenalkylpiperazines 
which are not only a chemical lead structure of nearly all D4 selective ligands but, known 
so far, also of many D3, D2 and even 5-hydroxytryptamine (5-HT) ligands. 
In the specific case of [18F]FAUC 316 it was shown by in vitro autoradiography of 
animal brain tissue that an extremely high amount of non-specific binding of about 90 % 
prevents this radioligand from an in vivo imaging with positron emission tomography 
(PET).  
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Therefore 6-(4-benzylpiperazine-1-yl)benzodioxine was selected as new lead structure 
where now the benzyl moiety is the fluorine-carrying side. This situation enabled a direct 
labelling procedure of the corresponding amide. In order to challange the problem of 
non-specific binding, in this case the basic structure was derivatized systematically 
towards more hydrophilic compounds. This proved possible without falling below the 
lower threshold of lipophilicity for penetration of the blood-brain-barrier, which is 
assumed at a Log P/D of about 1.5 to 2. Thus, beside the unsubstituted 6-(4-[4-
fluorobenzyl]piperazine-1-yl)benzodioxine (33a) with a Log P7.4 of 2.7, the derivatives 6-
(4-[4-fluoro-(3-methoxybenzyl)]piperazine-1-yl)benzodioxine (33b) with a Log P7.4 of 2.4, 
6-(4-[4-fluoro-(3-hydroxybenzyl)]piperazine-1-yl)benzodioxine (33d) with a Log P7.4 of 1.7 
and 6-(4-[6-fluoropyridin-3-yl]piperazine-1-yl)benzodioxine (33e) with a Log P7.4 of 1.9 
were successfully prepared. Direct labelling of the analoguously synthesized precursor 4-
(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)piperazin-1-yl)(4-nitrophenyl)methanone (32b) 
resulted in a radiochemical yield of 50 % of and subsequent reproducible reduction of the 
amide to the amine ([18F]33a) resulted in a RCY of about 40 %. Nevertheless, the overall 
RCY after HPLC separation at the end of synthesis was only about 5 %. 
In contrast the 2-step build up reaction starting from the labelled aldehydes 4-
[18F]fluorobenzaldehyde ([18F]34a), 4-[18F]fluoro-3-methoxybenzaldehyde ([18F]34b), 4-
[18F]fluoro-3-benzyloxybenzaldehyde ([18F]34c), 6-[18F]fluoronicotinaldehyde ([18F]34e) 
resulted in significant higher yields. For the 18F-fluorination of the aldehydes the excellent 
leaving group trimethylammonium triflate could be employed, what was not possible for 
the direct labelling of 32b. Using this leaving group for SNAr of the aldehydes, RCY of 70-
80 % were achieved which were on average 50 % higher than with the nitro leaving 
group.  
For the subsequent coupling of the aldehydes to the pierazine 30 the above described 
reductive amination using NaBH3CN and acetic acid was used. Both reaction steps, 
fluorination and reductive amination, could be performed in DMSO without interim 
separation. Thereby RCY at the end of synthesis and HPLC-purification of 35 %, 20 %, and 
15 % were obtained with [18F]33a, [18F]33b, and [18F]33e, respectively, and with molar 
activities of 30-60 GBq/μmol. In this case the build-up synthesis exceeds the normally 
desired direct labelling in yield and reaction time. [18F]33d required the additional 
cleavage of the benzyl protection group of the intermediate [18F]33c using Pd and 
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ammonium formate in methanol, which was almost quantitative with a total RCY of 9 %. 
Fixation of [18F]33c on a lipophilic EN cartridge led to a good pre-purification. 
Nevertheless, the RCY of [18F]33d was the lowest due to the additional purification and 
reaction step. 
Results confirm that the reductive amination reaction with NaBH3CN is an excellent 
method in radiofluoro-chemistry leading to high yields in short reaction times with high 
reproducibility. Especially the latter is decisive and not general with n.c.a. syntheses. 
Since dimethylsulfoxid (DMSO) is an excellently suited solvent for fluorination and 
reductive amination the whole procedure is simplified distinctly, since interim isolation is 
obsolete. 
In vitro autoradiographic competing binding studies on rat brain slices of [18F]33a, 
[18F]33b, [18F]33d and [18F]33e with the unlabelled standard compounds and spiperone 
confirmed the dependence of non-specific binding on lipophilicity. While [18F]33a and 
[18F]33b, as well as [18F]FAUC 316 before, were not suitable for further applications due to 
a high non-specific binding of 96 % and 79 %, respectively, the less lipophilic ligands 
[18F]33d and [18F]33e with a non-specific binding fraction of 33 % and 7 %, respectively, 
showed excellent qualifications.  
The pyridine derivative [18F]33e got preference over [18F]33d and was selected for 
further pharmacological evaluation due to its better selectivity and its lowest non-specific 
binding as well as shorter radiosynthesis. The time dependence of organ uptake and 
metabolism as well as ex vivo distribution in brain was determined with Naval Medical 
Research Institute (NMRI) mice. The brain uptake of [18F]33e amounted with 5 %ID/g 
after 5 min and still 1 %ID/g after 30 min exceedingly high. All observed peripheral 
metabolites were hydrophilic and did not penetrate the blood brain barrier. 
Defluorination was excluded due to a low bone uptake, and no significant metabolites 
were observed in brain. Ex vivo autoradiography showed an accumulation of [18F]33e in 
parts of the limbic system, especially the hippocampus, as well as the frontal cortex. 
These are regions where occurrence of the D4 receptor is postulated. Only the high 
accumulation in cerebellum could not be concretely explained but is not necessarily 
negative. 
In conclusion, with [18F]33e a radioligand was developed which holds great promise as 
tracer for the in vivo visualization of the D4 receptor system. The results encourage 
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continued evaluation in preclinical studies using small animal PET. In case of a 
confirmation of the pharmacological parameters determined and the density distribution 
pattern with in vivo experiments, the whole radiosynthesis has to be adapted to a 
procedure suitable for an automated synthesis device. Since one-pot syntheses require 
few reaction and separation steps the automation of the radiosynthesis appears feasible. 
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